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Abstract 
 
Recent evidence has shown that SOX9 is required for the proliferation and 
multipotentiality of neural progenitors in the developing CNS. Notably, these findings 
suggest that in contrast to previous studies, SOX9 is important for differentiation along 
the neuronal lineage, both in the adult and embryonic CNS. Here, a phenotypic analysis 
of the CNS-specific Sox9-null forebrain, including detailed analysis of cortical 
lamination, shows that neurons of the appropriate layer-identity are born and migrate to 
their destined layers. All other parameters in this analysis were normal, with the 
exception of the formation of glia from the ventral and dorsal telencephalons, and midline 
glial structures, which were absent in the mutant. Since Sox9 is expressed long before the 
onset of gliogenesis in these brain regions, the possibility that Sox9 may ‘prime’ the 
progenitors of the ventricular zone to respond to a gliogenic signal arose. To investigate 
this, populations of Sox9-deficient and wild-type dorsal telencephalon cells were enriched 
for progenitors and subjected to transcriptional profiling. Bioinformatic analysis revealed 
that ‘vascular endothelial growth factor’ receptors, which are important for gliogenesis, 
were down-regulated, in addition to two transcription factors. Previously, Sox9-deficient 
neural progenitors have been shown to generate neurospheres poorly, and so the dataset 
of potential targets was used to identify candidates that might mediate this reduced 
neurosphere-forming ability. Thirteen down-regulated targets were confirmed by qPCR, 
six of which were expressed in the same distribution as Sox9 in the embryonic 
telencephalon; three were also expressed in neurosphere cultures. Of these, one encoded a 
K+ channel (Kir4.1), and the other a modulator of the GABAA channel (DBI). In order to 
show that reduced expression of one of these might contribute to the Sox9-deficient 
neurosphere phenotype, pharmacological modulators were used and showed that blockade 
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of Kir4.1 or enhancement of GABAA channels mimicked the effect of Sox9 loss, leaving 
open the possibility that Kir4.1 or DBI expression might mediate this effect. 
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Chapter 1 General Introduction 
 
Process of Neural Development 
 
The vertebrate brain and spinal cord arise from a neural plate, which is a region of 
ectoderm (the outer layer of the embryo), that has obtained a neural fate through 
signalling from the underlying mesoderm layer (Harland, 2000). Once induced, the neural 
plate folds up and fuses in the midline to give a neural tube (beginning at embryonic day 
[E] 8.5), and from this structure, all the components of the mature central nervous system 
(CNS) are laid down over the remaining 10 days of development (Copp et al., 2003). The 
walls of the neural tube are composed of specialised epithelial cells, called neuroepithelial 
(or NE) cells, which divide symmetrically (forming two NE cells with each division) for a 
number of days prior to the onset of differentiative divisions, which give rise to the 
mature cell types of the CNS, neurons and glia (reviewed in Zhong and Chia, 2008). This 
‘neuroepithelium’ is later termed the ventricular zone (VZ). Neurons are the cells that will 
eventually convey information in the nervous system through the co-ordinated firing of 
action potentials, whereas glia are conventionally thought not to be involved in this 
process, and are divided into two categories, astrocytes and oligodendrocytes. Astrocytes 
eventually vastly outnumber any other cell type in the mature CNS, and have a variety of 
functions, including providing physical support and nutrition to neurons, as well as 
buffering of substances that would otherwise interfere with the proper functioning of 
neuronal circuits, such as potassium ions (Kandel et al., 2000). They also form the blood-
brain barrier that protects the brain from potentially toxic substances in the blood. 
Oligodendrocytes are responsible for the laying down of an insulating substance, myelin, 
on the axons of neurons, which allow fast, ‘saltatory’ conduction through the setting up of 
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circuits that ‘jump’ between gaps in the myelin sheath, called the nodes of Ranvier 
(Kandel et al., 2000). 
 
Following a period of symmetrical division during which the total surface area of the 
neuroepithelium expands, most prominently at the rostral end, which will become the 
brain, various ‘hinge points’ develop that define the mid- and forebrain. At the onset of 
neurogenesis, the neuroepithelium begins to undergo asymmetrical divisions that give rise 
to a progenitor and a lineage-committed cell, in this case, a neuron. At the onset of 
‘asymmetrical’ divisions, the metaphase plate is no longer perpendicular to the plane of 
the neuroepithelium, resulting in a neuronal-lineage committed cell, which is destined to 
migrate and differentiate (Zhong and Chia, 2008). This transition from symmetrical to 
asymmetrical division is thought to result in daughter cells inheriting less of a protein 
(such as the suppressor of Notch signalling ‘Numb’) that resides on the apical side of the 
original mother cell, prompting its differentiation along a neuronal lineage. Following 
this, direct cell-to-cell signalling, such as Notch signalling, where cell-surface ligands on 
one daughter cell stimulate Notch receptors on the other, reinforces differences between 
the cells. Alongside this transition from symmetrical to asymmetrical division, the 
neuroepithelial cells also begin to adopt a number of characteristics suggestive of a glial 
identity, such as cytoplasmic glycogen granules (Choi and Lapham, 1978), and 
expression of Brain Lipid-Binding Protein (Feng et al., 1994), the glutamate transporter, 
GLAST (Shibata et al., 1997), and Tenascin (Yuasa, 2001). The adoption of these 
markers signifies the transformation of NE cells into radial glia, which occurs at the onset 
of neurogenesis (Doetsch, 2003). 
 
It was initially thought that radial glia, with their vast projections extending from the 
apical to the basal sides of the ventricular wall, simply provided a scaffold over which 
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newly-formed neurons could migrate; however, work in the late 1980s challenged this 
dogma, and genetic lineage tracing has put the progenitor status of radial glia beyond 
doubt (Misson et al., 1988, Malatesta et al., 2003, Anthony et al., 2004). This was 
demonstrated with a system involving a ‘Cre recombinase’, which is an enzyme capable 
of excising the intervening DNA between two ‘LoxP’ sites. The gene encoding Cre 
recombinase was placed under the control of the regulatory region of a gene normally 
expressed in radial glia, and the LoxP sites flanked a STOP cassette in a reporter 
transgene, such that when the Cre was expressed (specifically in the radial glia), the 
STOP cassette was excised and all future progeny expressed the reporter, in this case, 
green fluorescent protein (GFP). The result was that all the cells of the mature CNS were 
shown to be GFP+, and hence had originated from radial glia (Anthony et al., 2004). 
 
Aside from radial glia, recent work has shown that neurons are not the only progenitors in 
the CNS. In the context of the dorsal telencephalon, the result of an asymmetrical division 
of a neural progenitor was thought to always be one neuron and one radial glial cell. 
However, elegant retroviral lineage tracing studies have shown that a different type of 
asymmetrical division commonly occurs from the peak of neurogenesis, where a transit-
amplifying cell is formed instead of a neuron, and this cell, termed an intermediate 
progenitor cell (IPC), then migrates to a second progenitor layer, overlying the VZ, called 
the subventricular zone (SVZ; Noctor et al., 2004). These IPCs usually divide only once 
to give rise to two neurons, but have been shown occasionally to generate pairs of 
progenitors (Noctor et al., 2004). It has been suggested that the development of IPCs 
produced an amplification step essential for the expansion of cortical surface area 
throughout mammalian evolution (Pontious et al., 2008). This is underlined by the human 
phenotype that results from homozygous loss of genes important for IPC generation (such 
as PAX6 or TBR2), which produces microcephaly (a small brain), polymicrogyria (an 
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increased number of small gyri) and cortical thinning (Glaser et al., 1994, Baala et al., 
2007). 
 
Following the onset of neurogenesis in the dorsal telencephalon, the layers of the future 
cortex are laid down by divisions of both radial glial cells and IPCs. An initial wave of 
neurogenesis, occurring at around E11.5, generates neurons that migrate to form the 
preplate, a layer just superficial to the VZ, then a later wave, at ~E12.5, produces the first 
layer of the cortical plate (the future cortex), splitting the preplate into a deep ‘subplate’ 
and a superficial ‘marginal zone’. Subsequent waves of neurogenesis generate cohorts of 
neurons that migrate along the basal endfeet of the radial glia, past the preceding layer of 
the cortical plate, to establish the next most superficial layer; in this way, the cortex is 
often describe as being formed in an ‘inside-out’ fashion (reviewed in Gupta et al., 2002). 
The final cortex is a six-layered structure. 
 
The Gliogenic ‘Switch’ 
 
It is a general principle in the developing CNS that neurogenesis (the production of 
neurons from radial glia) precedes gliogenesis (the production of glia). A good example 
of this is the ventral half of the developing spinal cord. The VZ of the spinal cord (the 
region where progenitors reside) is divided into discrete domains by the expression of 
homeodomain transcription factors in the dorso-ventral axis. These domains are initially 
established by a concentration gradient of a morphogen secreted from the floorplate, 
Sonic Hedgehog (SHH), and then refined and reinforced by cross-inhibitory effects of the 
transcription factors induced by this morphogen (reviewed in Briscoe and Ericson, 2001). 
One of these domains, the pMN domain, produces first motoneurons, and then, at around 
E14.5, oligodendrocyte precursors (Sun et al., 1998, Lu et al., 2002, Takebayashi et al., 
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2002). Astrocytes arise from other parts of the spinal cord, but only after neurons have 
been produced from these domains (Pringle et al., 2003). The same principle holds true in 
the dorsal telencephalon, where the neurons of the cortical plate are formed initially, but 
thereafter, oligodendrocyte precursors are generated, as well as astrocytes (Kessaris et al., 
2008). 
 
Adult Neurogenesis 
 
Until very recently, it was believed that once the brain and spinal cord were formed in 
their entirety, no new neurons were born. Work over the last twenty years challenged this 
long-held belief, and an important part of this was the finding that neurospheres could be 
formed from various parts of the adult brain and spinal cord (Reynolds and Weiss, 1992). 
The neurosphere assay was in fact developed by these authors, and provides a means of 
retrospectively identifying neural stem cells, by demonstrating that cells are present 
within a cellular population that have the potential to undergo self-renewing divisions to 
generate spheres (in the presence of epidermal growth factor and also basic fibroblast 
growth factor in some protocols), and also to generate all the lineages of the CNS when 
growth factors are withdrawn. This is achieved by seeding plates of media with the cell 
population of interest at very low density and seeing if they give rise to spherical 
aggregates of cells (the ‘neurospheres’), and if these aggregates, once dissociated, will 
generate neurospheres themselves. These neurospheres can also be transferred to an 
artificial matrix, called Matrigel, and allowed to differentiate in media that lacks growth 
factors, before immunohistochemistry is used to determine what cell types are formed. 
The major criticism of this method of identifying neural stem cells is that it only 
demonstrates the potential of cells to proliferate and acquire multipotency, not necessarily 
that they had these properties in vivo (Pastrana et al., 2011). It is also possible that other 
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transit-amplifying cells, such as oligodendrocyte progenitors, might give rise to 
neurospheres, but these should not form neurons or astrocytes upon differentiation. 
 
Once it was accepted that neurogenesis did indeed occur within the adult brain, it was 
initially proposed that it might be the ependymal cells that line the ventricles that had the 
properties of neural stem cells (Johansson et al., 1999). However, it is now established 
that it is the subventricular zone GFAP+ cells, known as ‘Type B cells’ that possess these 
properties (Doetsch et al., 1999). These are very slowly dividing cells that give rise to 
transit-amplifying cells, known as ‘Type C cells’, which go on to form migratory 
neuroblasts called ‘Type A cells’. These Type A cells migrate along the walls of the 
lateral ventricles through tunnels formed by the processes of Type B cells, and eventually 
join the rostral migratory stream that leads to the olfactory bulbs, where they differentiate 
as interneurons (Pastrana et al., 2011). 
 
Sox9 and Sox Transcription Factors 
 
Sox9 is a member of the family of Sry-related box genes (or Sox genes), so-called because 
of the homology they share with the mammalian sex-determination gene, Sry, within their 
high mobility group (HMG) box. Around 20 Sox genes have been described to date in 
mammals, and these have been implicated in diverse processes within development. The 
common feature of the Sox genes is the presence of an HMG box, which is the domain in 
the proteins they encode that mediates DNA binding (reviewed in Wilson and Koopman, 
2002). The HMG box forms an L-shaped complex in the minor groove of DNA, and 
induces a significant bend in the helix (Ma et al., 1998b). All SOX proteins have been 
shown to recognise a common binding site (A/T A/T CAA A/T G), and must share at 
least 50% homology with SRY in their HMG box to be defined as a SOX protein (Denny 
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et al., 1992, Harley et al., 1994, Pevny and Lovell-Badge, 1997). SOX proteins (and 
genes) are further categorised on the basis of structural homology outside their HMG 
boxes, for example, the SOXE family, of which SOX9 is a member (along with SOX8 
and SOX10). All SOXE proteins have the same three functional domains, arranged in the 
same pattern within the protein. At their N-terminus, they have a dimerisation domain and 
contiguous HMG box, and toward the C-terminus, they have a transactivation domain. 
 
Multiple Developmental Roles of Sox9 
 
Sox9 is expressed strongly in a number of tissues during development, such as 
mesenchyme destined to become cartilage and bone, the gonads, and the CNS, as well as 
other sites such as the heart and gastrointestinal tract (Ng et al., 1997). During 
chondrogenesis, Sox9 is expressed in mesenchymal condensations prior to their 
differentiation as hyaline cartilage, and it is known to transactivate a number of genes 
essential for this process, such as Col2a1 (Bell et al., 1997). During gonadal development, 
expression of Sox9 begins at ~E10.5 in cells that have migrated from the coelomic 
epithelium, and which subsequently differentiate as Sertoli cells (Morais da Silva et al., 
1996, Sekido et al., 2004). These cells express SRY for a short period, during which Sox9 
is strongly up-regulated. Recent work has established that Sox9 is required for the 
maintenance of Sertoli cell identity, and this may be achieved by the synergistic action of 
SF1 and SOX9 on a region of the testis-specific regulatory element of Sox9 (Sekido and 
Lovell-Badge, 2008). In the CNS, Sox9 is expressed from E9.5 in the ventricular zone 
(VZ) of the developing spinal cord, and maintained in astrocytes and oligodendrocyte 
progenitor cells (OPCs) migrating out of the progenitor zone (Stolt et al., 2003). In the 
adult brain, SOX9 expression continues in the limited number of radial glia maintained 
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into adulthood, such as the Bergmann glia in the cerebellum (Pompolo and Harley, 2001), 
and also in the GFAP+ NSCs of the adult SVZ (Scott et al., 2010). 
 
Campomelic Dysplasia 
 
In humans, infants with CD display a variety of skeletal defects and male-to-female sex 
reversal, although some authors have also reported mild mental retardation in the few 
children with this condition who survive early childhood (Maroteaux et al., 1971). The 
condition was first described (as a distinct clinical entity) by Lee and colleagues in 1972, 
and subsequently found to be caused by deletions or mutations in or around the Sox9 gene 
(Foster et al., 1994, Wagner et al., 1994). The authors of the original paper describe three 
babies with severe skeletal deformities, all of whom failed to breathe spontaneously at 
birth, and died within the first few weeks of life. The skeletal deformities were wide, but 
the characteristic features were bowing of the long bones of the arms and legs, a small, 
bell-shaped thoracic cage and hypoplastic scapulae. In each case, radiographs showed 
poor bone mineralisation. The defects of chondrogenic tissue were not limited to the 
skeletal system, and affected the cartilaginous rings of the trachea, essential for its 
patency, which may have contributed to their respiratory distress at birth, and subsequent 
death. In addition to the defects of the tracheobronchial tree, all three children had severe 
cleft palates, which further complicated their breathing, and ‘peculiar facies’, the 
consistent features of which being hypertelorism of the eyes, a flat nose and low-set ears 
(both lacking normal cartilage structure), and a hypoplastic mandible. Interestingly, these 
babies had a number of neurological findings, including hypotonia (reduced muscle tone), 
and hyporeflexia (reduced tendon reflexes), which are usually associated with a defect of 
lower motoneurons, as opposed to the upper motoneurons that reside in the CNS. Bi and 
colleagues (2001) were the first to produce a null allele of Sox9, and found that in the 
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heterozygous state this mutation appeared to phenocopy CD in humans: The mice had 
bowing of the long bones, and these were of smaller than usual size. They also had cleft 
palates, and they died perinatally, as has been the case with CD neonates until recently. 
 
The Role of Sox9 in Gliogenesis 
 
Since the deletion of Sox9 in the germline results in embryonic lethality at E11.5 due to 
morphogenetic defects of the heart (Akiyama et al., 2004), Stolt and colleagues (2003) 
studied the effects of Sox9 deletion on the development of the CNS using the Cre/LoxP 
system, and discovered that their spinal cords were profoundly deficient in astrocytes and 
OPCs. They noted that the defect of oligodendrogenesis recovered at later stages of 
development whereas astrogliogenesis did not. Further to this, they describe a prolonged 
phase of motoneuron generation from the pMN domain of the spinal cord, which is also 
the site from which oligodendrocyte progenitors arise, and hence proposed that there was 
a delay in the progression from neuro- to gliogenesis. Recent evidence has shown that a 
key driver of the ‘gliogenic switch’, as it is called, is the up-regulation of Nfia by SOX9, 
and that a heterodimer formed from SOX9 and NFIA activates gliogenic gene targets, 
which are themselves capable of restoring gliogenesis in the absence of either factor 
(Kang et al., 2012). 
 
These observations raised a number of questions: Firstly, if Sox9 is crucial for the timely 
onset of gliogenesis in the spinal cord, why is it that Sox9 is expressed from the earliest 
point of neurogenesis (~E10.5)? Later we see a similar phenomenon in the dorsal 
telencephalon in my own analysis of the Sox9Flox/Flox;NesCre mutants (Chapter 3). Two 
potential solutions seem most prominent: Either SOX9 may ‘prime’ the progenitors of the 
CNS to respond to a gliogenic signal, such as ciliary neurotrophic factor (CNTF), or 
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alternatively, SOX9 might perform some other function within the VZ prior to 
gliogenesis, for instance in neurogenesis. 
 
Sox Genes and the Progenitor State 
 
A number of Sox genes have established roles in stem cell behaviour. The first and most 
notable example of this is Sox2, which is known to be required for the pluripotency of 
embryonic stem cells within the inner cell mass (Avilion et al., 2003). Also, in the neural 
crest, Sox10 has been shown to be required for maintaining both the neurogenic and 
gliogenic potential of neural crest stem cells (NCSCs; Kim et al., 2003). In this paper, the 
authors show that BMP2 and TGFβ, which normally extinguish glial or neuronal 
potential, respectively, when added to cultures of NCSCs are prevented from doing so by 
the over-expression of Sox10, and hence this factor is thought to maintain the 
multipotency of these cells. Within the neuroepithelium, Sox1-3 are thought to maintain 
progenitors in an undifferentiated state, and inhibition of these factors is sufficient to 
induce differentiation (Bylund et al., 2003). Sox1, 2 and 3, collectively referred to as the 
SoxB1 genes due to their considerable homology, are all expressed in progenitors, and 
over-expression of any one of them in the chick spinal cord severely disrupts 
neurogenesis. The authors of this study initially hypothesised that this was caused by an 
increase in the number of progenitors vs. differentiated progeny; however, markers of 
cycling cells were not up-regulated. Repression of SoxB1 targets using a construct in 
which Sox3 had been fused to an Engrailed domain led to cell cycle exit and up-
regulation of some neuronal markers, a phenotype that is reminiscent of the effect of 
Neurogenin2 (Ngn2) over-expression. This led the authors to speculate that Ngn2 brings 
about neuronal differentiation by inhibiting SoxB1 targets, and later experiments showed 
that Ngn2 was able to repress Sox3. The authors posited that repression of SoxB1 targets 
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was necessary for neuronal differentiation, and this claim was substantiated by the finding 
that co-electroporation with Sox3 inhibited the ability of Ngn2 to initiate neuronal 
differentiation. However, it is important to bear in mind that as with any experiment 
involving electroporation, both Sox3 and Ngn2 would have been introduced into cells that 
would not normally express them, and also that the level of this expression may far 
exceed that seen in normal physiology. 
 
The Role of SOX9 in Progenitor Identity 
 
Vidal and colleagues’ paper (2005) on the role of Sox9 in hair follicle development and 
postnatal function was one of the first to identify a central role for this transcription factor 
in the genesis or maintenance of a stem cell population. Hair follicles of the mouse pelage 
arise at E14.5 as a result of signalling from mesenchymal cells acting on overlying 
epidermal cells (reviewed in Fuchs et al., 2001), which induces thickening of the 
epidermal layer (a structure referred to as the hair placode). The cells of this placode then 
invade the mesenchyme, and invaginate a small group of mesenchymal cells near the 
basement membrane, forming the ‘hair bulb’. The epidermal cells between the hair bulb 
and the skin surface then differentiate into the inner and outer root sheaths of the hair 
(IRS and ORS, respectively) and, innermost within the follicle, the hair shaft itself. 
Matrix cells at the base of the hair serve as a reservoir of transient-amplifying cells that 
give rise to the new cells of the ever-elongating hair. For some time it has been known 
that stem cells originating in an out-pouching of the ORS, the bulge, migrate towards the 
bulb to replace matrix cells that have differentiated. Vidal and colleagues found that Sox9 
is expressed in the ORS and in the CD34-expressing stem cells of the bulge, and that loss 
of Sox9 through a skin-specific Cre led to transdifferentiation of the ORS towards a more 
epithelial character, and the complete loss of the bulge stem cells, resulting in alopecia in 
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adult mutants. They show, through elegant transplantation studies, that Sox9 is not 
necessary for the formation of the hair follicle, only for the formation of this specialised 
group of stem cells required for completion of the hair cycle. 
 
A similar observation was made in the context of the intestinal crypts (crypts of 
Leiberkühn), which are themselves stem cell niches (Blache et al., 2004). The villi that 
maximise the internal surface area of the small and large intestine are constantly subject 
to damage from movement of the bowel contents, resulting in the tips of the villi being 
sloughed off. New epithelial cells are continually generated from stem cells within the 
crypts (reviewed in Crosnier et al., 2006), and migrate up the walls of the intestinal villi 
to replace those epithelial cells being sloughed off at the tips. The fact that these stem 
cells are maintained in an undifferentiated state by Wnt signalling (van de Wetering et al., 
2002) suggested to Blache and colleagues that a Sox gene may be involved in this effect 
since a number of Sox genes contain TCF/LEF response elements (which mediate the 
activation of Wnt target genes) in upstream regulatory regions, and have also been 
implicated in maintaining progenitor identity (Avilion et al., 2003, Bylund et al., 2003, 
Kim et al., 2003). They found that Sox9 is robustly expressed in the proliferating cells of 
the crypt, presumed to be the stem cells, and regulated by the canonical Wnt pathway. 
Furthermore, the authors show that ectopic expression of Sox9 is capable of repressing 
two genes expressed in the differentiating progeny of the crypt stem cells. However, they 
do not provide direct evidence that Sox9 is required for the maintenance of stem cells in 
the crypts, such as loss of function data, and they concede that no intestinal defect has yet 
been described in the human condition associated with haploinsufficiency of SOX9, 
Campomelic Dysplasia (CD). 
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The same relationship of Sox9 expression to progenitor identity is observed in the 
pancreas, where its expression is restricted to the PDX1+ cells, found initially in the 
dorsal aspect of the forming gut and then maintained in a subset of cells in the pancreatic 
anlagen, that are known to generate all the cell lineages of the endo- and exocrine 
constituents of this organ (Seymour et al., 2007, Lynn et al., 2007, Gu et al., 2002). SOX9 
is excluded from differentiated cell types, such as glucagon-expressing cells (Lynn et al., 
2007), and its deletion using a Pdx1-Cre results in a severely hypoplastic pancreas 
(Seymour et al., 2007). Although in all cases, Sox9ΔPdx1/ΔPdx1 pancreases were small 
rudiments of the wild-type organs, the authors noted that there was considerable variation 
in their size. Further analysis using a Cre reporter (containing the lacZ gene) revealed that 
some cells were escaping Cre-mediated excision and those cells that made up the 
hypoplastic pancreases in these mutants were over-represented by β-gal-negative cells, 
i.e. those that had not undergone recombination, suggesting a high degree of selection for 
unrecombined cells. Moreover, organ size correlated with the frequency of non-
recombined cells in the Sox9ΔPdx1/ΔPdx1. These observations suggest that loss of Sox9 
precludes proper generation of the cell lineages of the pancreas from PDX1+ progenitors, 
emphasised by the clear selection for unrecombined cells where mosaicism exists. 
However, the authors of a subsequent paper (Lynn et al., 2007) found that Sox9 was also 
expressed in endocrine lineage transient-amplifying cells, not only the stem cells, and 
challenged its position as a gene that maintains the undifferentiated state of progenitors 
by showing that it transactivates a number of genes required for endocrine cell fate, 
pointing to a role in setting up further differentiation along this lineage. 
 
In the context of the developing CNS, Scott and colleagues (2010), whose work will be 
discussed in more detail in the next section, showed that the onset of neurosphere-forming 
ability, a retrospective means of identifying neural stem cells (NSCs), arises at the same 
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time as Sox9 expression, and that in the absence of Sox9, radically fewer neurospheres are 
formed. The authors also found that ectopic expression of Sox9 in neuroepithelial (NE) 
cells before the onset of neurosphere-forming ability gave rise to this property, suggesting 
that Sox9 was capable of inducing an NSC-like state from symmetrically-dividing, pre-
neurogenic NE cells. In the case of adult neurogenesis, deletion of Sox9 in the cells of the 
SVZ that contact the ventricular lumen using a Cre adenovirus and mice carrying a floxed 
allele of Sox9, revealed a loss of GFAP expression in the cells in which Sox9 was deleted, 
and a significant increase in cells carrying markers of migrating neuroblasts. This would 
appear to suggest that Type B cells of the SVZ niche have undergone differentiation as a 
result of Sox9 loss. However, the authors assert that the increase in neuroblast number 
reflects a failure of their final differentiation into interneurons. 
 
Sox9 has a similar ability to produce stem cell characteristics in cell types that do not 
normally possess them in the context of the adult mammary gland. In the context of this 
organ, Sox9, acting in concert with Slug, was found to facilitate the conversion of 
differentiated luminal epithelial cells of the mammary gland into mammary stem cells, 
capable of forming a complete ductal tree when transplanted back into mammary fat pads 
(referred to as 'organoids'; Guo et al., 2012). The authors of this paper found that Slug 
alone was able to convert ductal progenitors into organoid-forming cells, but was not 
capable of inducing organoid-forming ability in differentiated luminal cells. However, co-
transfection with Sox9 facilitated this conversion, suggesting that Sox9 is a key regulator 
of stem cell identity in this context. Furthermore, Slug and Sox9 are co-expressed in the 
putative stem cells of the adult mammary gland, and knockdown of both Slug and Sox9 
impairs their ability to form organoids in culture and also in gland reconstitution assays. 
Interestingly, only transient expression of Slug and Sox9 was required for conversion of 
differentiated luminal cells into mammary stem cells, and once expression of these genes 
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was silenced (by doxycycline withdrawal in a Tet-O system), the downstream gene 
regulatory changes were maintained. 
 
In summary, Sox9 has been shown to be necessary for the acquisition of a stem cell state 
in the development of the hair follicle and the pancreatic anlagen in vivo (Vidal et al., 
2005, Seymour et al., 2007), and the NSC populations of the developing CNS in vitro 
(Scott et al., 2010). Further to this, in the developing CNS and mammary gland, ectopic 
expression can induce stem cell properties in cells that would otherwise not exhibit these 
properties (Scott et al., 2010, Guo et al., 2012), emphasising an important role in stem cell 
identity. 
 
SOX9 and Neural Stem Cells 
 
As outlined in the previous section, work by Scott and colleagues (2010) has implicated 
SOX9 in the identity of NSCs. These authors first observed that SHH protein could 
transform non-neurosphere-forming, pre-neurogenic NE cells into cells capable of 
producing primary and secondary neurospheres. Treatment with recombinant SHH also 
conferred the ability to form all three lineages of the CNS in differentiation assays. 
Together these observations suggested that SHH could induce the two properties required 
by the definition of NSCs, namely self-renewal and multipotency. Using transcriptional 
profiling, the authors identified Sox9 as a potential target of SHH signalling that might 
mediate the ability of SHH to transform NE cells into an NSC-like state. Subsequently, 
they found that Sox9 expression coincided with the onset of neurosphere-forming ability 
in both the mouse and the chick, and that over-expression of this transcription factor had 
the same ability to transform NE cells. Experiments showing that a dominant negative 
Sox9 construct could ablate the transformative effects of SHH, and that expression of 
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Sox9 in the presence of an inhibitor of SHH signalling could recapitulate its effects, 
established the epistasis of a pathway in which SHH induces Sox9, thus bestowing the 
properties of NSCs. This raises a number of questions about the mechanism by which 
Sox9 is able to achieve this, such as what are its downstream targets in NE cells? This is 
an interesting question, but one that is not addressed in this thesis (attempts were made, 
but were frustrated by the difficulties of over-expressing Sox9 in very early NE cells). 
 
Having demonstrated through gain of function that Sox9 is sufficient for NSC identity in 
vitro, the authors use a germline Cre approach to delete Sox9 before it is expressed in the 
CNS. This strategy has the disadvantage that Sox9 is lost from all tissues of the 
developing embryo, and by the time the neuroepithelium was assessed (at E11.5), these 
embryos would already have developed severe defects of their hearts (Akiyama et al., 
2004). A significant reduction in neurosphere numbers is indeed seen, but this may be 
secondary to poor perfusion as a result of the cardiac abnormalities. In addition to the use 
of a germline Cre, a LoxP strategy involving the NesCre, intended to deleted Sox9 
specifically within NPCs, was used. Using this strategy, the authors again see a loss of 
neurosphere-forming ability, and surprisingly, loss not only of glial potential but also 
impaired ability to form neurons in neurosphere differentiation assays. This defect of 
neurogenesis was also seen in vivo in the developing Sox9Flox/Flox;NesCre embryos in 
Scott and colleagues’ analysis. This raised a new possibility that Sox9 might be important 
in some way for the generation of neurons from neural progenitors and prompted us to 
investigate this in the region of the developing brain that gives rise to the cortex (the 
dorsal telencephalon). Although an interesting finding, in my own analysis, I found no 
difference in the onset of neurogenesis between Sox9Flox/Flox;NesCre and wild-type 
embryos (Figure 3-8), and when I looked in some detail at the generation of the cortical 
layers using markers for each layer, I see no difference in the process of corticogenesis 
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(Figures 3–10 and 3–11). Two potential reasons for the differences between my findings 
and those of Scott and colleagues (with regards to impaired neurogenesis in 
Sox9Flox/Flox;NesCre embryos) have been raised; one is that there may have been some 
mistake in genotyping, although the phenotype that I do observe is seen consistently, and 
never in embryos genotyped as wild-type. Another is that the NesCre transgene may have 
become dysfunctional, as a result perhaps of mutations. However, immunohistochemistry 
(Figure 3-2), in situ (Figure 5-7), qPCR (Figure 5-2), RNA-Seq (Figure 4-3) and 
microarray data have confirmed loss of SOX9/Sox9 in the Sox9Flox/Flox;NesCre embryos 
analysed in this thesis. 
 
The impaired neurosphere-forming ability that Scott and colleagues observe persists 
throughout neurogenesis and is seen at the latest stages of embryogenesis. This suggests 
that whatever change in the cellular physiology of Sox9Flox/Flox;NesCre neural progenitors 
that results from loss of Sox9 is persistent in the NPCs at mid-neurogenesis and beyond. 
In Chapters 5-7 of this thesis, I use transcriptional profiling data obtained to investigate 
the impaired gliogenesis in Sox9Flox/Flox;NesCre embryos, to find potential Sox9 
downstream targets that might mediate this deficient ability to form neurospheres. 
Although this data came from dorsal telencephalons towards the end of embryogenesis 
(E16.5), it was still a time-point at which deficient neurosphere formation would have 
been seen. 
 
Aside from its role in the developing telencephalon, Scott and colleagues also 
investigated a role for Sox9 in the NSCs of the adult SVZ niche. In order to do this, they 
inject a Cre adenovirus into the lateral ventricles of Sox9Flox/Flox embryos, deleting Sox9 
from all cells that contact the ventricle (Type B cells as well as ependymal cells). The 
inclusion of a ROSA26 reporter transgene in their crosses permits the progeny of Sox9-
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deleted cells to be traced, and a dramatic increase in migratory neuroblasts is seen. They 
also find that these neuroblasts fail to form fully-differentiated interneurons in the 
olfactory bulbs, which is the final destination of neuroblasts migrating along the rostral 
migratory stream. These observations imply either that Sox9 loss induces the Type B cells 
(or ependymal cells) to undergo differentiation into neuroblasts, or as the authors suggest, 
that Sox9 loss has prevented the neuroblasts formed from Sox9-deleted NSCs from 
undergoing terminal differentiation into interneurons. 
 
Functional Redundancy within the SoxE Group 
 
One important observation that has to be borne in mind when attempting to tease out the 
function of individual Sox genes is the significant redundancy within the Sox family. As 
mentioned, virtually all SOX proteins have been shown to bind to the same sequence. The 
high degree of functional redundancy within the SOXE family is revealed by the fact that 
individual mutants often have a starkly less severe phenotype than double mutants. For 
instance, in developing OPCs, deletion of Sox9 following their initial specification 
produces no defect in oligodendrogenesis. Also, replacement of Sox10 with a lacZ 
cassette produces no phenotype in the oligodendrocyte lineage (even in the homozygous 
state) until terminal differentiation, which is deficient in these mutants. Compound 
deletion of both Sox9 (after OPC specification) and Sox10 results in widespread apoptosis 
within the oligodendrocyte lineage (Finzsch et al., 2008), demonstrating the ability of 
these two factors to compensate for each other during oligodendrocyte differentiation. 
The same phenomenon is seen in the developing testes. Sox9 is required for specification 
of the testes, and in its absence, XY sex-reversal is seen. Sox8 is not required for testis 
specification, but is required in Sertoli cells for the production of sperm from the 
seminiferous tubules. When Sox9 is selectively deleted in the Sertoli cells of Sox8-/- 
 
- 36 - 
mutant mice (after sex determination), failure of the seminiferous tubules is seen earlier 
than in Sertoli cells deleted for either factor individually, suggesting that Sox8 is able to 
compensate for Sox9 loss during testis maturation (Barrionuevo et al., 2009). However, it 
is clear that this functional ‘redundancy’ is not universal: Kellerer and colleagues (2006) 
replaced the open reading frame of Sox10 with that of Sox8 and found that although mice 
homozygous for this mutant allele showed rescue of some aspects of the Sox10-/- 
phenotype such as normal specification of glia and sensory neurons in the dorsal root 
ganglia, other aspects, such as loss of melanocytes showed no rescue. This demonstrates 
that the subtle differences between these two proteins, most likely outside their HMG 
boxes (since they bind the same sequence), are functionally important. 
 
SOX Proteins Tend to Bind DNA in Complexes 
 
A number of Sox genes are expressed in a variety of different tissues, and play diverse 
roles in development. Sox9 is a good example of this since it has been shown to have 
crucial roles in the development of a range of tissues. For this transcription factor to play 
a role in each of these settings, it must have a distinct set of target genes in each context. 
It is known that SOX proteins tend to bind DNA in partnership with other individual 
factors (Kamachi et al., 2001, Yuan et al., 1995), or even in larger complexes (Ma et al., 
2000, Lefebvre et al., 1998), and this provides a mechanism by which a single 
transcription factor can influence the expression of different sets of genes in different 
tissues, depending on the repertoire of partner proteins expressed. 
 
This synergism with other factors was elegantly demonstrated for SOX2 by the work of 
Kamachi and colleagues (2001), who showed that SOX2 and PAX6 stabilise each other’s 
binding to chromatin. They demonstrated this by showing, using chromatin-
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immunoprecipitation (ChIP), that both SOX2 and PAX6 bind an enhancer of the δ-
crystallin gene when they are expressed together, but when they are expressed 
individually, neither factor binds to this enhancer, showing the binding of one depends on 
the other. In a different transcriptional setting, the pre-implantation embryo, SOX2 has 
been shown to interact with a different partner (POU5F1, more commonly known as 
OCT4) in activating the transcription of Fgf4 (Yuan et al., 1995). In this case, the 
physical separation of the binding sites for these factors seems to be of critical 
importance. An increase from 3 to 6bp in their separation was sufficient to prevent 
transactivation (Ambrosetti et al., 1997). The authors show that this effect was not caused 
by the rotation of the factors relative to each other, since increasing the separation to 10bp 
(equivalent to one turn of the DNA helix) did not rescue the effect. Interestingly, SOX2 
would still bind if the spacing between the OCT4 and SOX2 binding sites were increased, 
but not OCT4, suggesting that SOX2 stabilises the binding of OCT4 to DNA. 
 
In addition to binding with individual partners, SOX proteins have also been shown to 
synergistically activate enhancers in concert with more than one other transcription factor, 
such as in the case of the activation of the Slit gene in the midline of the Drosophila CNS. 
Slit can be activated in vitro by the binding of a heterodimer of Single-minded (SIM) and 
Tango (TGO; both bHLH-PAS proteins). However, further factors are required for the 
strong Slit expression seen in the midline of the Drosophila brain. Ma and colleagues 
(2000) found that the SIM-TGO heterodimer associates with both a SOX protein, Fish-
hook (FISH), and a POU domain protein, Drifter (DFR), to initiate this level of 
expression. The authors also identified a number of other bHLH-PAS factors that 
associate with FISH, suggesting that this class of transcription factor might commonly 
form complexes with SOX proteins. A similar phenomenon has been observed for SOX9, 
which has been found to activate the transcription of Col2a1 in chondrogenic 
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mesenchymal condensations through synergism with two other SOX proteins, the long 
form of SOX5 (L-SOX5) and SOX6. In 10T1/2 cells, transfection with these three factors 
produces activation of a Col2a1 regulatory region that is many fold greater than that 
elicited by transfection with any of the factors individually (Lefebvre et al., 1998). 
 
Although generally regarded as transcriptional activators, a number of SOX proteins have 
also been shown to act as repressors in certain circumstances, such as SOX2, which aside 
from activating a number of downstream targets in germs cells and in the inner cell mass, 
can also prevent the transactivation of Osteopontin by OCT4 in these cell types (Botquin 
et al., 1998). Repressive interactions have also been described for other SOX proteins that 
are conventionally thought of as transcriptional activators, such as SOX6, which represses 
Fgf3 transcription by recruiting CtBP2 (Murakami et al., 2001). 
 
SOX Transcription Factors As Architectural Proteins 
 
The idea that SOX proteins might serve as ‘architectural’ factors that modify the 
secondary structure of DNA, rather than enhancing transcription directly, stems from 
studies of the specific mutations of SRY that lead to sex-reversal in humans. The authors 
of one particular study (Pontiggia et al., 1994) identified a mutation of SRY that causes 
sex-reversal by altering the angle of DNA-bend induced by SRY binding, without 
significantly affecting its affinity for its target sequence, suggesting that this angle is 
important for the function of SRY in testis specification. The theory that SRY merely 
affects the structure of chromatin, perhaps by bringing two factors on either side of its 
binding site into apposition, is consistent with the observation that only its HMG box is 
conserved in different vertebrate species (Tucker and Lundrigan, 1993, Whitfield et al., 
1993). However, many SOX proteins, including those of the SOXE subfamily, have 
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delineated transactivation domains, so are likely to interact with the basal transcriptional 
complex directly (Hosking et al., 1995, Sudbeck et al., 1996, van de Wetering et al., 
1993). Although this potential mechanism for SOX protein action is of historical interest 
in the development of our understanding of how SOX factors influence transcription, it is 
unlikely to be a major factor in the action of SOX9 due to its well-demarcated 
transactivation domain and also the fact that the mutations causing CD are distributed 
throughout the coding region of SOX9 (not just in the HMG box; reviewed in Pevny and 
Lovell-Badge, 1997). 
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Background and Aims of Thesis 
 
As I alluded to at the beginning of this Introduction, part of the initial impetus for this 
work came from studies carried out in the lab by Charlotte Scott (Scott et al., 2010). In 
this article, the authors show that the capacity of neuroepithelial (NE) cells to form 
neurospheres in culture, and to give rise to all the lineages of the mature CNS, which are 
the defining characteristics of NSCs, are ‘induced’ at a specific time-point in 
embryogenesis, which coincides with neurogenesis. This runs counter to the classical 
paradigm, which would be that from the induction of neural tissue onwards, 
developmental potential is progressively narrowed. Scott and colleagues (2010) note that 
Sonic Hedgehog (SHH) can prompt NE cells that lack the ability to form neurospheres 
(prior to neurogenesis; at E9.5) to become multipotent NSCs, and through transcriptional 
profiling techniques identified Sox9 as a potential mediator of this transformation. Sox9 
itself was found to induce NSC properties from E9.5 NE cells, and was shown to lie 
downstream of SHH. These data showed that Sox9 is necessary and sufficient for the 
induction of cells with NSC properties from NE cells. The authors then used the 
Cre/LoxP system to delete Sox9 from neural progenitors and found that these cells also 
had an impaired ability to form neurospheres throughout neurogenesis. Since the Cre acts 
after SOX9 is first expressed, and cells with NSC properties are first induced, this 
suggests that Sox9 is also required for the maintenance of NSC properties. The authors 
also observed that Sox9 deletion led to a thinned cortical wall, dilated ventricles and 
haemorrhage into the ventricles by the time of birth. The findings of this work prompted 
me to gain a fuller understanding of the phenotype of the Sox9Flox/Flox;NesCre, which 
appeared to have undergone defective neurogenesis, since the ventricular walls of these 
embryos were reported to be thinner, and their cortices disordered (Scott et al., 2010). 
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Therefore, the first results chapter in this thesis contains a phenotypic analysis of the 
development of the dorsal telencephalon in the Sox9Flox/Flox;NesCre embryo, including an 
analysis of the developing cortex, which should represent a sensitive assay of any change 
in the developmental potential of neurons born from Sox9-deficient radial glia. 
Surprisingly, the only abnormalities detected can be related to abnormal or delayed 
gliogenesis. I expected to see a phenotype involving neurogenesis, not only because it 
was reported in Scott et al., but also because Sox9 is expressed from the very earliest 
point of neurogenesis in both the spinal cord (Stolt et al., 2003) and the dorsal 
telencephalon (my own data). Earlier in this introduction, I set out two possible 
explanations for why Sox9 might be expressed in radial glia long before the onset of 
gliogenesis: The first possibility is that Sox9 might be performing a function unrelated to 
gliogenesis during this period, and perhaps has some role in endowing neurogenic radial 
glia with their full developmental potential, such as the ability to form all types of cortical 
neurons. The second possibility is that Sox9 may be involved in ‘priming’ the radial glia 
of the VZ to respond to a gliogenic signal, such as CNTF, a platelet-derived growth 
factor, or a vascular endothelial growth factor. The first explanation is made less likely by 
the result of our phenotypic analysis in Chapter 3 which reveals neurogenesis to be 
normal. In order to investigate the second possible explanation, I used transcriptional 
profiling techniques to determine if any receptor or component of a second messenger 
system that might transduce gliogenic signals were down-regulated in the 
Sox9Flox/Flox;NesCre. This work forms the second results chapter (Chapter 4). 
 
Since Scott and colleagues (2010) note that cells from the Sox9Flox/Flox;NesCre dorsal 
telencephalon exhibit poor neurosphere-forming ability throughout embryonic 
development (at both E14.5 and E18.5), I used the transcriptional profiling data, 
originally obtained to answer the gliogenesis question, to identify potential mediators of 
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the poor proliferation of Sox9Flox/Flox;NesCre NSCs. This forms Chapter 5, and 
interestingly, identifies a number of cell-surface receptors and a modulator of a cell-
surface channel. In order to establish if any of these targets might feasibly mediate the 
continued poor proliferation of Sox9Flox/Flox;NesCre NSCs in the neurosphere assay, I 
employed a number of agonists/antagonists to see if any could recapitulate this 
phenotype, and this work forms the last two results chapters (Chapters 6 and 7). 
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Chapter 2 Materials and Methods 
 
Deletion of Sox9 in the CNS 
 
The floxed Sox9 mice were originally derived by Akiyama and colleagues (2002), and the 
Nestin-Cre (NesCre) mice were produced by Tronche et al. (1999). In order to delete 
Sox9 selectively in the CNS, Sox9Fl/WT;NesCre mice were crossed with Sox9Fl/Fl mice, and 
the litters harvested at various stages of embryonic development. A quarter of the 
embryos resulting from these crosses are Sox9Fl/Fl;NesCre, and these are referred to as 
Sox9Δ/Δ in subsequent chapters. 
 
Genotyping 
 
The following protocol was used for genotyping: First, earpieces were taken, placed in an 
Eppendorf tube and submerged in 200μl of Tail Lysis Buffer (recipe below; 
supplemented with 20mg/ml proteinase K). These tubes were left in a waterbath at 55°C 
for >8 hours, and then 200μl of TE was added, followed by 400μl of 
Phenol/Chloroform/Isoamylalcohol (mixed in the ratio 25:24:1). The tubes were then 
agitated, and spun in a bench-top centrifuge for 2 mins; 1μl of the upper, aqueous phase 
was used in each PCR reaction. The following primers were used: GGC GGA TCC GAA 
AAG AAA A / CAG GGC GCG AGT TGA TAG C (NesCre); GTC TTT GGT CCA 
GGA / AGC TCG CTC TGT TGA TCC AT (floxed Sox9). The ‘floxed Sox9’ primers 
flank one of the LoxP sites in the floxed Sox9 allele, such that when it is present, a 375bp 
amplicon is generated, whereas in the wild-type allele, a 341bp amplicon is generated. 
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 Tail Lysis Buffer:- 
 For 500ml (ml) 
1M Tris-HCl pH8.5 50 
0.5M EDTA 5 
10% SDS 10 
4M NaCl 25 
H2O 410 
 
Histology 
 
Pregnant mice were killed by one of the methods included in Schedule One of the 
Animals (Scientific Procedures) Act 1986. The uterine horns were removed and placed in 
ice-cold PBS. Then, in a separate Petri dish containing ice-cold PBS, brains were 
dissected from the embryos and fixed in Bouin’s for 48 hours, then washed five times in 
70% EtOH (~30 mins per wash) before being passed to the Histology Section at N.I.M.R. 
for sectioning and staining with haematoxylin and eosin (H&E) or luxol fast blue. 
 
Immunohistochemistry 
 
Embryonic brains intended for use in immunohistochemistry (IHC) were dissected into 
PBS on ice, fixed for 1 hour in pre-chilled 4% paraformaldehyde (PFA) in PBS (on a 
rocking platform at 4°C), washed 3 × 10 mins in 0.1% Triton X-100 in PBS, then 
embedded in O.C.T. compound. Sections were then cut using a Leica cryostat, to a 
thickness of 12μm, before being dried at room temperature for >10 mins, and stored at -
20°C. The antibodies used are as follows: SOX9 (1:200; non-commercial, purified by 
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Silvana Guioli), GFAP (conjugated to Cy3; 1:200; Sigma, C9205); NeuN (1:200); PAX6 
(1:20; Abcam); TuJ1 (1:1000; Covance, MMS-435P); INSM1 (gift from John Jacob, 
Briscoe group); TBR1 (1:500, Abcam, ab31940); BRN2 (1:100; Santa Cruz, sc-6029); 
CTIP2 (1:500; Abcam, ab18465); PDGFRα (1:500; BD Biosciences, 558774); OLIG2 
(1:1000; Chemicon, AB9610). Once thawed, the sections were washed for 5 mins in PBS-
0.01% Triton X-100, and then blocked for >30 mins with PBS-10% Donkey Serum-0.1% 
Triton X-100. If the antigen in question was a membrane or cytosolic protein, Tween-20 
was substituted for Triton X-100 because it is a milder detergent. After blocking, the 
antibody was diluted as required in the blocking buffer and incubated overnight in a 
humidified chamber at 4°C. For unconjugated antibodies, the sections were washed the 
following day 3 × 10 mins with PBS-0.01% Triton X-100, then incubated for >30 mins 
with an appropriate secondary antibody (conjugated to a fluorophore) at room 
temperature. Finally, sections were washed 3 × 10 mins in PBS-0.01% Triton X-100 
supplemented with DAPI, mounted with Aqua-Poly/Mount (Polysciences) and 
coverslipped. Where conjugated antibodies were used, the sections were simply washed 
in PBS-0.01% Triton X-100 (+ DAPI; 3 × 10 mins), mounted and coverslipped. Images 
were taken with a Leica SP5 confocal microscope. 
 
In Situ Hybridisation 
 
With the exception of the in situ hybridisations in Chapter 3 and those for Rlbp1 and 
Hopx in Chapter 5, for which the sections were prepared in the same way as for IHC, 
specimens for in situ were fixed in modified Carnoy’s (60% EtOH, 11.1% formaldehyde, 
10% glacial acetic acid) overnight, then embedded in paraffin wax before being sectioned 
at a thickness of 5μm. In situ probes were made by PCR amplification of E16.5 whole 
telencephalon cDNA using primers specific to the gene of interest that were designed to 
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produce a single amplicon common to all known transcript variants (primers shown in 
Table 2.1). At the beginning of the reverse primer, the sequence of the T7 bacteriophage 
promoter was included so that the amplicon would contain this promoter and could be in 
vitro transcribed using the T7 RNA polymerase (Promega, P207B) in the presence of 
digoxigenin (DIG)-labelled dNTPs to give a DIG-labelled riboprobe. In situ hybridisation 
was then performed according to the modified Paris protocol (Etchevers et al., 2001), 
with the exception that proteinase K treatment of slides was omitted and 50% formamide-
1X SSC-0.1% Tween 20 used for post-hybridisation washes (the authors used the same 
recipe but with 2X SSC). 
 
Obtaining RNA from FAC Sorted Cells 
 
Crosses were set between Sox9Fl/Fl and Sox9Fl/WT;NesCre animals, and the litters harvested at 
E16.5. All embryos were liberated from extraembryonic tissues, the dorsal telencephalons 
dissected and each pair placed in a separate 15ml Falcon tube containing 900μl 0.1M 
Hepes (in PBS). These samples were then transferred to a tissue culture hood and 
triturated; first using a P1000, then by drawing up and down using a fine polished Pasteur 
pipette that had been drawn out over a flame to a very fine tip. The cell suspension was 
then filtered through a 40μm cell strainer (Invitrogen), pelleted and re-suspended in 900μl 
of Sort/Stain Buffer (PBS-5% foetal calf serum, containing penicillin and streptomycin). 
A CD133-PE conjugated antibody (eBioscience, 12-1331) was added to each of these cell 
suspensions (with the exception of a no antibody control) at a dilution of 1:100 and 
incubated for 20-30 mins (whilst protected from light). Finally, the samples were pelleted 
and re-suspended in fresh buffer twice to wash, then filtered into a FACS tube via a 40μm 
cell strainer. The suspensions were then taken to the FACS Facility at N.I.M.R. where 
they were sorted according to their fluorescence at 594nm. A gate was established to sort 
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the top quartile of 594nm-fluorescing cells from each sample. Once sorted, the CD133-
enriched samples were centrifuged and total RNA extracted from the pellets using an 
RNeasy Mini Kit Plus (Qiagen). This kit was used in place of the standard RNeasy Mini 
Kit because contamination with genomic DNA had been a problem in our early attempts 
to purify RNA from these samples because sheared genomic DNA would obscure the 18 
and 28S peaks of ribosomal RNA required for proper evaluation of RNA integrity. 
 
RNA-Seq 
 
cDNA libraries for sequencing were made in accordance with Illumina’s Sample 
Preparation Guide (Revision D), with the exception that poly-A selection and size-
selection of cDNA fragments were omitted. The latter, size-selection on a gel, was not 
performed because the SPRI beads, used later in the DSN normalisation protocol, have a 
preference for fragments in the 150-300bp range at the cation concentrations used. 
Library normalisation was performed as set out in the ‘DSN normalisation’ protocol 
(Illumina, Revision C). This involved suddenly denaturing the library at 95°C, and then 
allowing the single-stranded cDNA molecules to slowly re-anneal at 65°C. After 5 hours, 
a duplex-specific nuclease was added, and then the reaction stopped and the remaining 
intact cDNAs purified. The expectation was that during the 5 hours of re-annealing time, 
highly prevalent transcripts, such as ribosomal and mitochondrial RNA would easily find 
their complementary partners, whereas rarer mRNA molecules would be very unlikely to 
find theirs. When the duplex-specific nuclease was added, all the common transcripts 
would be degraded, leaving the rarer mRNAs for sequencing. Finally, the cDNA libraries 
were briefly amplified in a PCR reaction, and taken forward for cluster generation and 
sequencing by the High-Throughput Sequencing Facility at N.I.M.R. Sequencing was 
performed using an Illumina GenomeAnalyser IIx. The raw reads from the sequencing 
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runs (in FASTQ format) were aligned to the July 2007 (NCBI37/mm9) assembly of the 
mouse genome with CLC Genomics Workbench, then the number of reads mapping to 
each CDS (‘total exon reads’) were extracted and fed into the R/Bioconductor 
implementation of Anders and Huber’s method for calling differential expression in 
RNA-Seq data (Anders and Huber, 2010). 
 
Affymetrix Arrays 
 
Six Affymetrix GeneChip 430 2.0 arrays were used to analyse gene expression in three 
Sox9Δ/Δ and three Sox9Fl/Fl controls. The Sox9Δ/Δ embryos comprised two females and one 
male, and the controls for each of the Sox9Δ/Δ were littermates of the same sex. 
Normalisation was performed using the PLIER+16 algorithm in GeneSpring GX. Probe 
sets with low expression values (<20% of the maximal expression value) were filtered 
out, and differentially-expressed probe sets called using a combination of fold-change and 
the probability of an observed difference being due to chance (determined using Student’s 
t-test). 
 
Bioinformatics 
 
The GO term categorisation, GO term enrichment analyses and KEGG pathway analyses 
were performed using WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt/). The 
‘Placental Mammal Basewise Conservation’ data and the multiple alignment of the 
Kcnj10 and Dbi loci in various mammalian species were obtained from University of 
California’s Genome Bioinformatics website (http://genome.ucsc.edu/), and the locations 
of SOX9 binding sites were taken from the SOX9 ChIP dataset (made available to us by 
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the Guillemot group at N.I.M.R.). Consensus binding sites in the vicinity of SOX9 
binding sites were located using MatInspector (http://www.genomatix.de/). 
 
Quantitative PCR 
 
For the purposes of confirming the targets that were up- or down-regulated in both the 
RNA-Seq and microarray experiments, cDNA was reverse transcribed from total RNA 
samples prepared in exactly the same way as for the sequencing or hybridisation to the 
microarray chips, using Superscript III (Invitrogen) and oligo-dTs. qPCR was performed 
on an ABI 7500 instrument using ABsolute Blue qPCR Master Mixes (Thermo 
Scientific). The following PCR program was used:- 
 
95°C 15 mins  
95°C 15 secs 
60°C 30 secs 
72°C 30 secs 
 
40 cycles 
 
qPCR primers were designed using an implementation of the Primer3 algorithm on the 
NCBI website (Primer-BLAST; http://www.ncbi.nlm.nih.gov/tools/primer-blast/). A 
region of the gene in question common to all known transcript variants as close as 
possible to the 3’ end was selected (since this region is less likely to be affected by 
truncated reverse transcription). This region supplied to Primer-BLAST with all settings 
as default except an amplicon of 80-300bp was specified, and the program was set to look 
for primers separated by at least one intron. The primers used for qPCR are shown in 
Table 2.2. 
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Gene Symbol Forward Reverse (+T7) 
Rlbp1 AGGAGCAGGAGCTCCGAGCA GGTAATACGACTCACTATAGGGCCTGCTGCCTGCTGCATGGT 
Hopx CCGGAGGCAGCACTTGAGGC GGTAATACGACTCACTATAGGGCCTTCTGACCGCCGCCACTC 
Tnfrsf19 GACGGTGCTCTTCGCTGCCA GGTAATACGACTCACTATAGGGGCAGAGCTGCGGGCCTCTTC 
2810459M11Rik GGAGTGCTGGTGGCCGACAC GGTAATACGACTCACTATAGGGCTGGGTTGGCAGCCCTTCGG 
5830403L16Rik CAGCCAGAACCTGCTGCCCA GGTAATACGACTCACTATAGGGTGGTGGCGAACGCTACGTCG 
AI646023 TGCGCTGGCTGCGAGAGATC GGTAATACGACTCACTATAGGGGGTCCACCCAGGCCAACACG 
Arhgef3 TTCCCCGGAGCCGGCTAGTG GGTAATACGACTCACTATAGGGGCAGTCCGACTCGCTGTCCG 
Dbi CACTTCAAACAAGCTACTGTGGGCG GGTAATACGACTCACTATAGGGTCATGGCACTTTCCTTGGAAGTCCC 
Hs3st1 AACGCCTGCCTGCAAGGTCC GGTAATACGACTCACTATAGGGCAGCACGCGCTCTGATGGGT 
Kcnj10 CCCGCTGCCCCGCGATTTAT GGTAATACGACTCACTATAGGGGGCATGCTGGCTGAAGCGGA 
Mmd2 CGGGATTTGCGATCCGGGAGAC GGTAATACGACTCACTATAGGGAGGCAGTAGAAAGCCCCTCCTGT 
Plce1 TGGTGTCCCAGGTCCAGAGCC GGTAATACGACTCACTATAGGGTCCCGCACCCTTCCACTTGC 
Col2a1 TCCCCGTGGACGCTCAGGAG GGTAATACGACTCACTATAGGGAACCTGCTGTTGCCCTCGGC 
Pdgfra GAGTGACCATCCGGCCGTGG GGTAATACGACTCACTATAGGGGCGCGTGTGGGACTCTCACC 
Table 2-1 PCR primers used to make DNA templates for in vitro transcription into DIG-labelled riboprobes for in situ hybridisation. 
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Reverse Transcription (RT)-PCR 
 
In order to determine if expression of the candidate genes identified in Chapter 5 is 
maintained in neurosphere cultures, RNA was extracted from neurospheres derived from 
E14.5 dorsal telencephalon cells, grown in Neural Proliferation Media (NPM; see 
Neurosphere assay) for 7 days, with the media changed every 2-3 days, and intact E14.5 
dorsal telencephalons. TRIzol LS (Invitrogen) was used to extract RNA from pelleted 
neurosphere cultures and an RNeasy Mini kit (Qiagen) for the intact dorsal 
telencephalons (after homogenisation using a Rotor-Stator). cDNA was made from this 
RNA using Superscript III (Invitrogen), and PCR performed using the same primers used 
to amplify those genes by qPCR (Table 2.2; PCR program below). 
 
95°C 5 mins  
95°C 1 min 
60°C 1 min 
72°C 1 min 
 
35 cycles 
72°C 5 mins  
4°C Forever  
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Gene Symbol Forward Reverse 
Rlbp1 TGGGAAACGGTGGGCCTGAGA GAAAGTGCCCACCCCGTCTGA 
Mmd2 TGATGGAACCGCGGCGATGT TACCTCTTGTGCGCCGGGACT 
Tesc GGGACCAGCCCACCATTCGC TCGCCCAGGGTGGTGTCGAT 
Kcnj10 TCCCGCTGCCCCGCGATTTA TGCTCCGGCCGTCTTTCGTG 
Dbi GCGCTTTCGGCATCCGTATCAC CCCACTTGGCTTTGCCCTTGAGG 
Arhgef3 CGCGGGGCCTTCAGCAACAA CGGGACCCTGGACCAGTCCC 
AI646023 ACCACCTCACTCCGCACTCC GAGGCTGGGCAGCAGCAGAT 
Heph GCCTGCCTGGTTGGGCTTCC TGGGTCTGCCTCAGTGGGGG 
Pdpn GCGTGGGACGAAGCCTCCCT TCCCTCCGACGAAGCCAATGG 
Pla2g16 CGTGATCCACCTGGCTCCTCCA GTCCTTCCCGGCCACATGGC 
Rab40b TCTCCTTACGGCCACCCGGC TGCCAGGTGCAGCCGATTTCC 
Tnfrsf19 GACGGTGCTCTTCGCTGCCA TTCCTTGAACCGGTGCGGCC 
Hopx GAGGCGGGTCTCACGGAGGA GGCAAGCCTTCTGACCGCCG 
Plce1 TGGCTGTATTGGGCCAGCTGC TCCCCTCTTCTCACGGCACTGT 
Tbp ACCACTGCACCGTTGCCAGG ACGCAGTTGTCCGTGGCTCT 
Hs3st1 CGCCTGCCTGCAAGGTCCTC GCCACACGCGCCTGGATCAT 
Col2a1 GGAGACCGGCGAGACTTGCG TTGCCAGCCGCTTCGTCCAG 
Pdgfra TGGTCCTCAGCTGTCTCCTCACAG GGCTGCGGAGGCGTTAACCAC 
2810459M11Rik GGGTCCTCGGAGGCAGAGGAA CAGTCTCCAGTGGGGAATACAGGT 
Table 2-2 qPCR primers. 
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Neurosphere Assay 
 
Neurosphere cultures were prepared using dorsal telencephalons dissected from E14.5 
wild-type MF1 embryos using a method modified from that originally described by 
Reynolds and Weiss (1992). The dorsal half of each telencephalic vesicle was dissected in 
ice-cold PBS, then mechanically dissociated by three periods of pipetting with a P1000 
(15-20 times), interspersed by 3-5 mins of incubation at room temperature. The resulting 
cell suspension was then filtered through a 40μm filter, and cells seeded to 6cm dishes 
containing Neural Proliferation Media (NPM; recipe below) that had been pre-warmed in 
a 5% CO2 incubator at 37°C (at a density of 5 × 104 cells/ml). Pharmacological agents 
were then added to the dishes at a range of concentrations (usually two log-dilutions 
either side of the range in which their IC50/EC50 lay). All compounds used in functional 
studies (BaCl2, fluoxetine, muscimol, SR95531 and bicuculline) were purchased from 
Sigma-Aldrich. The effect of these agents on proliferation in the context of the 
neurosphere assay was then determined by counting all neurospheres in each dish 
>300μm in diameter 6-9 days after plating. 
 
In order to determine if any of these agents affected the differentiative capacity of NPCs, 
neurospheres were grown in NPM for 7 days and then distributed amongst the wells of a 
chamber slide (~5/well) that had been pre-coated in Matrigel (BD Biosciences) and 
containing 0.5ml/well of Neural Differentiation Media (NDM; recipe below). Different 
agents were then added to the wells and the neurospheres allowed to differentiate 
(changing the media every other day). After 4 days, the cells that had differentiated and 
migrated onto the surface of the slide were fixed and stained for markers of neurons, 
astrocytes and oligodendrocytes.  
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Neural Proliferation Media (NPM):- 
 For 100ml (ml) 
DMEM/F-12 (-L Glut) 93.5 
40% glucose in DPBS 1.5 
Pen/Strep 1 
L-Glut 1 
The above should be filtered through a 40μm filter unit, then the following added:- 
N2 1ml 
B27 2ml 
bFGF (1μg/μl) 2μl 
EGF (1μg/μl) 2μl 
 
Neural Differentiation Media (NDM):- 
 For 100ml (ml) 
DMEM/F-12 (–L Glut) 93.5 
40% glucose in DPBS 1.5 
Pen/Strep 1 
L-Glut 1 
The above should be filtered through a 40μm filter unit, then the following added:- 
N2 1ml 
B27 2ml 
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Chapter 3 The Role of Sox9 in the In Vivo 
Development of the Forebrain 
 
In light of the findings of Scott and colleagues (2010) that Sox9 is required for the 
induction of NSC-like cells from the neuroepithelium at the onset of neurogenesis, I 
performed a phenotypic analysis of the Sox9Flox/Flox;NesCre dorsal telencephalon, which 
will now be referred to as Sox9Δ/Δ for simplicity. Since the Cre acts shortly after Sox9 
expression initially arises in the CNS, the cells of the neuroepithelium may have already 
been exposed to SOX9. However, two findings in Scott and colleagues’ paper point to a 
role of SOX9 in maintaining NSCs; firstly, Sox9Δ/Δ dorsal telencephalon cells form 
radically fewer neurospheres in culture, even at mid-neurogenesis (E14.5), and secondly, 
the authors report that Sox9Δ/Δ embryos die at around the time of birth, exhibiting dilated 
ventricles into which haemorrhage is occasionally seen. Of particular interest in this 
phenotypic analysis is the process of corticogenesis, in which cortical progenitors 
sequentially generate neurons with different properties, a feature that is at least in part 
intrinsically regulated (Shen et al., 2006). Any perturbation of neural progenitor 
behaviour, such as premature differentiation, or reduced potential, might result in a 
disordered cortex, which could inform our understanding of the defect within those 
progenitors. As the full knockout of Sox9 leads to death at around E11.5 from defects of 
heart morphogenesis (Akiyama et al., 2004), I employed the same strategy used by Stolt 
et al. (2003) and Scott et al. (2010), namely the Nestin Cre (NesCre) and a floxed allele of 
Sox9. The NesCre involves a Cre transgene driven by a Nestin promoter and enhancer 
that produces specific expression in the progenitors of the CNS (Tronche et al., 1999), 
and the floxed Sox9 mice carry an allele of Sox9 in which the latter two exons of the gene 
are flanked by LoxP sites (Akiyama et al., 2002; Figure 3-1). Although previous 
investigators have addressed the role of Sox9 in the spinal cord (Stolt et al., 2003), to our 
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knowledge no-one has examined it in the brain, where it is expressed most strongly 
within the VZ of the dorsal telencephalon. 
 
 
Figure 3-1 Diagram depicting strategy used to delete Sox9 specifically within the CNS. 
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Introduction 
 
Formation of the Embryonic Brain 
 
The embryonic brain begins as a flat sheet of neuroepithelial cells specified from dorsal 
ectoderm, which folds to form a neural tube and, at its anterior end, forms three ‘bulges’ 
that give rise to the major subdivisions of the CNS: The prosencephalon, mesencephalon 
and rombencephalon. The prosencephalon then dilates either side of the midline, giving 
rise to two telencephalic vesicles. From very early in the development of the brain, there 
is a clear functional distinction between the dorsal and ventral halves of the 
telencephalon: the dorsal half generates a variety of projection neurons that eventually 
form the cortex, and the ventral half gives rise to the striatum and pallidum, which are 
dominated by a different class of neuron, the medium spiny neuron (Kemp and Powell, 
1971). 
 
Progenitors in the Developing CNS 
 
The adult brain is composed of three main lineages of cell: Neurons, astrocytes and 
oligodendrocytes. In the course of embryonic and early post-natal development, these cell 
types are generated from a progenitor zone, which is initially the region lining the 
ventricles, but at later stages, also comprises a second layer of progenitors, known as the 
subventricular zone (or SVZ). The primary progenitors of the CNS, radial glial cells, were 
first described by Ramón y Cajal at the end of the 19th century (Ramon y Cajal, 1881). 
These cells extend one process to the adjacent ventricular (apical) surface and another to 
the far-off pial (basal) surface. For many years, until Misson and colleagues showed in 
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the late 80s (Misson et al., 1988) that radial glia are actively dividing cells, radial glia 
were thought to be merely a scaffold for the radial migration of new neurons. The ability 
of radial glia to generate neurons was first demonstrated by Noctor (2001) using a 
retrovirus to trace the immediate progeny of radial glia. However, the position of radial 
glia as the sole primary progenitor of the mammalian CNS was put beyond doubt by 
Cre/LoxP lineage tracing. First, Malatesta and colleagues (2003) found, using hGFAP-
Cre and a reporter construct activated by the excision of a floxed stop codon, that all the 
projection neurons of the dorsal telencephalon were derived from radial glia, but not the 
interneurons of the ventral telencephalon. Under this system, all the progeny of a cell in 
which Cre has acted will express the reporter. However, the lack of staining of 
interneurons was later found to be caused by the hGFAP promoter not being active in the 
rodent ventral telencephalon. When these experiments were repeated with a Blbp-Cre, all 
the cells of the postnatal brain were found to have derived, directly or indirectly, from 
radial glia (Anthony et al., 2004). 
 
During the expansion of the neuroepithelium that precedes neurogenesis, the 
neuroepithelial cells divide symmetrically to increase their numbers as the surface area of 
the telencephalic vesicles increases. However, at around mid-gestation, these progenitors 
switch to asymmetrical division, generating a new neuron with each turn of the cell cycle 
(Chenn and McConnell, 1995). This mechanism of neurogenesis is phylogenetically very 
old, and is the sole mechanism of corticoneurogenesis in reptiles and birds (reviewed in 
Abdel-Mannan et al., 2008). Concurrent in evolutionary terms with the development of 
the more complex, six-layered structure of the mammalian cortex, is the generation of 
intermediate progenitors. Once generated from radial glia, these progenitors immediately 
translocate to a region above the VZ, which becomes known as the SVZ (Miyata et al., 
2004, Noctor et al., 2004). Intermediate progenitor cells (IPCs) usually divide only once, 
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giving rise to two neurons, although there have been reports of some dividing up to four 
times. Once formed, new neurons, regardless of which cell type they were generated 
from, migrate along the processes of radial glia to form, or elaborate, the structure of the 
cortical plate (CP; Levitt and Rakic, 1980). 
 
Corticogenesis 
 
The adult mammalian cortex is a complex laminated structure, in which neurons residing 
in each layer share hodological and morphological properties, as well as characteristic 
gene expression profiles. Neurons destined to form a particular layer are born in the VZ at 
the same time in a distinct ‘wave’ of neurogenesis (reviewed in Molyneaux et al., 2007). 
The first neurons to be formed from these progenitors arise at ~E11.5 and migrate radial 
out of the VZ to form a layer superficial to it, termed the ‘preplate’. A later wave of 
neurogenesis gives rise to neurons that migrate to form a layer that splits the preplate, 
forming the first layer of the CP, and dividing the preplate into a superficial layer (the 
marginal zone) and a deep layer (the subplate). Subsequent waves of neurogenesis, 
produce ever more superficial layers of the CP. In this way, every new batch of neurons is 
required to migrate through an existing layer, leading some to describe the CP as being 
formed in an ‘inside-out’ fashion. The final wave of corticogenesis occurs at ~E15.5, and 
gives rise to neurons that will eventually form layers II-IV. 
 
Interestingly, the transcription factor profile of new neurons formed at different stages of 
neurogenesis is different. For instance, early-born neurons (formed between E12.5 and 
E13.5), which are destined to become layer V and VI neurons, express the transcription 
factor Otx1 from the very point of their birth in the VZ (Inoue et al., 2004), whereas later-
born neurons destined for layers II-IV express Brn2 from the point of their formation and 
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continue to express it after reaching their destination in the CP. The sequential expression 
of transcription factors typical of different layers of the CP can be recapitulated in vitro 
(Shen et al., 2006), suggesting that individual cells advance through the program of 
neurogenesis in a cell-autonomous fashion. However, another series of experiments 
suggested that extrinsic signalling molecules also have a crucial role to play. As described 
above, progenitors in the VZ generate deep neurons first, then more superficial layers. 
McConnell and colleagues (1991) found that progenitors isolated at the beginning of 
neurogenesis, which would normally give rise to layers V and VI, when transplanted into 
brains at later stages of development, produce more superficial (layer II-IV) neurons. This 
shows that cell extrinsic factors are also capable of influencing the outcome of neurogenic 
divisions, although interestingly McConnell and colleagues showed that this effect is only 
seen if the progenitors go through their final mitosis in the new environment. 
 
Interneurons 
 
Aside from cortical projection neurons, another neuronal subtype, interneurons, are 
essential for the proper functioning of the mature cortex. They are characterised by short, 
spiny axons, which project locally. Stimulation of these neurons exerts an inhibitory 
effect on the neurons they synapse with, through the release of γ-aminobutyric acid 
(GABA). Other neurotransmitters employed by interneurons include acetylcholine, 
calretinin, parvalbumin, somatostatin, neuropeptide Y and nitric oxide (Marin et al., 
2000). 
 
During development, interneurons are generated from progenitors in the lateral and 
medial ganglionic eminences (Anderson et al., 1997, Lavdas et al., 1999), and migrate 
tangentially into the cortex. Using transplantation techniques, Wichterle and colleagues 
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(2001) found that interneurons generated from the LGE tended to migrate anteriorly to 
populate the striatum, whereas those from the MGE migrate tangentially into the dorsal 
telencephalon to populate the cortex. In Nkx2.1-/- mice, which lack an MGE, ~50% fewer 
interneurons are seen in the cortex after birth (Sussel et al., 1999), strengthening the 
conclusion that the MGE is the dominant contributor to the cortical interneuron 
population. Interneurons are a highly heterogeneous population, with most (if not all) 
secreting other neurotransmitters in addition to GABA. An example of this would be two 
non-overlapping groups of GABAergic neurons in the cortex, which are characterised by 
expression of either parvalbumin or somatostatin, together with the GABA-synthesising 
enzyme, GAD67 (Kubota et al., 1994). Attempts to locate the origins of different 
subtypes of interneurons have been frustrated by the fact that these cells take many weeks 
of postnatal development to mature and begin to express the neurotransmitters that define 
their identity. 
 
Oligodendrogenesis 
 
Oligodendrocytes are the myelin-forming cells of the CNS, and their role is to insulate 
axons, allowing fast salutatory conduction. Because of their ubiquity in the adult CNS, 
oligodendrocytes were originally thought to be produced from all regions of the VZ. 
However, it is now known that they are formed at specific locations. Within the spinal 
cord, the first region to be identified as being important for oligodendrogenesis was the 
pMN region of the ventral spinal cord, which also generates motor neurons. The pMN 
origin of oligodendrocytes is supported by three lines of evidence: First, in mice 
expressing a hypomorphic allele of Pax6, in which the pMN region is shifted dorsally, the 
region of OPC production is also shifted dorsally (Sun et al., 1998); secondly, genetic 
ablation of Olig2, a bHLH transcription factor expressed in the pMN region, results in the 
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loss of both motor neurons and oligodendrocytes (Lu et al., 2002, Takebayashi et al., 
2002) and finally, Cre/LoxP fate mapping shows that Olig2+ progenitors give rise to both 
these cell types (Lu et al., 2002). However, analysis of a mutant in which the pMN region 
is absent (Nkx6.1-/-Nkx6.2-/-) revealed that oligodendrocytes are still formed (Cai et al., 
2005, Vallstedt et al., 2005), suggesting that other regions within the developing spinal 
cord are capable of generating these cells. Later, Cre/LoxP fate mapping revealed that a 
region dorsal to the pMN zone also produced oligodendrocytes, although at a slightly 
later time-point (E15.5 vs. E13.5; Fogarty et al., 2005, Kessaris et al., 2008). This ventral-
to-dorsal progression of oligodendrogenesis is mirrored in the embryonic brain, with the 
first OPCs being formed from the MGE and anterior entopeduncular area (AEP) at 
~E11.5 (Kessaris et al., 2006). Later, another wave of oligodendrogenesis occurs in the 
LGEs and caudal ganglionic eminences (CGEs; Kessaris et al., 2006). Then, at around the 
time of birth a final cohort of OPCs are generated from the progenitors of the dorsal 
telencephalon (Kessaris et al., 2006). 
 
Unlike neurons, which undergo their terminal division as they are generated in the VZ, 
oligodendrocytes begin life as migratory precursors, that continue to mature as they move 
toward their final destinations in the brain. Oligodendrocyte precursors were first 
identified by Martin Raff in the early 1980s (Raff et al., 1983), when he described cells 
isolated from the rat optic nerve that, depending on the culture conditions, could 
differentiate into either oligodendrocytes or a certain type of astrocyte (type-2 astrocytes). 
This property led to them being named ‘oligodendrocyte-type-2 astrocyte’ (O-2A) 
precursors. However, cells with the antigenic profile of these precursors were never found 
in vivo (Kessaris et al., 2008). In fact, differentiation into any identifiable type of 
astrocyte has not been consistently observed, so it may be that these cells are in reality, 
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oligodendrocyte progenitors, which under ‘extra-physiological’ conditions can be 
transformed into astrocytes. 
 
Clearly, Sonic hedgehog (SHH) is important for oligodendrogenesis in certain contexts. 
SHH signalling is required for the establishment of the pMN zone (Briscoe et al., 2000), 
and embryos lacking Shh do not produce oligodendrocytes from this region of the ventral 
spinal cord (Cai et al., 2005). Furthermore, the expression of Olig1 and 2 can be induced 
by SHH in vitro (Lu et al., 2000). However, other authors have also demonstrated SHH-
independent routes for oligodendrocyte production (Cai et al., 2005, Chandran et al., 
2003). Conversely, BMPs probably have a inhibitory effect on the production of OPCs. 
This finding stems from the observation in the chick neural tube that over-expression of 
BMPs ablates oligodendrogenesis, whereas Noggin, an inhibitor of BMP signalling, 
enhances it (Mekki-Dauriac et al., 2002). Finally, within the pMN domain, Notch 
signalling is also clearly important: Disruption of Notch signalling gives rise to an excess 
of motoneurons, at the expense of OPCs, whereas ectopic expression of a constitutively 
active form of the Notch receptor leads to the opposite, more OPCs at the expense of 
motoneurons (Appel et al., 2001, Park and Appel, 2003). 
 
Olig2 is probably the most important cell-intrinsic determinant of oligodendrocyte fate, 
since no oligodendrocytes are formed in the spinal cords of Olig2-/- mice (Lu et al., 2002, 
Takebayashi et al., 2002). However, oligodendrocytes are generated in the hind- and 
forebrain, indicating functional compensation from Olig1 in this setting. By contrast, loss 
of Olig1, which is expressed in an identical pattern in the ventral spinal cord, has no 
effect on OPC number, only a slight slowing of OPC maturation (Lu et al., 2002). 
Although recent evidence contradicted this finding, with another research group finding 
that maturation of oligodendrocytes in Olig1-/- mice was severely affected, leading to 
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death in the third postnatal week (Xin et al., 2005). Further to this, absence of Olig1 
prevents re-myelination following experimental ablation of myelin (Arnett et al., 2004), 
reinforcing its importance in mature oligodendrocytes. In the forebrain, loss of Mash1 
depletes the OPCs generated from the ventral telencephalon (Parras et al., 2007). In the 
spinal cord, SoxE genes have also been shown to be important in the oligodendrocyte 
lineage. Loss of Sox9 results in an initial depletion, and then a resurgence of OPC 
numbers (Stolt et al., 2003), and compound loss of Sox9 and Sox8 eliminates all OPCs 
from the spinal cord (Stolt et al., 2005). OPCs are formed in Sox10-/- embryos, but they 
fail to mature (Stolt et al., 2002). 
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Results 
 
In order to further our understanding of the role of Sox9 in the developing telencephalon, 
mice carrying a floxed allele of Sox9 (Akiyama et al., 2002) were crossed with a line 
carrying a Cre transgene, driven by the Nestin promoter and a neural-specific enhancer 
(Tronche et al., 1999), to delete Sox9 specifically in the CNS from ~E10.5. The deletion 
of Sox9 was verified by IHC, and the results are shown in Figure 3-2. 
 
 
Figure 3-2 SOX9 immunostaining on Sox9F/F and Sox9F/F;NesCre embryonic brains. 
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Survival of Sox9Δ/Δ Pups 
 
Among litters harvested at P2, 15.9% were found to be Sox9Δ/Δ, compared to the expected 
proportion of 25% (Figure 3-3; p=0.28, N=44). However, at the time of weaning (at ~4 
weeks of age), only 3% of animals were Sox9Δ/Δ, which is very different to the expect 
proportion and highly statistically significant (p<0.0001, N=101). These data suggest that 
the Sox9Δ/Δ pups are dying at some point between P2 and weaning, although a small 
proportion of animals (~12%; 3 vs. the expected number of 25.25), do survive to weaning 
and beyond. The surviving adults lack a corpus callosum (Figure 3-4), suggesting that this 
is not the reason for the inviability of the majority of Sox9Δ/Δ pups. The fact that some 
Sox9Δ/Δ mice survived into adulthood was surprising since two previous papers that 
employed the same strategy to delete Sox9 found that these mice are not viable (Stolt et 
al., 2003, Scott et al., 2010). However, the fact that surviving adults show agenesis of the 
corpus callosum, a phenotype seen in all of the Sox9Δ/Δ embryos and none of the 
heterozygotes serves as evidence that these mice are not mis-genotyped. The genotypes of 
Sox9Δ/Δ adults were also confirmed prior to sectioning for histology. 
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 Figure 3-3 Survival of Sox9Δ/Δ pups at P2 and at weaning (~4 weeks of age). 
 
Figure 3-4 Luxol fast blue staining of the brain of a surviving Sox9Δ/Δ adult and a wild-type 
littermate (P63).  
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SOX9 Expression in the Forebrain 
 
In the wild-type situation, SOX9 is expressed in the VZ at all stages examined (Figure 
3-5). At E12.5, there are some scattered cells expressing SOX9 in the parenchyma of the 
MGE, and some are also seen in the LGE at E14.5; in both cases these cells are likely to 
be OPCs. At E18.5, the VZ is considerably thinner, and there are many SOX9+ cells, 
which are presumably migrating away from their site of generation in the VZ. These are 
likely to be OPCs, but may also be astrocytes. 
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Figure 3-5 SOX9 expression (by immunohistochemistry) at E12.5, E14.5 and E18.5. 
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Embryonic Analysis 
 
In order to ascertain if there were any gross abnormalities in the anatomy of Sox9Δ/Δ 
brains, E18.5 Sox9Δ/Δ brains were sectioned and stained using hematoxylin and eosin 
(H&E). Upon examination of these sections, the corpus callosum was noted to be absent, 
as was the hippocampal commissure, whereas the anterior commissure was unaffected 
(Figure 3-6). This exact pattern of agenesis of the corpus callosum (known as ACC) and 
absence of the hippocampal commissure was seen in all 5 Sox9Δ/Δ brains examined, and 
although commissural tracts were only examined specifically in 5 cases, I have not 
encountered a Sox9Δ/Δ brain in which either of these tracts are present. Instead of 
projecting into the contralateral hemisphere, callosal axons form ‘bundles of Probst’ 
either side of the midline. These were originally described as involving axons curling 
back on themselves, forming “whorls”, instead of crossing the midline (Probst, 1901); 
however, it is now known that they in fact turn left or right, in a rostral or caudal direction 
(Lee et al., 2004). One of three heterozygous brains also showed this phenotype, 
suggesting that this aspect of the phenotype has variable penetrance in the heterozygous 
situation. Loss of commissural tracts was never observed in any wild-type embryo. In 
addition to abnormalities of commissural tracts, in one of the 5 Sox9Δ/Δ brains sectioned, 
the lateral and third ventricles were dilated and filled with blood. 
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 Figure 3-6 A. H&E-stained sections of the anterior cortex of E18.5 embryos. CC = corpus 
callosum;  AC = anterior commissure; HC = hippocampal commissure; BoP = bundle of Probst. 
B. Number of times a given commissure is present in a given number of brains of each genotype. 
 
In light of the fact that Sox9 has been previously reported to be essential for the formation 
of glia in the CNS (Stolt et al., 2003), and the finding of ACC, I examined the formation 
of the midline glial populations, and the ‘glia sling’ in the Sox9Δ/Δ, which are midline 
features of the developing brain that have been shown to be essential for the formation of 
the corpus callosum (Smith et al., 2006). Using an antibody against GFAP to identify the 
glial populations, it was found that in the wild-type, both the indusium griseum and the 
midline zipper glia have formed by E18.5 (Figure 3-7). In the Sox9Δ/Δ, neither of these 
populations form and instead GFAP+ cells are dispersed within the bundles of Probst. In 
addition to Sox9Δ/Δ brains lacking midline glial populations, they also lack the ‘glial sling’ 
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(Figure 3-7B), which is actually composed of neurons (Shu et al., 2003a) that migrate 
concurrently with the pioneer axons of the corpus callosum. Due to its neuronal identity, 
this structure is better known as the ‘subcallosal sling’. The characteristic ‘U’ shape of the 
subcallosal sling is lost in the Sox9Δ/Δ, and because of the usual anatomy, it is unclear 
where these neurons have migrated. Some authors have suggested that the subcallosal 
sling is involved in guiding axons across the midline (Silver and Ogawa, 1983); however, 
others propose that it may be the initial axons of the corpus callosum that guide the 
subcallosal neurons in their migration (Donahoo and Richards, 2009). 
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Figure 3-7 A. Midline glial populations in the Sox9Δ/Δ at E17.5 and E18.5. B. The ‘glial’ sling 
fails to form in the Sox9Δ/Δ (E17.5). IG = indusium griseum, MZG = midline zipper glia, SS = 
subcallosal sling. 
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Early Neurogenesis 
 
Since Sox9 is expressed in the VZ of the CNS from the earliest stages of neurogenesis 
(~E9.5; Stolt et al., 2003), I asked if there was any defect in the distribution of cortical 
radial glia, or if there was any delay in the onset of neurogenesis. I find that by PAX6 
immunohistochemistry, there is no apparent depletion of cortical radial glia in the Sox9Δ/Δ 
at either E12.5 or E14.5. Additionally, the initial step in corticogenesis, the formation of 
the preplate, is seen to an identical extent in the Sox9Δ/Δ and wild-type littermates (Figure 
3-8B, by TuJ1 immunohistochemistry). However, as described in the introduction to this 
chapter, radial glia are not the only progenitors of the CNS; they also give rise to 
intermediate progenitors, which usually divide once, generating two neurons, and are 
particularly important for mammalian neurogenesis. Therefore, the percentage of DAPI+ 
cells that were also positive for a marker of IPCs, INSM1, were counted in Sox9Δ/Δ and 
wild-type sections. The resulting data showed that there are no statistically significant 
differences in the prevalence of IPCs at E12.5, E14.5 or E18.5 (Figure 3-9). 
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Figure 3-8 A. The distribution of PAX6+ cortical radial glia is similar between Sox9Δ/Δ and wild-
type littermates at E12.5 and E14.5. B. The initial phase of neurogenesis, formation of the 
preplate, is normal in the Sox9Δ/Δ. 
  
 
- 76 - 
  
Figure 3-9 A. Immunostaining for INSM1, which is a marker of intermediate progenitor cells 
(IPCs), at E12.5, E14.5 and E18.5. B. Percentage of DAPI+ cells that are also INSM+ at these 
three stages of development. 
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Corticogenesis 
 
Although radial glia and IPCs are present in apparently normal numbers and preplate 
formation commences at the expected time in the Sox9Δ/Δ, it is still possible that the 
complex structure of the cortical plate (CP) fails to form properly. In order to determine if 
this was the case, IHC was performed using a number of markers specific to particular 
layers of the emerging CP: CTIP2, which markers layers V and VI, TBR1, which marks 
only layer VI, and BRN2, which is expressed in layers II-IV but unlike the other two, is 
also expressed in the newly-formed neurons destined to contribute to these layers as they 
migrate (shown in Figure 3-10). In order to assess the distribution of neurons positive for 
these markers, radial segments of the ventricular wall of multiple Sox9Δ/Δ and wild-type 
embryos were divided up into ‘bins’ such that Bin 1 was closest to the pial surface of the 
brain and Bin 9 to the ventricular surface. The percentages of marker positive cells that 
fell into each bin were then determined, and the data plotted to give an impression of their 
distribution (Figure 3-11). No statistically significant differences were observed in any 
bin for BRN2, showing that there is no defect in the distribution of these cells in the 
Sox9Δ/Δ. Among the data for CTIP2+ neurons, only one bin showed a statistically 
significant difference (Bin 6; p = 0.004); however, a difference in one bin does not 
amount to an overall trend and in any case, this difference was not mirrored by the TBR1 
data, in which no differences reached the necessary level of significance. 
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Figure 3-10 Immunohistochemistry showing the distribution of three antigens, each marking a 
particular subset of cortical plate layers. The ventricular zone is to the right of each image, and the 
pial surface to the left. 
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Figure 3-11 Binning on immunostainings for three markers of different cortical layers, BRN2 
(marks layers II-IV of the future cortex), CTIP2 (marks layers V and VI) and TBR1 (marks layer 
VI only). The bars represent the percentage of the total number of marker-positive cells in a radial 
segment of dorsal telencephalon that reside within the each bin, where Bin 1 is closest to the pial 
surface, and Bin 9 to the ventricular surface. 
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Generation of Interneurons in Sox9Δ/Δ Embryos 
 
Aside from projection neurons, the other neuronal subtype generated during 
embryogenesis is that of interneurons. In order to screen our Sox9Δ/Δ embryos for defects 
of interneuron formation, two markers of different interneuron classes were used: Lhx6, 
which is expressed in all interneurons destined to populate the dorsal telencephalon, and 
maintained in the parvalbumin- and somatostatin-expressing interneurons of the adult 
(Liodis et al., 2007), and Isl1, which marks the future cholinergic interneurons of the 
striatum (Fragkouli et al., 2009). No qualitative differences were seen in Lhx6 expression 
by in situ, with Lhx6+ interneurons being formed in the medial ganglionic eminences 
(MGEs) and beginning their migration away from this region in both the Sox9Δ/Δ and 
wild-type littermates (Figure 3-12A). Cholinergic (Isl1+) interneurons are also seen in a 
similar distribution in Sox9Δ/Δ and wild-type littermates at E12.5, suggesting that these 
neurons are normally specified (Figure 3-12B). 
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Figure 3-12 A. In situs showing the distribution of Lhx6 transcripts at E12.5 and E14.5. B. In situs 
showing the distribution of another marker of interneuons (Isl1) at E12.5. 
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Formation of OPCs in Sox9Δ/Δ Embryos 
 
As described in the introduction to this chapter, the first OPCs arise deep within the 
ventral forebrain, in the MGEs, with progressive waves of oligodendrogenesis arising 
from progressively more dorsal locations, such as the caudal, and lateral ganglionic 
eminences (LGE and CGE, respectively). The final wave arises from the cortex (Kessaris 
et al., 2006). The OPCs generated from the MGEs, LGE and CGE are the only ones to 
arise during embryonic development; only those from the dorsal telencephalon arise 
postnatally. In order to determine if this initial wave was dependent on Sox9, IHC was 
performed with two antibodies (OLIG2 and PDGFRα), which together identify early 
OPCs in the ventral telencephalon. It was found that whilst OLIG2 expression is similar 
between the wild-type and Sox9Δ/Δ ventral telencephalons, almost all expression of 
PDGFRα is lost in the Sox9Δ/Δ, suggesting a severe depletion of OPCs (Figure 3-13). 
 
Oligodendrogenesis was also assessed at a later stage (P5), and a depletion of OPCs is 
again seen (Figure 3-14). In this case, OLIG2/OLIG1 and OLIG2/PDGFRα were counted 
in a defined region of the medial-most dorsal telencephalon across three adjacent 
sections, in three Sox9Δ/Δ brains and three wild-type littermates. The resulting data shows 
a small (non-statistically significant) reduction in the numbers of OLIG2+/PDGFRα+ cells 
in the Sox9Δ/Δ, and a large and highly significant reduction in OLIG2/OLIG1 double-
positive cells (50.5%; p = 0.005). Both of these combinations should identify OPCs, 
although there are fewer PDGFRα+ cells compared to OLIG1+ cells, perhaps suggesting 
that expression of OLIG1 is seen across a wider time-window in the oligodendrocyte 
lineage than is PDGFRα. 
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 Figure 3-13 Oligodendrocyte progenitors (OPCs) in the ventral telencephalon at E12.5. 
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Figure 3-14 Fewer oligodendrocyte progenitor cells (OPCs) are found in the cortex of Sox9Δ/Δ 
brains versus wild-type littermates at P5. 
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Discussion 
 
In light of the strong expression of Sox9 in the VZ of the developing forebrain from at 
least E12.5 (our data), and probably earlier, I expected loss of Sox9 to have a profound 
effect on the behaviour of progenitors in the forebrain, especially considering the effect of 
Sox9 deletion in the neurosphere assay, and its ability to transform neuroepithelial cells 
into a state that is suggestive of a more radial glia-like phenotype (Scott et al., 2010). 
However, I have not uncovered any depletion of radial glia (using PAX6 IHC), or 
premature differentiation into neurons (TuJ1 IHC) in the Sox9Δ/Δ. Additionally, no change 
in the tendency of radial glia to generate IPCs was seen at any stage during 
corticoneurogenesis. Furthermore, and perhaps most convincingly, I see that all the layers 
of the adult cortex are laid down by the end of gestation in the Sox9Δ/Δ, and there is no 
consistent evidence of slowing of this process, or loss of progenitor potential, which 
would manifest as a lack or reduction of a particular layer. 
 
Having said this, the Sox9Δ/Δ mice are not generally viable as adults, with the vast 
majority dying between P2 and weaning (~4 weeks of age). I initially thought that this 
was likely to be due to the severe midline defects seen in Sox9Δ/Δ brains from E16.5, 
which involve the failure of the corpus callosum and hippocampal commissure to form, 
and perhaps the failure of the telencephalic vesicles to fuse, a process that forms the 
commissural plate, which is a prerequisite for commissural tract formation. However, the 
few surviving Sox9Δ/Δ adults that I have examined show complete agenesis of the corpus 
callosum, indicating that this defect is not in itself sufficient to explain their deaths. A 
more likely explanation is the drastic, although not complete, loss of OPCs in the Sox9Δ/Δ. 
This affects the earliest source of forebrain OPCs (those arising from the AEP/MGE), and 
is also evident in the postnatal dorsal telencephalon. The fact that this defect is still seen 
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at P5 suggests that other sources of forebrain OPCs are also affected, because otherwise, I 
would expect those OPCs generated from the LGE/CGE or postnatally from the dorsal 
telencephalon to compensate for the loss of the early population. Indeed, this is what 
Kessaris and colleagues observe when they ablate early sources of OPCs (Kessaris et al., 
2006). 
 
Previous work and our own supports a role for Sox9 in the specification of OPCs, which 
are a population of migratory precursors that divide as they migrate, passing through a 
number of intermediate phenotypes before differentiating as oligodendrocytes. As I 
alluded to in the General Introduction, SOX proteins are known to commonly function in 
partnership with other transcription factors. High on the list of potential SOX9 binding 
partners in the oligodendrocyte lineage would have to be other proteins that have been 
shown to be required for the induction of OPCs, such as OLIG2 or MASH1. 
 
One possible explanation for the failure of corpus callosal and hippocampal commissure 
formation in the Sox9Δ/Δ is the absence of midline glial populations. These midline glial 
populations are essential for the formation of the corpus callosum, probably through a 
mechanism involving SLIT/ROBO signalling. This is consistent with the presence of 
bundles of Probst, which suggest that the defect in Sox9Δ/Δ embryos lies in midline 
crossing, rather than neurite outgrowth or axon guidance in general. However, the fact 
that axons involved in another commissural tract, the anterior commissure, cross the 
midline successfully shows that these mice do not have any fundamental defect in the 
mechanism of midline crossing. One important midline glial population, the indusium 
griseum, is formed by the delamination of radial glia in the medial VZ, which then 
migrate to a central region above the future corpus callosum and adopt an astrocytic 
morphology. In Chapter 5, I show that a number of down-regulated genes in the Sox9Δ/Δ 
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are expressed in exactly the pattern that would be expected for radial glia just prior to 
their delamination, supporting a potential role for Sox9 in this process. Sox9 has similarly 
been shown to be important for specifying neural crest cells, prior to their delamination 
from the dorsal neural tube (Spokony et al., 2002, Cheung and Briscoe, 2003). The 
location of these transcripts seem to favour the defect being one of specification of 
indusium griseum cells or delamination, although it is also possible that there is a 
generalised failure of the anterior fusion of the telencephalic vesicles, a process which is 
also thought to be mediated by another migratory population of glia, the midline zipper 
glia. 
 
The normal architecture of the Sox9Δ/Δ CP is surprising because SOX9 is strongly 
expressed in the VZ of the forebrain long before the onset of gliogenesis, and in fact from 
the very beginning of neurogenesis. SOX9 must be performing some role in these cells, or 
the enhancers that maintain its expression in the neurogenic VZ would degenerate as a 
result of random mutations. One explanation is that the phenotype of Sox9 deletion is 
hidden by compensation from other transcription factors. This theory is supported by the 
finding that a number of Sox genes are expressed in the VZ of the dorsal telencephalon 
(described in more detail in the General Discussion, Chapter 8) because, due to the 
homology of their DNA-binding domains, they are highly likely to exhibit a degree of 
functional redundancy. For instance, between the HMG Boxes of SOX8 and SOX9, only 
one of the 79 amino acids are different (Barrionuevo and Scherer, 2010). 
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Chapter 4 Transcriptional Targets of SOX9 in 
the Neural Progenitors of the Dorsal 
Telencephalon 
 
SOX9 is expressed in the VZ of both the spinal cord and the dorsal telencephalon well 
before the onset of gliogenesis in either region of the CNS. Since our phenotypic analysis 
has indicated that Sox9, at least when deleted with the NesCre, does not appear to have a 
role in corticogenesis, this leaves the other hypothesis I alluded to in the General 
Introduction; that Sox9 may set up conditions in neural progenitors prior to gliogenesis 
that allows them to respond to gliogenic signals when they arise. In order to answer this 
question, I took Sox9Δ/Δ dorsal telencephalons, two days before the expected onset of 
gliogenesis from this part of the forebrain (at E16.5; Kessaris et al., 2006), and FACS 
sorted them with the aim of purifying or enriching a population of neural progenitors, and 
used transcriptional profiling techniques to compare their gene expression profiles with 
that of similarly-sorted wild-type E16.5 dorsal telencephalon cells. I then used 
bioinformatics techniques to identify patterns of gene expression changes that might 
implicate a particular pathway or receptor that could explain the reduction or delay in 
gliogenesis seen in the Sox9Δ/Δ. 
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Introduction 
 
Enriching a Population of NPCs 
 
There are a number of potential strategies for enriching a population of progenitors from 
the embryonic dorsal telencephalon: The first would be to use a reporter strain in which a 
fluorescent protein is expressed under the control of an NPC-specific enhancer, such as in 
the Sox2-GFP mice. Another option would be to combine an inducible Cre, expressed in 
NPCs (such as the Sox1-CreERT2), with a reporter transgene such as the ROSA26-EYFP, 
in which a STOP cassette is flanked by LoxP sites. Then, after activating the Cre by 
administration of tamoxifen, YFP+ cells could be sorted. Alternatively, an antibody that 
recognises an antigen specific to the cell population of interest could be used for sorting. 
 
The first option (using the Sox2-GFP mice) would seem like an excellent strategy for 
obtaining a pure population of NPCs; however, when GFP expression was assessed by 
IHC (data not shown), expression was detected in the progeny of NPCs suggesting that 
GFP is more stable than the SOX2 protein, precluding its use in sorting NPCs. The 
second option (using a Cre reporter strain) is not feasible because we are already using a 
Cre transgene (the NesCre) to delete Sox9 so, since all cells of the CNS arise from Nestin+ 
progenitors, they would all have activated expression of YFP. This leaves the option of 
sorting using a cell-surface marker, of which a handful have been described in the 
literature: CD133 (Uchida et al., 2000, Panchision et al., 2007), CD15, CD29, CD56, 
CD146 and FORSEI (Pruszak et al., 2009). I chose CD133 since in the developing human 
and mouse CNS, it has been shown to mark neurosphere-forming cells (Uchida et al., 
2000, Panchision et al., 2007), which are those residing in the VZ; however, IHC 
demonstrated that, at least in the mouse forebrain, it is not specific to VZ cells and is also 
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expressed in the IZ, and to a lesser extent, in the SVZ (Figure 4-1). Having said this, since 
it is not expressed in CP cells, this method could be used to remove contaminating CP 
cells, thus slightly enriching for VZ cells relative to unsorted samples. 
 
CD133 is a cell-surface receptor present on a variety of progenitor cell types, and also in 
‘cancer stem cells’ which are thought to be responsible for tumour growth in some, if not 
all, solid tumours (Meregalli et al., 2010, Singh et al., 2004). In the context of the 
haemopoietic system, CD133 has been used to enrich a subset of haemopoietic stem cells 
(granulocyte-macrophage progenitors; Yin et al., 1997). In the human and murine foetal 
CNS, CD133High cells isolated from the brain and spinal cord have been shown to contain 
a higher proportion of neurosphere-forming cells compared to unsorted cells, and 
CD133Low cells contain few, if any, cells with this capacity (Uchida et al., 2000, 
Panchision et al., 2007). Furthermore, a recent study identified that CD133 is strongly 
(but heterogeneously) expressed in NS cells derived from the embryonic mouse CNS, and 
the authors found that the strongly expressing NS cells tended to be those in the S, G2 or 
M phase of the cell cycle (Sun et al., 2009) 
 
Transcriptional Profiling 
 
Currently, two techniques exist to acquire information about the global transcriptional 
state of cells, allowing comparisons to be made between different cells or tissues, such as 
mutant versus wild-type, or diseased versus non-diseased samples. There is the tried-and-
tested method of microarray chips, and with recent advances in next-generation 
sequencing, allowing massively-parallel sequencing of cDNA molecules, ‘RNA 
sequencing’ (RNA-Seq) has become possible. Both techniques require that total RNA 
from cells is converted into cDNA. Microarrays determine the quantity of each transcript 
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by measuring the fluorescent signal produced by the hybridisation of cDNA molecules to 
complementary oligonucleotides synthesised on a glass surface. The same information 
can be acquired from RNA-Seq because, for a given depth of sequencing, the number of 
times each transcript is sequenced represents its concentration in the original sample. 
RNA-Seq is also not subject to the vagaries of background fluorescence or cross-
hybridisation that afflict microarrays, but does carry the potential for ‘mutant’ reads 
(those containing sequencing errors) to falsely align within the genome (Mortazavi et al., 
2008). 
 
DNA Microarrays 
 
The first example of a microarray chip was designed and made by Schena and colleagues 
in 1995, followed swiftly by the production of the first array chip to include probes to all 
known and predicted genes in yeast (Lashkari et al., 1997), a concept that was then 
extended to mammalian genomes. The type of microarray used in this chapter involves a 
glass or silicon surface onto which short oligonucleotides (or ‘probes’) have been 
synthesised at known points in a vast array; these points are called ‘features’. The array is 
designed so that each transcript is detected by 10 probes (called ‘perfect-match’ or PM 
probes). Each of these PM probes has a corresponding mismatch (MM) probe that is 
identical to it except that it differs in a few bases in the middle of the sequence, which 
should prevent it from annealing to the same sequence as the PM probe. Since 
microarrays rely on fluorescent signal detected at these features, the signal at the MM 
probe gives a read out of background fluorescence. Collectively, these 20 probes are 
known as a ‘probe set’. In order to obtain expression data, the RNA sample in question is 
first converted into cDNA, and then labelled with a fluorescent molecule such as Cy3 or 
Cy5. This labelled cDNA is applied to the surface of the chip, and then the chip is washed 
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several times to remove non-specifically bound cDNAs, and scanned for fluorescent 
signal. The intensity of signal is then measured at each feature. Some analysis methods 
ignore the MM signal and summarise the PM values, such as the Robust Multichip 
Analysis (RMA) algorithm, whereas others subtract the MM intensity from the PM 
intensity to give a normalised value for each probe (MAS5 algorithm). 
 
Microarrays are subject to two major sources of error. Firstly, cross-hybridisation of 
similar sequences leads to a high degree of background fluorescence, which may obscure 
differences in low-expressed genes. Also, in order to use small quantities of RNA in 
microarray analysis, several rounds of PCR amplification are required, which may not be 
linear for all transcripts. There are also limitations inherent to a system based on 
fluorescence, because the signal can become saturated: If a feature on one chip in an 
experiment is saturated, and not in another chip, it is impossible to say whether it is 10, 
100 or 1000 times more expressed in the former situation. This limitation is not seen in 
RNA sequencing, where the output variable is the number of times a particular transcript 
was sequenced, which is a proxy measure of its original concentration. 
 
Second-Generation Sequencing 
 
The majority of new, second-generation sequencing techniques are based on the dye-
terminating technology originally performed by Sanger in 1977, which has been the 
dominant method of sequencing since the early 1980s. The Sanger method involves first 
cloning the DNA fragment of interest into a vector, and then using a polymerase to extend 
the 3’ end of a sequencing primer in the presence of dNTPs that contain a small 
percentage of a particular nucleotide (A, T, C or G) that cannot be used for further 
extension of the strand. This process is carried out in four different reaction mixes, one 
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containing a small percentage of terminating As, another with a small percentage of 
terminating Ts, and so on. When each of these reactions is complete and run out on a gel, 
a variety of bands will be seen and the length of each band will show the positions of that 
particular nucleotide in the sequence. Sanger sequencing can be used for transcriptional 
profiling through the production and sequencing of libraries of expressed sequence tags 
(ESTs), where all the RNA molecules within a sample are converted to cDNA, cloned 
into vectors and then sequenced. After sequencing all of these clones, highly expressed 
sequences will be read more often than less prevalent sequences, and the incidence of 
reading sequences can be compared across samples from different sources, such as wild-
type and mutant cells, and differentially-expressed genes detected. The major limitations 
of this approach are its huge cost, and the rate-limiting step of transforming and picking 
colonies (Shendure and Ji, 2008). Another problem is the limited parallelisation of Sanger 
sequencing; a machine will only sequence 96 or 384 clones simultaneously, so many 
thousands of runs would be required to sequence an entire transcriptome to the required 
level of depth. 
 
In order to overcome this problem, second-generation sequencers have been developed 
with the aim of sequencing vast number of cDNAs in parallel, without the need to clone 
or pick bacterial colonies. These sequencers typically produce short reads ~35bp in 
length, but may be as long as 100bp (454 sequencing). A number of different approaches 
to parallelisation have been taken, but the common characteristic is that cDNAs are 
immobilised on a surface or on beads. The technique that is available at our Institute is 
that developed by Illumina, and involves reversible dye-terminator chemistry – a 
development of the Sanger method. 
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With the availability of the mouse genome sequence, allowing the alignment of short 
reads to a reference genome, it is now possible to use this technique to look for 
differentially-expressed genes between samples by comparing the number of reads 
aligning to a particular locus, which represents the abundance of that transcript in the 
original sample. The process of RNA-Seq is complex, but essentially it involves the 
production of double-stranded cDNA from fragmented RNA, followed by its attachment 
to a solid surface (the flow cell), and sequencing by a reversible dye-terminator 
chemistry. Sequencing occurs in the presence of nucleotides with a nucleotide-specific 
fluorophore attached, which, like the terminating nucleotides of Sanger sequencing, halt 
primer extension; the difference is, an enzyme can be added to remove the fluorophore, 
and convert the nucleotide into one that is capable of being extended. At the first cycle, 
one fluorescent dNTP is added to a vast number of sequences extending in parallel, and 
an image taken. The fluorescent signal at each spot represents the nucleotide at that point 
in the sequence. Then, a cleavage enzyme is added and the process is repeated, so that the 
sequence of millions of cDNAs attached to the surface of the flow cell are determined in 
parallel. 
 
cDNA Normalisation 
 
In order to compare the transcriptomes of two samples, the first step is to fragment the 
RNA, and to convert it into single-stranded cDNA. Then, following the degrading of the 
RNA by an RNase, a second strand can be formed, giving double-stranded cDNA 
fragments. Before proceeding to this step, it is commonplace to remove all RNA species 
apart from messenger RNAs (mRNAs). This is primarily to ensure that rarer protein-
coding transcripts are sequenced to sufficient depth. Without any attempt to remove 
abundant RNA species such as ribosomal RNA, much of the resources of the sequencing 
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machine would be consumed in sequencing these transcripts to huge depth, whilst very 
few rarer transcripts would be sequenced. The drawback of this approach is that 
interesting non-coding RNAs, such as microRNAs, are also eliminated. Another 
drawback, which precludes this approach from being used in our case, is the large 
quantity of starting material that is required for poly-A selection (1μg). In place of poly-A 
selection, we have used duplex-specific nuclease (DSN) normalisation to remove 
abundance RNA species. This relies on the principle that once you have denatured a 
cDNA library, abundant transcripts will find their complementary partners very quickly, 
whereas rare transcripts will take a very long time to find theirs (Zhulidov et al., 2004). In 
DSN normalisation, double-stranded cDNA molecules are rapidly denatured, then 
allowed to re-anneal at 65°C for several hours. After 5 hours, a duplex-specific nuclease, 
which degrades double-stranded DNA is added to eliminate those denatured cDNA 
strands that have found complementary partners. The overall effect of this process is to 
reduce the proportion of the cDNA that represents common transcripts, allowing 
differential expression amongst low-abundance transcripts to be more readily detected. 
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Bridge Amplification 
 
Once constructed, the cDNA library must be attached to a solid surface (the ‘flow cell’) 
prior to sequencing by the ‘sequencing by synthesis’ (SBS) method described previously. 
However, the fluorescence signal from a single nucleotide would be extremely difficult to 
detect using optics suitable for scanning a large area of flow cell; therefore, an 
amplification step is required, and this is performed by ‘bridge amplification’. The flow 
cell itself is composed of a solid surface onto which both forward and reverse primers 
have been covalently bonded by their 5’ ends. These primers are complementary to the 
adaptors ligated to either end of the cDNA molecules during library construction. When 
the denatured library is added to a lane of the flow cell, one end of each cDNA molecule 
will anneal to a primer. Because the 3’ ends of both primers are protruding, the cDNA 
molecule cannot, at this stage, anneal to both primers in a ‘bridge’ fashion. dNTPs and a 
polymerase are added, and the sequence is extended from the primers to give double-
stranded cDNA. Formamide is added to denature the strands, releasing the original cDNA 
template into solution, which is discarded. The remaining complementary copies of these 
cDNAs are a continuation of the primers. The trailing end of the attached copy is the 3’ 
end, and so it can ‘flop’ over and anneal to one of the reverse primers if it is derived from 
a forward primer, or vice-versa. Extension from this primer results in a complementary 
strand being extended from the new primer. This bridge can then be denatured with 
formamide, and the process repeated again. After 35 cycles, each cluster (derived from an 
individual single-stranded cDNA molecule) has grown to ~1,000 copies, which contains a 
mixture of both sense and antisense strands, attached to the flow cell by their 5’ ends. 
Finally, an enzyme is used to cleave one of the primers, leaving each cluster composed of 
a single, identical sequence. As SBS proceeds, the fluorescent signal is read from a vast 
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number of cDNAs in a particular spot on the flow cell, each having incorporated the same 
fluorescently-labelled dNTP. 
 
Alignment and Analysis 
 
Once short reads have been obtained from each library, they must be aligned either to a 
reference genome, or more appropriately for transcriptional profiling, a reference 
transcriptome. From this alignment, the total number of reads aligning to each transcript 
can be determined, and once these counts are normalised for the total size of the library 
(i.e. total number of mapped reads), the expression of each gene can be compared 
between samples. Naturally, almost all transcripts will show small differences in 
expression between samples, so the challenge becomes one of finding statistically 
significant differences between two sets of replicates. Because RNA-Seq data is in the 
form of count data, it has traditionally been modelled using the Poisson distribution; 
however, it was found that this tended to underestimate the variance of replicates. A 
recent paper by Ander and Huber (2010) claims to have overcome this problem of ‘over-
dispersion’ by using a statistical test based on the negative binomial distribution. Hence, 
we have used their implementation of this method to interpret our own data in 
R/Bioconductor. 
 
RNA-Seq has many potential advantages over microarrays, such as its huge dynamic 
range and its ability to more readily distinguish differential expression in low abundance 
transcripts. However, RNA-Seq is not devoid of errors. For example, because it relies on 
the alignment of short reads, many problems arise from sequence similarity within the 
genome. Mortazavi et al. (2008) investigated this problem by segmenting the genome into 
25-mers, and found that only 76% of these mapped uniquely within the mouse genome. 
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The remainder mapped to multiple sites, such as paralogs. Other potential mischief may 
be caused by occasional wrong base calls. Mortazavi and colleagues suggest that this 
might be a particular problem in gene families where one member of the family is highly 
expressed and another is very slightly expressed, or not expressed at all. The highly 
expressed family member would be expected to generate ‘mutant reads’ at a certain rate 
(the error of base calls is ~1% on the Illumina platform; Shendure and Ji, 2008), and some 
of these might erroneously align to the non-expressed family member. 
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Results 
 
In order to obtain total RNA from Sox9Δ/Δ and wild-type dorsal telencephalon cells, 
crosses were set between Sox9Fl/Fl and Sox9Fl/WT;NesCre animals, and the litters harvested 
at E16.5. From each embryo, the dorsal half of the telencephalic vesicles were dissected, 
and triturated to give separate, single cell suspensions. As described in the introduction to 
this chapter, in order to obtain as pure a population of VZ cells as possible, i.e. those cells 
which in the wild-type situation are expressing Sox9, the CD133 antigen was used to 
enrich a population of dorsal telencephalon cells for progenitors. In order to confirm that 
there is no change in CD133 expression in the absence of Sox9, and also that CD133 is 
expressed in VZ cells in both the mutant and wild-type, immunohistochemistry with an 
antibody against CD133 was performed (shown in Figure 4-1). The results show that in 
the wild-type, the cells of the VZ co-express SOX9 and CD133 (panels A and D, 
magnified in B and E; SOX9 is nuclear and in green, CD133 is found in the membrane 
and is in red). CD133 appears to be strongly expressed in the cells of the VZ, SVZ and 
IZ, but is significantly less strongly expressed in the CP, which is also consistent with the 
FACS plots (Figure 4-2) that show that approximately 60% of the cells of the E16.5 
dorsal telencephalon fall into the CD133High population. Although an antibody capable of 
sorting a pure population of VZ cells would have been ideal, using this antibody will have 
cleansed our original sample of CP cells, and thus marginally enriched our population for 
those cells (the VZ cells) which, in the wild-type situation, express Sox9. Therefore, this 
method was used to enrich populations of CD133High cells from three Sox9Δ/Δ dorsal 
telencephalons and three Sox9Fl/Fl controls (such that each control was a ‘paired’ 
littermate of the same sex). RNA was then extracted from these samples and subjected to 
transcriptional profiling by microarray and RNA-Seq. 
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Figure 4-1 CD133/SOX9 immunohistochemistry on sections of the E16.5 forebrain from Sox9Δ/Δ 
and wild-type littermates. All images are at 240X, except B and E, which are magnifications of A 
and D, respectively (at 1200X). VZ – ventricular zone, SVZ – subventricular zone, IZ – 
intermediate zone, CP – cortical plate. 
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Figure 4-2 FACS plots of  CD133-PE- and unstained populations. 
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RNA-Seq 
 
RNA extraction from each sample yielded about 300-400ng of total RNA. Because this 
was below the 1μg required for library construction under the standard Illumina protocol, 
which involves poly-A selection with poly-T attached beads, the decision was taken to 
make the cDNA libraries directly from total RNA and to reduce the prevalence of highly-
abundant transcripts by ‘normalising’ them after construction using a duplex-specific 
nuclease from the Kamchatka crab (DSN normalisation; Zhulidov et al., 2004), which 
requires only 100ng of total RNA as a starting material. Hence, 100ng of each of the 
RNA samples was used to make cDNA libraries in accordance with Illumina’s Sample 
Preparation Guide (revision D), with the exception of the poly-A selection step, which 
was omitted, proceeding directly to RNA fragmentation. In brief, library construction 
involved synthesising first-strand cDNA from the fragmented RNA, and then degrading 
the RNA and filling in the second strand using DNA polymerase. To these short segments 
of double-stranded DNA, double-stranded adaptors were ligated, and primers against the 
adaptors used to amplify the library by PCR. DSN normalisation was then performed as 
described in the Illumina protocol ‘DSN Normalization’ (revision C), and the library 
amplified by a final PCR. 
 
The six normalised libraries were then each seeded to a lane of a flow cell and underwent 
cluster generation by bridge amplification before being sequenced on the Illumina 
platform. Each sample produced ~50 million paired reads. The reads from each sample 
were then separately aligned to the July 2007 (NCBI37/mm9) assembly of the mouse 
genome. Alignment of reads to the Sox9 locus is shown in Figure 4-3. Consistent with a 
Sox9 floxed allele in which exons 2 and 3 are flanked by loxP sites, reads only aligned to 
the 5’ untranslated region (UTR) and first exon in the Sox9Δ/Δ; in the wild-type, reads 
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aligned evenly over the entire gene. From each alignment, total exon reads at all 
annotated features of the genome were extracted and analysed for differential expression 
using DESeq, which is an implementation of the method of Anders and Hubel (2010) in 
R/Bioconductor. The resulting volcano plot is shown in Figure 4-4A. From a list of genes 
found to be statistically significant (at a p-value cut-off of 0.05), 115 were more than 
1.25-fold down-regulated, and 142 were more than 1.25-fold up-regulated (lists shown in 
Appendix A). 
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Figure 4-3 Alignment of reads from the sequencing of RNA extracted from CD133High cells to the 
Sox9 locus in the Sox9Δ/Δ and wild-type situation. 
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Microarray 
 
Because RNA-Seq is a relatively new technique, and we were performing a normalisation 
step that had never been used at this Institute before, we decided to perform arrays on 
independent samples for comparison. After filtering out probe sets with low expression, 
which are thought to be unreliable in a hybridisation-based system, differentially-
expressed probe sets were called using a Student’s t-test with a p-value cut-off of 0.05. 
The resulting volcano plot is shown in Figure 4-4B. Probe sets not associated with an 
NCBI-annotated gene and those that map to multiple genes were removed from the list. 
Where the list of differentially-expressed genes contained multiple probe sets mapping to 
the same gene, the entry with the highest fold change was kept and the other entries 
deleted to ensure that each gene was represented only once in the list. The most 
differentially-expressed probe set was used instead of averaging the fold change among 
multiple probe sets to preserve a p-value associated with differential expression of that 
gene (although the fact that two independent probe sets are present means that the true p-
value is much lower). Reassuringly, Sox9 was the most differentially-expressed gene at 
31.8-fold down-regulated. Once this entry was removed, 64 down-regulated and 76 up-
regulated genes were differentially-expressed at a fold-change cut-off of 1.25 (lists shown 
in Appendix B). 
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Figure 4-4 Volcano plots for RNA-Seq (A) and microarray data (B). 
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Gene Ontology Categories 
 
The categories of molecular function into which these genes fall are shown in Figure 4-5 
(defined by the Gene Ontology Consortium); however, it is difficult to draw conclusions 
from this data because certain categories may be highly represented in a gene list simply 
because a large number of genes in the genome fall into that category. For example, the 
dominant categories in both the RNA-Seq and Microarray Down-Regulated datasets are 
‘protein binding’ and ‘ion binding’. 24.3% of the RNA-Seq Down-Regulated dataset and 
31.1% of the Microarray Down-Regulated dataset fall into the protein binding category, 
compared to 17.4% of genes in the mouse genome as a whole. In the case of ion-binding, 
this category accounts for 18.9% of the RNA-Seq dataset and 27.0% of the array dataset, 
compared to 10.4% genome-wide. In terms of the location of the gene products in the 
cells, the majority in both datasets are located in the cell membrane (27% [RNA-Seq], 
41% [microarray]), the next largest category being the nucleus (17% [RNA-Seq], 15% 
[microarray]). The graphs depicting ‘Biological Process’ categories are more difficult to 
interpret. The two largest categories for both datasets are ‘Metabolic Process’ and 
‘Biological Regulation’; however, these each comprise 27% of the genome so little can be 
gleamed from this information. However, in both datasets, ‘Localisation’, 
‘Developmental Process’, and ‘Cell Communication’ are enriched above their prevalence 
in the genome as a whole (11%, 11% and 5%, respectively). In order to determine if 
these, or any other perceived enrichments of GO categories are statistically significant, 
we turned to GO Term Enrichment Analysis, which returns a fold enrichment of genes 
from a particular category in a dataset, relative to the number expected from that category 
by chance, and a p-value associated with that enrichment. 
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Figure 4-5 The different Gene Ontology categories into which the genes of each gene list fall.  
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Down-Regulated Gene Lists 
 
Among the down-regulated datasets, only one category, ‘Platelet-derived growth factor 
binding’, is enriched in both the RNA-Seq and the array lists (Figure 4-6 and Figure 4-7), 
and in both cases this enrichment results from the presence of two genes, ‘platelet-derived 
growth factor receptor alpha polypeptide’ (Pdgfra) and ‘collagen type II, alpha 1’ 
(Col2a1). Pdgfra encodes a tyrosine kinase receptor that is bound primarily by platelet-
derived growth factor A (PDGF-A; Betsholtz et al., 2001). 
 
PDGF-A was discovered in the 1980s as a potent mitogen for fibroblasts, smooth muscle 
cells and glial cells in culture, and is secreted by neurons in the CNS (Yeh et al., 1991). It 
is essential for the proliferation of Pdgfra+ oligodendrocyte progenitor cells (OPCs) in 
vivo, and only 10% of the normal complement of OPCs are seen in PDGF-A-/- mice 
(Calver et al., 1998, Fruttiger et al., 1999). Col2a1 encodes a helical protein that is 
secreted from the cell and, in regions of chondrogenesis, is cleaved and undergoes 
spontaneous assembly into a triple helix with other COL2A1 polypeptides, forming 
‘tropocollagen’ which is the building block of collagen fibrils. Interestingly, Col2a1 has 
already been found to be a transcriptional target of SOX9 in chondrogenic tissue (Bell et 
al., 1997). The classification of COL2A1 as PDGF-binding stems from the observation 
that PDGF is bound and immobilised in the extracellular matrix (ECM; Whitby and 
Ferguson, 1991). Later in vitro binding assays showed that PDGF is bound by a variety of 
collagens, including type-II (Somasundaram and Schuppan, 1996). Although these two 
genes, Pdgfra and Col2a1, are interesting individually, the fact that they both bind PDGF 
(one transducing its signal and the other binding and inactivating it), may be a co-
incidence. 
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One further category that is enriched only in the microarray dataset is ‘Transporter 
Activity’ (Figure 4-7). This is a large category with 864 members, although the seven 
transporters present in our dataset amount to a 4.3 fold-enrichment (adjusted p-value 
0.02). These seven include two glucose transporters, Slc5a2 and Slc2a13, a potassium 
channel, Kcnj10, a constituent protein of nuclear pores, nucleoporin 133 (Nup133), a 
retinaldehyde-binding protein (Rlbp1), expressed in the VZ but better studied in the 
context of the retina where it plays an essential role in the replenishment of visual 
pigments, a Na2+/K+ ATPase (Atp1a2) and an ATP-binding cassette transporter (Abcb9). 
Using a larger microarray down-regulated dataset with no fold-change cut-off, we see an 
enrichment of genes encoding proteins with vascular endothelial growth factor (VEGF) 
receptor activity. In fact, half of all genes known to bind VEGFs (Flt1, Flt4 and Pdgfra) 
are seen in this dataset. VEGFs are best known for their role in lymphangiogenesis. 
However, in recent years other functions specific to the CNS have emerged, such as in the 
specification of OPCs (Le Bras et al., 2006) and in guiding their migration (Hayakawa et 
al., 2011). 
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Figure 4-6 GO Term Enrichment Analysis (restricted to Molecular Function categories) on RNA-
Seq Down-Regulated dataset (p-value ≤ 0.05, fold change ≥ 2 [66 genes]), using Entrez genes as a 
background list. Statistical test: Hypergeometric. Multiple-testing correction: Benjamini-
Hochberg. Cut-off: Adjusted p-value < 0.05. 
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KEGG Pathway Analysis 
 
In addition to finding categories of gene function that are enriched in these gene lists, it is 
also possible to look for genes that act in the same pathway, using KEGG pathways. This 
tool is used to determine if the constituents of a particular metabolic pathway are enriched 
in a gene list. Using this tool, three pathways were found to be enriched in both the RNA-
Seq Down-Regulated and Microarray Down-Regulated datasets. They were: ‘Focal 
adhesions’, ‘Calcium signalling pathway’ and ‘Cytokine-cytokine receptor interaction’ 
(Figure 4-8 and Figure 4-9). Focal adhesions are circumscribed regions of the cell 
membrane that mediate attachment to the basement membrane. When analysing the 
phenotype of Sox9Δ/Δ embryos (Chapter 3), we found that midline glial populations are 
missing, and this might be caused by a failure of the cells that constitute this population to 
delaminate from the dorsal VZ. If this were the case, one might expect the down-
regulated of components of focal adhesions, since if cells are not delaminating and 
migrating to form these structures, there would be less turn-over of focal adhesion 
proteins. Perturbations in calcium signalling might also be interesting because changes in 
intracellular Ca2+ concentration ([Ca2+]i) are important in the transduction of a number of 
extrinsic signals within cells. As described in later chapters, Sox9 appears to control the 
expression of a K+ channel subunit, Kir4.1, and one of the ways that expression of this 
channel might influence cell behaviour is through an effect on [Ca2+]i. Thus, a change in 
the Ca2+ signalling pathway might be secondary to a change in K+ currents across the cell 
membrane. 
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Figure 4-7 GO Term Enrichment Analysis on the ‘Microarray Down-Regulated’ dataset (p-value 
≤ 0.05, fold change ≥ 1.35 [26 genes]), using the genes represented by a probe set on the 
Affymetrix 430 2.0 GeneChip as a background list. Statistical test: Hypergeometric. Multiple-
testing correction: Benjamini-Hochberg. Cut-off: Adjusted p-value<0.05. 
 
 
  
 
- 114 - 
  
Figure 4-8 KEGG pathways that are enriched in RNA-Seq Down-Regulated dataset (p-value < 
0.05, fold change ≥ 1.4 [106 genes]), using Entrez genes as a background list. Statistical test: 
Hypergeometric. Multiple-testing correction: Benjamini-Hochberg. Cut-off: Adjusted p-value ≤ 
0.1. 
 
Figure 4-9 KEGG pathways that are enriched in Microarray Down-Regulated dataset (p-value < 
0.05, fold change ≥ 1.25 [67 genes]), using the gene recognised by probe sets on the Affy 
GeneChip 430 2.0 array as a background list. Statistical test: Hypergeometric. Multiple-testing 
correction: Benjamini-Hochberg. Cut-off: Adjusted p-value ≤ 0.1. 
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Up-Regulated Gene Lists 
 
Within the RNA-Seq Up-Regulated dataset, the GO term category ‘regulation of cell 
proliferation’ was enriched (3.7-fold, p-value 0.09), as was one of its descendents, 
‘negative regulation of cell proliferation’ (Figure 4-10). The up-regulation of genes that 
negatively regulate cell proliferation in the Sox9Δ/Δ mouse is consistent with the 
proliferation defect previously noted in Sox9Δ/Δ cells in vitro (Scott et al., 2010). 
Unfortunately, these categories are not enriched in the Microarray Up-Regulated dataset, 
although one of the 4 genes present in the RNA-Seq dataset, ‘runt-related transcription 
factor 3’ (Runx3), is also up-regulated in the array dataset (fold change 1.3). It is 
interesting to note that Runx3 is also down-regulated in glioblastomas, a cancer of the 
brain originating from glial cells (mediated by promoter methylation; Mueller et al., 
2007), in which Sox9 is strongly expressed (Kordes and Hagel, 2006). This lends support 
to the idea that Runx3 might be repressed by SOX9. 
 
The picture for the Microarray Up-Regulated dataset is more complex, and so we have 
displayed it in the form of a directed acyclic graph (Figure 4-11). Taking only those 
categories that are enriched in our dataset at an adjusted p-value < 0.05, we see that 12 
categories are enriched, although some of these are the parents of more specific GO 
terms, such as in the relationship of ‘central nervous system development’ to ‘brain 
development’. Ignoring the parent categories, we are left with 5 ‘pinnacle’ terms: 
‘Regulation of cell shape’ (3 genes); ‘negative regulation of neuron differentiation’ (3 
genes); ‘gliogenesis’ (3 genes); ‘brain development’ (6 genes); ‘organ morphogenesis’ 
(10 genes); and ‘pattern specification process’ (6 genes). ‘Negative regulation of neuron 
differentiation’ and ‘gliogenesis’ seem the most interesting categories for a gene that has 
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been postulated to be part of the ‘gliogenic switch’, that is, the transition to gliogenesis at 
the end of neurogenesis (Stolt et al., 2003). 
 
The constituents of these two categories are shown in Figure 4-12, and contain one 
common member, Nr2e1, which is more commonly referred to in the literature as ‘Tlx’. 
In the context of adult NSCs, Tlx strongly represses the expression of two well-
characterised markers of astrocyte identity, S100β and GFAP, and when transfected into 
NSCs in vitro, astrocyte differentiation (driven by the addition of LIF to the culture 
medium) is markedly reduced (Shi et al., 2004). Since Sox9 is expressed in early 
astrocytes, it makes sense that it should repress a repressor of astrocyte identity, making 
Tlx an attractive candidate for transcriptional repression by SOX9. However, the fact that 
Tlx and Sox9 are expressed in similiar patterns at E12.5 (Stenman et al., 2003b) seems to 
argue against such a relationship. Tlx expression begins earlier than Sox9 expression, 
peaks at E12.5 and then rapidly dissipates (Monaghan et al., 1995), whilst Sox9, having 
arisen at ~E9.5, continues to be expressed throughout embryogenesis (Stolt et al., 2003, 
Scott et al., 2010). However, it is possible that increasing levels of SOX9 in the period 
E9-E12 might gradually extinguish Tlx expression, or that another factor is required for 
SOX9-mediated repression. Reports of Tlx repressing neuronal differentiation appear to 
be restricted to findings in the retina, where reduced numbers of neurons are formed in 
each of the three neuronal layers of the retina of the Tlx-/- mouse (Miyawaki et al., 2004), 
a phenotype not seen in other parts of the CNS. 
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Figure 4-10 GO Term Enrichment Analysis on RNA-Seq Up-Regulated dataset (p-value ≤ 0.05, 
fold change ≥ 2.5 [81 genes]), using Entrez genes as a background list. Statistical test: 
Hypergeometric. Multiple-testing correction: Benjamini-Hochberg. Cut-off: Adjusted p-value < 
0.1. Categories represented by fewer than 3 genes in the gene set were ignored. 
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Figure 4-11 GO Term Enrichment Analysis on the ‘Microarray Up-Regulated’ dataset (p-value ≤ 
0.05, fold change ≥ 1.25 [89 genes]) , using the gene represented by a probe set on the Affymetrix 
430 2.0 GeneChip as a background list. Statistical test: Hypergeometric. Multiple-testing 
correction: Benjamini-Hochberg. Cut-off: Adjusted p-value < 0.05. Minimum: 3. 
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Figure 4-12 The members of two GO term categories enriched in our Microarray Up-Regulated 
dataset. 
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Discussion 
 
In this chapter, a bioinformatics approach was used to determine if any categories of gene 
function or metabolic pathway was enriched in either or both of the down-regulated lists 
(from microarray and RNA-Seq), or up-regulated lists. No categories containing more 
than two constituents were common to both the down-regulated lists or both the up-
regulated lists. Individually, however, the datasets do provide useful information. 
 
My original rationale for performing these transcriptional profiling experiments was to 
identify receptors or second messengers that might be down-regulated in the Sox9Δ/Δ and 
could explain why the effect of Sox9 loss on NPCs does not manifest in vivo until 
gliogenesis commences. The finding that three of the six known VEGF receptor genes 
(Flt1, Flt4 and Pdgfra) were down-regulated in the Sox9Δ/Δ (microarray data) appeared to 
support this hypothesis. Flt1, Flt4 and Pdgfra encode VEGFR-1, VEGFR-3 and 
PDGFRα, respectively. Two of these receptors have been shown to be important for OPC 
specification/proliferation (VEGFR-3 and PDGFRα): Mice lacking the VEGF ligand 
VEGF-C, which is transduced via VEGFR-3, are profoundly deficient in oligodendrocyte 
progenitor cells (OPCs; Le Bras et al., 2006), as are mice lacking Pdgfa, which encodes 
PDGF-A, the main ligand of PDGFRα (Fruttiger et al., 1999, Betsholtz et al., 2001). 
Therefore, consistent with our initial hypothesis, it appears that Sox9Δ/Δ CD133High cells 
lack two receptors that are important in the initial specification or proliferation of OPCs. 
Some may argue, however, that down-regulation of these receptors could reflect a loss of 
OPCs in the Sox9Δ/Δ, and this is possible since our CD133High cells are not a pure 
population of progenitors and may be contaminated in the wild-type sample with OPCs 
that were not present in the Sox9Δ/Δ sample. 
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Although I originally set out to identify receptors or second messengers that might 
transduce a gliogenic signal, in the process I have also come across two transcription 
factors, Nr2e1 and Runx3, which may be important in the Sox9Δ/Δ phenotype. Within the 
RNA-Seq Up-Regulated dataset, one category relevant to the observed phenotype jumps 
out: Negative regulation of cell proliferation, and one of the four genes enriched in this 
category, Runx3, is also in the Microarray Up-Regulated dataset. Runx3 is expressed 
exclusively in post-mitotic neurons in the CNS, which do not express Sox9. This is 
consistent with a situation in which SOX9 represses Runx3 transcription in glia and in 
progenitors. Analysis of the Microarray Up-Regulated dataset also yields a promising 
finding. Two of the enriched categories are ‘Negative regulation of neuronal 
differentiation’ and ‘Gliogenesis’, which fits with the previous observation that Sox9 is 
important in the gliogenic switch in the CNS. Moreover, these two categories contain a 
common member, Nr2e1 (better known as Tlx). Tlx is up-regulated in the absence of Sox9 
(1.42-fold), and represses two markers of astrocyte identity (S100β and GFAP) in 
differentiating neural stem cells (Shi et al., 2004). Unfortunately, the negative effect of 
Tlx on neuronal differentiation appears only to have been seen in the retina, and not in the 
CNS (Miyawaki et al., 2004). Tlx remains, however, a good candidate for a gene that 
might be repressed by SOX9 and mediate the failure of midline glial cells (which 
resemble astrocytes and express GFAP) to differentiate in the Sox9Δ/Δ. Also, Plce1 has 
been shown to be repressed by TLX (Zhang et al., 2006), and since Plce1 is robustly 
down-regulated in the Sox9Δ/Δ, this would fit with the de-repression of Tlx down-
regulating Plce1 in these mice. 
 
KEGG pathway analysis identified ‘Focal Adhesions’, ‘Cytokine-cytokine interactions’ 
and ‘Ca2+ signalling’, although in all three cases this was based on the enrichment of only 
two genes. The idea that the proteins involved in Ca2+ signalling might be altered in the 
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Sox9Δ/Δ was of interest because Ca2+ signalling is very important in the transduction of 
extracellular signals (mediated by calmodulin), and activates the MAP kinase pathway 
(Rosen et al., 1994). However, this enrichment was based on the presence of two genes, 
Plce1 and Pdgfra. When activated, PLCE1 hydrolyses phosphatidylinositol bisphosphate 
(PIP2), releasing inositol 1,4,5-triphosphate (IP3) and diacyl glycerol (DAG). IP3 then 
stimulates the release of Ca2+ from intracellular stores. Focal adhesions may also warrant 
further investigation since the down-regulation of proteins required for their formation 
might represent a defect of delamination in the Sox9Δ/Δ, which may be the cause of the 
failure of midline glial populations to arise from the medial VZ. 
 
In conclusion, amongst these datasets, the most convincingly enriched gene set is that of 
the VEGF receptors, since three of the six known receptors are down-regulated in the 
Microarray Down-Regulated dataset. In addition to this, gene set enrichment analysis has 
also highlighted two potential repressive targets of SOX9, one that inhibits astrocyte 
differentiation (Tlx), and another, Runx3, that exerts a negative effect on cell proliferation, 
supporting the theory that Sox9 is important both for astrocyte differentiation and 
progenitor identity, which is by definition a proliferative cell population. 
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Chapter 5 Identifying Candidate SOX9 Primary 
Targets 
 
Previous work in our laboratory has shown that Sox9Δ/Δ neural progenitors, derived from 
the spinal cord and dorsal telencephalon, form radically fewer neurospheres than wild 
type cells when cultured in the presence of basic fibroblast growth factor (bFGF) and 
epidermal growth factor (EGF; Scott et al., 2010). It was felt that the data obtained from 
the transcriptional profiling experiments in the previous chapter might shed light on the 
mechanisms involved in this phenotype. To this end, a list of targets that were robustly 
up- or down-regulated in both the microarray and RNA-Seq datasets was generated and 
subsequently confirmed by qPCR. In order to find direct targets of Sox9 that might also 
be involved in the behaviour of neural progenitors, in situ hybridisation was performed 
using probes against all the candidate down-regulated targets. Subsequently, three of 
these candidates were found to be expressed to a similar extent in neurospheres as they 
were in E14.5 dorsal telencephalons, and thus represent good candidates for factors that 
might mediate the Sox9Δ/Δ neurosphere phenotype. 
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Introduction 
 
Neurosphere Assay 
 
The neurosphere assay is a system for determining the proliferative and differentiative 
capacity of neural progenitors, originally devised by Reynolds and Weiss (1992). It 
involves the dissection of a particular region of the CNS, which is triturated and cultured 
in the presence of EGF and bFGF, which are both mitogenic factors important for the 
proliferation of neural progenitors. Over the course of 6-10 days, large spherical colonies 
of cells arise, measuring up to 300-400μm in diameter. Although originally thought to be 
composed of homogeneous Nestin+ progenitors, it is now known that neurospheres 
contain a heterogeneous population including progenitors, as well as more differentiated 
progeny (reviewed in Pastrana et al., 2011). Historically, the neurosphere assay has been 
used to identify neural stem cells, although in this thesis we use it to investigate the effect 
of loss of Sox9 on neurosphere growth rates, which may represent an impairment of 
proliferation, a reduction in the size of the neurosphere-forming population, or indeed 
another sphere-forming population, such as early OPCs. Another aspect to the 
neurosphere assay is its ability to assess the differentiative capacity of the neurosphere-
forming cells, which involves culturing them on a three dimensional matrix (Matrigel) in 
media in which growth factors have been removed, followed by fixation and staining for 
markers of differentiated cells. 
 
 
  
 
- 125 - 
Results 
 
Having obtained detailed information about the genes differentially expressed in the 
Sox9Δ/Δ embryonic CNS, and therefore potential direct targets of SOX9, we decided to 
use this to look for candidates that might mediate the poor proliferation and reduced 
potential of neural progenitors observed in Sox9Δ/Δ mice (Scott et al., 2010). We began 
this analysis by looking for genes that were either up-regulated in both the RNA-Seq and 
microarray experiments, or down-regulated in both. 
 
Generating Candidate Lists 
 
Since the RNA-Seq and microarray datasets were produced from independent, 
consecutive experiments, any gene that reaches significance at the traditional cut-off of 
0.05 in both datasets is extremely significant, because each p-value (representing the 
probability that that difference is due to chance) is specific to its experiment. With 
overlapping datasets, a p-value of 0.22 (√0.05) is more appropriate because the genes 
identified as meeting this criterion in both datasets can be considered to be significant at p 
< 0.05. The number of genes common to both the RNA-Seq and array datasets at a range 
of p-value cut-offs are shown as Venn diagrams in Figure 5-1. Taking a p-value cut-off of 
0.22 in each dataset, 33 down-regulated and 22 up-regulated candidates are common to 
both datasets. The size of this overlap in the down-regulated datasets increases as the 
stringencies of the respective statistical tests are increased, with 9.9% of the genes down-
regulated by RNA-Seq being present in the down-regulated array dataset at p < 0.22, 
increasing to 19.2% at p < 0.05, indicating that ‘noise’ in the two experiments is being 
removed, leaving we hope, the majority of the ‘true’ signal. This is not seen in the Venn 
diagrams for the up-regulated candidates, with the percentage overlap remaining largely 
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constant at ~5%. The robustness of the overlap in the down-regulated datasets, even at 
very high stringency (0.052), makes us very confident of these genes being down-
regulated, and the poor concordance between the up-regulated datasets make us less 
confident about these targets, an observation supported by qPCR analysis of the common 
up- and down-regulated candidates shown in the next section. Although the 33 down-
regulated and 22 up-regulated targets at a p-value cut-off of 0.22 (in each dataset) meet 
the conventional p-value cut-off of 0.05 overall, we decided to prioritise those genes that 
were differentially expressed at p<0.05 (p<0.052 overall), because we can be more 
confident that these genes are true signal, and also at this level we have a list of 
manageable size for downstream analyses. 
 
 
  
 
- 127 - 
  
Figure 5-1 A – Venn diagrams showing the overlap between the RNA-Seq and microarray 
datasets at a variety of p-value cut-off levels (α). B – Correlation between the fold change derived 
from the RNA-Seq and microarrays for i) the up-regulated genes and ii) the down-regulated 
genes. 
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Validation of Candidates by qPCR 
 
Differential expression in both overlapping datasets (which will be referred to as 
‘Combined Up-Regulated’ and ‘Combined Down-Regulated’) was confirmed by RT-
qPCR, using primers designed to produce the same amplicon across all known transcript 
variants. Ensembl was used as the source for transcript variant information. In cases 
where it was not possible to amplify all Ensembl transcripts with one set of primers, it 
was ensured that at least all RefSeq transcripts were included. In order to validate our 
primers, which were designed using the Primer3 algorithm, we performed qPCR on serial 
dilutions of E16.5 telencephalon cDNA, and verified that a single product was formed (by 
melt curve analysis) and that primer efficiency was in the range 95-105%. 
 
Of the 14 genes1 found to be down-regulated in both the RNA-Seq and array datasets, 13 
were confirmed to be down-regulated by qPCR, although two were not statistically 
significant (Arhgef3 and Hs3st1), and 7 candidates were more than two-fold down-
regulated: 2810459M11Rik, Col2a1, Dbi, Hopx, Kcnj10, Pdgfra and Rlbp1 (Figure 5-2A). 
One down-regulated candidate, 5830403L16Rik, was particularly problematic because no 
reliable transcript information was available, and this gene could not be satisfactorily 
amplified despite three different sets of qPCR primers being tried. Of the 5 candidate up-
regulated targets, 3 were confirmed to be up-regulated by qPCR (Figure 5-2B), although 
only two met the requirements of statistically significance. These were Heph, and Tesc, 
and only the latter was more than two-fold up-regulated. 
 
1 The 15th gene, Lhb, was only identified as being common to both datasets when the data was recently re-
analysed, so this was not included. 
 
- 129 - 
                                                 
Reassuringly, ChIP-Seq2 using chromatin extracted from NS cells, which are an in vitro 
model of radial glial cells (Conti et al., 2005), and an antibody against SOX9, identified 
SOX9 binding sites within 20kb of the transcriptional start sites (TSSs) of 11 out of our 
14 candidates in the Common Down-Regulated list (Figure 5-3), compared to a genome-
wide incidence of SOX9 binding within 20kb of TSSs of 14.5% (personal communication 
from B. Martynoga). The three lacking a SOX9 binding site within this range are 
5830403L16Rik, Hs3st1 and Pdgfra. 
 
  
2 Kindly made available to us by the Guillemot group at the N.I.M.R. 
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 Figure 5-2 qPCR expression data for Common Down-Regulated dataset (A), Common Up-
Regulated dataset (B) and Sox9 (C). 
 
 
Figure 5-3 Number of SOX9 binding sites identified by ChIP-Seq within 20kb of the 
transcriptional start sites of the candidate targets. 
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Spatial Expression Patterns of Candidates at Mid-Neurogenesis by In 
Situ Hybridisation 
 
The down-regulation of a particular mRNA in a sample of total RNA might represent the 
reduction of the absolute levels of that transcript in a cell that is expressing SOX9 (a 
direct target) or the loss or reduction of a specific cell population induced or maintained 
by Sox9. Determining the spatial distribution of the candidate down-stream targets at a 
time of peak neurogenesis in the telencephalon (E14.5) allows us to distinguish between 
these two causes of differential expression and to refine our list to a smaller number of, 
hopefully, primary targets that might feasibly mediate the aberrant behaviour of Sox9Δ/Δ 
neural progenitors in the neurosphere assay. In this section, the down-regulated candidate 
genes will be referred to simply as the ‘candidate genes’. 
 
In order to assess the spatial expression pattern of the candidate genes, we made in situ 
probes by a method that involves PCR amplification from cDNA with PCR primers 
specific to the transcript of interest that include the T7 bacteriophage promoter, such that 
the resulting amplicon can be used as a template for T7 RNA polymerase. When in vitro 
transcription is performed in the presence of a certain concentration of DIG-labelled 
nucleotides, a DIG-labelled riboprobe specific to that transcript is produced. 
 
These riboprobes were used to detect the mRNA of the candidates in sections of Sox9Δ/Δ 
and wild-type littermate brains at mid-neurogenesis (E14.5). This was done with two 
objectives in mind: Firstly, to see if there was any change in the distribution of the 
candidate genes in the Sox9Δ/Δ that might be indicative of the loss of a particular cell 
population, or indeed differential expression in terms of transcript level. The distribution 
of these transcripts in the wild-type situation is also of interest since any target expected 
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to influence the behaviour of progenitors would have to be expressed within those 
progenitors, i.e. within the VZ. The resulting in situs are shown in Figures 5.4-5.8. 
 
Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 (Hs3st1; Figure 5-4A) is expressed 
moderately in the ventral VZ, and strongly in the subventricular zone (SVZ) of the dorsal 
telencephalon, where intermediate progenitor cells (IPCs) reside (Noctor et al., 2004). 
There is also some expression in the emerging cortical plate (CP). Consistent with the 
qPCR data, the intensity of signal from this transcript is not noticeably reduced in the 
null. Mmd2 is also expressed specifically within the SVZ, although more weakly than 
Hs3st1. Again, expression of this transcript does not appear to be reduced in the null, 
although it is only mildly down-regulated by qPCR (1.44-fold). Pdgfra and Plce1 also 
follow the same expression pattern, although Pdgfra expression is more convincingly 
down-regulated than Plce1 in these images, consistent with it being the most down-
regulated of the four (2.2-fold by qPCR). 
 
HOP homeobox (Hopx; Figure 5-5A) is expressed diffusely in the dorsal VZ, but 
particularly strongly in the region of the dorsal VZ closest to the septum. Interestingly, 
this is the region from which radial glia delaminate and migrate to form midline glial 
structures (Shu et al., 2003b, Smith et al., 2006), which are absent in the Sox9Δ/Δ. This 
expression pattern is almost entirely lost in the absence of Sox9. Tumor necrosis factor 
receptor superfamily, member 19 (Tnfrsf19; Figure 5-5B), often referred to as Troy in the 
literature, is also expressed most strongly in the region of the dorsal VZ adjacent to the 
septum, suggesting it may also play a role in mediating this aspect of the Sox9Δ/Δ 
phenotype. Evidence of differential expression is weak, although this is to be expected 
with a gene that is down-regulated only 1.26-fold by qPCR. Interestingly, we have 
detected tumour necrosis factor (TNF) in conditioned media from both neurospheres 
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(after 6 days of culture) and NS cells (1480pg/ml and 2478pg/ml, respectively)3, 
suggesting that this cytokine is produced by NPCs. However, researchers disagree as to 
whether TNF is in fact a ligand for TNFRSF19, and it is currently regarded as an orphan 
receptor (Bossen et al., 2006). 
 
Retinaldehyde binding protein 1 (Rlbp1; Figure 5-6) is expressed strongly in the medial, 
and dorsolateral VZ, with expression bleeding into the most lateral part of the ventral VZ, 
and rapidly fading out in the lateral-to-medial direction. This expression pattern is 
reminiscent of that of Pax6, which defines the pallial region of the VZ (Stenman et al., 
2003b), destined to give rise to the glutamatergic projection neurons of the CP. 
Expression of this transcript is dramatically weaker in the VZ of the Sox9Δ/Δ, most 
pronounced caudally, but also rostrally. 
 
Diazepam-binding inhibitor (Dbi; Figure 5-7B) is strongly expressed in the VZ, both in 
the dorsal and ventral regions, and also in diffuse cells within the parenchyma of the 
telencephalon. The dorsal VZ expression is selectively lost in the Sox9Δ/Δ. Like Dbi, the 
inwardly-rectifying potassium channel, Kcnj10 (Figure 5-7C), is also expressed strongly 
and uniformly throughout the dorsal and ventral VZ, although with considerably less 
expression in the parenchyma. Again, expression of this gene is lost specifically in the 
dorsal VZ of the Sox9Δ/Δ, leaving the ventral expression almost untouched. 
 
A similar pattern is seen for Col2a1, which is again expressed uniformly throughout the 
VZ at this rostrocaudal position, although the expression pattern does appear to involve a 
greater thickness of the ventricular wall, perhaps encroaching into the intermediate zone 
(IZ). In the case of Col2a1, expression is lost in all regions of the VZ in the Sox9Δ/Δ (note 
3 Assay performed by Gavin Sewell, Department of Medicine, U.C.L. 
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that the expression in the chondrogenic field of the future skull base is similar in both the 
wild-type and Sox9Δ/Δ). Although it is perhaps surprising for a procollagen to be 
expressed in the progenitor zone of the embryonic brain, we are not the first to note this 
expression pattern: Ng and colleagues refer to the VZ expression of Col2a1 in their 1997 
paper, and VZ expression is clearly visible in the Allen Brain Atlas entry for Col2a14. A 
similar expression pattern is seen for three other transcripts: Arhgef3, 2810459M11Rik 
and AI646023, involving uniform expression in the dorsal and ventral VZs, and probable 
expression in the SVZ/IZ. Reduced expression in the Sox9Δ/Δ is seen in the first two, 
Arhgef3 and 2810459M11Rik, but not for AI646023. 
 
Finally, at the rostrocaudal level shown, 5830403L16Rik is expressed most strongly in 
the SVZ of the lateral ganglionic eminences (Figure 5-8), which comprise a population of 
neural precursors, which express GAD67, and are destined to give rise to either pyramidal 
neurons of the basal ganglia, or interneurons (Stenman et al., 2003a). 5830403L16Rik is 
also diffusely expressed within the dorsal ventricular wall; this might be thought of as 
being consistent with the tangential migration of interneurons from the SVZ of the LGE, 
however, if this were the case, expression would be expected to either be within the 
marginal zone and IZ (early born interneurons) or in the VZ (late born interneurons), 
when in fact it seems present in all layers of the dorsal ventricular wall (Jovanovic and 
Thomson, 2011). Once again, expression is lost selectively in the dorsal VZ. 
 
In conclusion, the expression patterns of the 14 genes identified as being down-regulated 
in the Sox9Δ/Δ have highlighted six targets that are robustly down-regulated, and 
expressed specifically and uniformly throughout the VZ of the telencephalon. Therefore, 
these genes are excellent candidates for mediating the progenitor defects seen in the 
4 Allen Developing Mouse Brain Atlas [Internet]. Seattle (WA): Allen Institute for Brain Science. ©2009. 
Available from: http://developingmouse.brain-map.org. 
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Sox9Δ/Δ, namely reduced neurosphere-forming ability, and loss of potential to form glia. 
However, before proceeding to functional analyses of these genes, we first attempted to 
confirm their expression in neurospheres. 
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Figure 5-4 The expression patterns (by in situ hybridisation) of those candidates whose dominant 
expression was deemed to be in the subventricular zone of the dorsal telencephalon. 
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 Figure 5-5 Expression (by in situ hybridisation) of Hopx (A) and Tnfrsf19 (B). 
 
 
Figure 5-6 Expression (by in situ hybridisation) of Rlbp1. 
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 Figure 5-7 The expression patterns (by in situ hybridisation) of those candidates that appear to be 
expressed specifically within the VZ of the developing telencephalon. A Sox9 in situ is included 
for comparison. 
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 Figure 5-8 The expression pattern (by in situ hybridisation) of 5830403L16Rik. 
 
Expression of Candidate Genes in Neurospheres 
 
Following the analysis of the expression patterns of these 14 down-regulated candidates, 
the list has been reduced to six genes that are felt likely to be primary targets of SOX9 
since they are expressed in the same pattern, namely Dbi, Kcnj10, Arhgef3, 
2810459M11Rik, AI646023 and Col2a1, with the first two being of particular interest 
because the others appear also to be expressed in the SVZ/IZ. The next logical step was to 
ask if any of these genes are expressed in neurosphere cultures. To this end, RT-PCR for 
the candidates was performed using total RNA extracted from E14.5 dorsal 
telencephalons from two embryos, and on two independently established neurosphere 
cultures, derived from E14.5 dorsal telencephalons, harvesting and extracting RNA after 
7 days in culture. The results are shown in Figure 5-9. Unfortunately, only those primers 
against Kcnj10, Dbi, Arhgef3 and AI646023 worked in the reaction mix used, however, 
these results do show that the first three, Kcnj10, Dbi and Arhgef3 are strongly expressed 
in neurospheres, whereas AI646023, whilst being moderately expressed in E14.5 dorsal 
telencephalons, is down-regulated in neurosphere cultures, ruling it out as a mediator of 
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the progenitor defects seen in the Sox9Δ/Δ. The PCRs for Col2a1 and 2810459M11Rik did 
not work; however, in any case, we decided to take forward only Kcnj10 and Dbi, 
because these were the genes for which the in situ data suggested expression specifically 
within the VZ, and not in the SVZ/IZ. 
 
 
Figure 5-9 The expression (by RT-PCR) of Kcnj10, Dbi, Arhgef3 and AI646023 in neurosphere 
cultures and embryonic brains (E14.5). 
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Discussion 
 
In this chapter, I have taken the transcriptional profiling data from our CD133High cells, 
originally obtained to aid in our understand of the Sox9Δ/Δ phenotype, and used this 
information to refine a list of potential candidates that might mediate the poor 
proliferation of Sox9Δ/Δ progenitors in the neurosphere assay (Scott et al., 2010). Scott and 
colleagues also note that in the context of the neurosphere assay, Sox9Δ/Δ VZ cells exhibit 
a narrowed developmental potential upon growth factor withdrawal (only neurons are 
formed), and therefore any targets may have relevance to this aspect as well. 
 
I began by overlapping both the down- and up-regulated lists from the RNA-Seq and 
array experiments to find genes that were differentially regulated in the same direction in 
both experiments. Since a p-value cut-off of 0.05 was chosen in each experiment, the 
likelihood of a gene appearing on one of the two overlapped datasets by chance is 0.0025. 
As expected, all of the down-regulated candidates were down-regulated by qPCR, 
although two of them, Arhgef3 and Hs3st1, did not meet statistical significance. Using an 
external ChIP-Seq dataset, performed using genomic DNA from NS cells, 11 of the 14 
down-regulated candidates were found to have at least one region bound by SOX9 within 
20kb of their TSSs, and many (2810459M11Rik, AI646023 and Kcnj10) had 2 such 
regions. Three genes, 5830403L16Rik, Hs3st1 and Pdgfra, did not have binding sites 
within the 20kb range, although it is possible that their transcription is activated by 
enhancers outside this range; it is also possible that they are indirect targets, with one or 
more intermediate transcription factors involved in their activation. Alternatively, these 
genes might be down-regulated because a cellular population fails to be generated in the 
Sox9Δ/Δ. This is particularly likely in the case of Pdgfra, which is one of the earliest 
markers of oligodendrocyte progenitor cells (OPCs), and a marker that is found to be 
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lacking in the ventral telencephalons of Sox9Δ/Δ embryos in Chapter 3. Pdgfra (along with 
three other candidates Hs3st1, Mmd2 and Plce1) appears to be expressed in the SVZ of 
the dorsal telencephalon. The fact that Pdgfra is a marker of OPCs, and they may be 
populating the embryonic cortex at this stage, leads us to speculate that loss of these 
markers might represent the depletion of an early population of OPCs, however, we have 
no direct evidence for this. Intermediate progenitor cells also reside in the SVZ of the 
dorsal telencephalon, although our investigation of these in Chapter 3 did not show any 
difference in their numbers. 5830403L16Rik is also expressed most strongly in regions 
that lie outside the domain of Sox9 expression, the ventral SVZ, from which interneurons 
are generated, raising the possibility that a population of interneurons might be depleted 
in the Sox9Δ/Δ. Interestingly, in many cases, the expression of candidate genes was lost 
specifically in the dorsal telencephalon, suggesting that in the ventral telencephalon, other 
compensating factors might maintain the expression of these genes. Three of the down-
regulated genes are found to be expressed to a similar degree in neurospheres as they are 
in the dorsal telencephalon in vivo, suggesting that these (Kcnj10, Dbi and Arhgef3) may 
be important in mediating the defect of NPC maintenance/proliferation seen in the 
neurosphere assay. 
 
Hopx and Tnfrsf19 May Mediate the Failure of Midline Glial 
Populations to Form in Sox9Δ/Δ Embryos 
 
As was seen in Chapter 3, two major commissural tracts, the corpus callosum and 
hippocampal commissure, fail to form in the anterior forebrain of Sox9Δ/Δ embryos. The 
fact that the anterior commissure forms normally suggests that there is no generalised 
defect of neurite outgrowth or axonal extension. Furthermore, the presence of bundles of 
Probst, which are aberrant tangles of axons either side of the midline at the rostrocaudal 
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level where the corpus callosum would be expected to form, suggests that it is the final 
step in commissural formation, midline crossing, that is lacking. 
 
In humans and in mice, the corpus callosum is the major fibre tract that connects the 
neurons of the two hemispheres. Axonal outgrowth from newly-formed neurons begins 
early, within a few hours of their arrival at their final position in the CP. These axons 
extend in a reverse-radial fashion towards the ventricle, in close proximity to the fibres of 
radial glia, before executing a 90° turn and travelling medially, in a tangential fashion 
towards the midline (reviewed in Donahoo and Richards, 2009). Once at the midline, 
permissive and repulsive signals, some of which are released by a specialised region of 
glial cells, the indusium griseum, ensure the successful completion of their passage into 
the contralateral hemisphere. 
 
Three populations of astrocytes make up the midline glial structures: The midline zipper 
glia, which populate the ‘seam’ formed after the fusion of the telencephalic vesicles, thus 
creating the substrate through which callosal axons can migrate (Silver et al., 1993); the 
glial wedges, which extend from the medial corners of the lateral ventricles towards the 
midline; and the indusium griseum, which lies at the dorsal-most extent of the 
commissural plate. The midline zipper glia are thought to participate in the process of 
midline fusion of the telencephalic vesicles on the basis of their expression in the 
trajectory of this fusion, which occurs in a ventral to dorsal direction (Silver et al., 1993). 
The glial wedges are thought to prevent callosal axons from projecting into the septum; 
they do this not only by forming a physical boundary, but also by expressing SLIT2 (Shu 
et al., 2003c), a secreted signalling molecule that serves to repel axon growth cones 
through an interaction with ROBO receptors expressed on their surfaces. The third 
structure, the so-called ‘glia sling’, is actually a population of neurons. Pioneer axons 
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from the cingulate cortex migrate over it, and immediately below the indusium griseum. 
These midline populations of glia are composed of astrocytes, and are born significantly 
earlier than the mainstay of forebrain astrocytes, which are generated postnatally. GFAP, 
a well-known marker of astrocytes is expressed in these populations at E16.5, and GFAP 
is not up-regulated in astrocytic precursors until ~2 days after their specification, so this is 
several days in advance of the majority of astrocytes, which are thought to arise from the 
transdifferentiation of radial glia cells (Kessaris et al., 2008). 
 
Hopx and Tnfrsf19 are both expressed in a similar distribution to that of Fgfr1 in the 
rostral forebrain at E14.5, and this gene has been shown to be essential for the 
development of midline glia populations (Smith et al., 2006). The authors of this paper 
showed that in the absence of Fgfr1, radial glia in the ventromedial aspect of the dorsal 
telencephalon fail to retract their endfeet and delaminate from the VZ, thus preventing 
them from migrating to form the indusium griseum. This raises the possibility that there 
may be some genetic interaction between FGFR1 and SOX9, such as co-operative 
binding between SOX9 and an effector of FGF signalling in regulatory regions of genes 
important for radial glial delamination. An alternative explanation is that Fgfr1 might lie 
downstream of Sox9, although no evidence of this is seen in our transcriptional profiling 
data. The reverse is unlikely to be true because Fgfr1 is expressed in only a small portion 
of the Sox9 expression domain. In order to ascertain if SOX9 and FGFR1 are acting in the 
same pathway to either specify, or trigger the delamination of, midline glial populations, 
it would be interesting to generate compound heterozygotes (Sox9F/WT;Fgfr1F/WT;NesCre) 
to see if midline glia are absent in these mutants (individually the heterozygotes are 
unaffected). However, before commencing any investigation of such a genetic interaction, 
I would want to confirm that Hopx and Tnfrsf19 are in fact important for the generation of 
midline glia by examining tissue from null mice. A Tnfrsf19-/- has been produced (Shao et 
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al., 2005), but to date, no Hopx-/- has been generated. Also, if SOX9 and an effector of 
FGFR1 signalling were to bind co-operatively to activate the transcription of Hopx and/or 
Tnfrsf19, one might expect these genes to be absent or more weakly expressed in the 
Fgfr1F/F;NesCre. One would also expect to find binding sites for potential effectors of FGF 
signalling in the vicinity of the SOX9 binding site identified in the SOX9 ChIP-Seq. 
 
In addition to investigating a possible interaction between SOX9 and FGFR1, part of my 
further work would be to see if it is possible to rescue the callosal agenesis phenotype 
with either Hopx or Tnfrsf19. This could be done in slice culture with Sox9Δ/Δ brains by 
electroporating these factors individually, or in combination, into the ventromedial part of 
the dorsal telencephalon to see if radial glial delamination and midline glial population 
formation was restored. Co-electroporation of a radial glial reporter construct, such as the 
Blbp-GFP used by Smith and colleagues (2006), would enable the process of 
delamination to be observed by time-lapse confocal microscopy. 
 
 
  
 
- 146 - 
Chapter 6 KCNJ10 as a Candidate SOX9 Target 
Involved in Mediating the Impaired Neurosphere-
Forming Ability of Sox9Δ/Δ Neural Progenitors 
 
Through the refining of our candidate list in Chapter 5, we have identified a gene, Kcnj10, 
that has a number of characteristics that suggest it as a potential mediator of the Sox9Δ/Δ 
neurosphere phenotype. Firstly, it is the most down-regulated gene (by qPCR) among the 
targets that were down-regulated (p < 0.05) in both our RNA-Seq and microarray 
datasets. Additionally, it has two SOX9 binding peaks within 20kb of its transcriptional 
start site (TSS), and it is expressed in the same distribution as Sox9 within the developing 
telencephalon (Figure 5-7C). Furthermore, Kcnj10 is expressed specifically and 
uniformly in the ventricular zone (VZ) suggesting that it may be important in some way 
for the function of radial glia. The combination of these two lines of evidence make 
Kcnj10 a promising candidate to explain the effect that deleting Sox9 has on the 
behaviour of progenitors, i.e. impaired neurosphere-forming ability and loss of glial 
potential in differentiation assays. 
 
Kcnj10 encodes an inwardly-rectifying potassium channel subunit, Kir4.1. In order to see 
if modulation of the expression of this potassium channel might be involved in the 
Sox9Δ/Δ neurosphere phenotype, I investigated the effect of blocking both inwardly-
rectifying channels in general and also Kir4.1 in particular, on the proliferation and 
differentiative capacity of neural progenitor cells (NPCs). 
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Introduction 
 
The Resting Membrane Potential 
 
The membranes of cells are composed of a bilipid membrane, which is innately 
permeable to gases and lipid-soluble molecules. Artificial bilipid membranes are not 
permeable to charged molecules (such as glucose) and ions; these must be transported 
across the membrane by ion channels or carriers. Although transporters exist for many 
molecules in vertebrate cells, the gradients of three ions, Na+, K+ and Cl- are of 
paramount importance. In all cells, the concentrations of these ions are radically different 
between the inside and outside of the cell: K+ is ~40 times more concentrated within the 
cell than outside it, and a similar concentration gradient, but with opposite polarity, exists 
for Na+ and Cl- ions, which have very low intracellular concentrations. The enormous 
concentration gradients of Na+ and K+ ions are established by the action of an integral 
membrane protein called the Na+/K+ ATPase (or Na+/K+ pump). With every action of this 
pump, two K+ ions are introduced into the cell, and three Na+ ions extruded. A 
consequence of segregating ions across the cell membrane is that a potential difference 
develops across it, which is known as the ‘resting membrane potential’ (RMP) and is 
always negative within the cell (relative to the outside). However, it is the relative 
‘leakiness’ of the cell membrane to K+ compared to Na+ (between 10- and 100-fold 
depending on the cell type) that is responsible for the large RMPs seen in many cells 
(such as glia and muscle cells). As a result of this difference in permeability, K+ ions can 
flow out of the cell along their concentration gradient, but Na+ ions cannot flow into the 
cell along theirs. Consequently, the cell becomes progressively more negative with 
respect to the outside. At some point, the electrical attraction of K+ ions to the interior of 
the cell equals its tendency to flow out along its concentration gradient, and the voltage at 
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which this happens is called the potassium equilibrium potential (EK), and it is very 
negative (~-90mV). In reality the cell membrane is permeable to other ions, which 
complicates the situation, so that the RMP never quite reaches this theoretical value. 
 
Almost all cells segregate ions across their membrane – this is important for their function 
for a number of reasons. Primarily, the establishment of resting gradients of certain 
ubiquitous ions, such as Na+ and K+, can be used to drive desired molecules, such as the 
substrates of chemical reactions important to the cell, into its interior. Another important 
consequence of resting membrane potentials in multicellular organisms is in transmitting 
signals over long distances, such as in motor neurons or the specialised cardiomyocytes 
that co-ordinate the contraction of the heart. This is achieved through ion channels that 
transiently disrupt (or depolarise) the RMP, which spreads over the membrane of the cell 
and can induce cellular events (such as exocytosis of signalling molecules) at distant 
processes. 
 
Potassium Channels 
 
Over 100 different K+ channel subunits have been identified to date, which assemble into 
four different classes of K+ channel: Voltage-gated, Ca2+-activated, ‘leak’, and inwardly-
rectifying K+ channels (Coetzee et al., 1999). All potassium channels are formed from the 
assembly of four subunits, some are homotetramers, others are heteromers, composed of 
compatible subunits from the same K+ channel class. One striking property of K+ 
channels is their selectivity: They are permeable to K+ ions, but not to smaller cations 
such as Na+ ions. The basis of this selectivity is the ‘pore’ of the K+ channel. Although 
both K+ and Na+ ions are attracted to the negatively charged interior of the channel, the 
diameter of the pore is perfect to strip the water molecules from the surface of K+ ions, 
 
- 149 - 
allowing them to pass into the cell, but not Na+ ions, which are repelled (Doyle et al., 
1998). Once the RMP is established, K+ ions are in dynamic equilibrium across the 
membrane of the cell, such that the rate of K+ ion entry equals K+ ion exit. The number, 
and precise properties of these channels modulate the extent of K+ entry, and hence the 
RMP. 
 
This raises the question, why would it be beneficial for a particular cell to have a high or 
low RMP? This is easily answered for many differentiated cell types: Neurons with low 
RMPs will be more excitable, cells that store charged ions or molecules will be more 
efficient at importing them at higher RMPs, such as in the case of iodine import into the 
follicle cells of the thyroid gland via the I-/Na+ symporter. The latter process couples the 
‘downhill’ movement of Na+ ions along their electrochemical gradient with the ‘uphill’ 
movement of I- against its electrochemical gradient (Levy et al., 1998). The ion 
conductance properties of excitable cells not only determines their threshold for 
depolarisation, but also the ensuing electrical events, such as the length of the period of 
depolarisation, and the refractory period of hyperpolarisation afterwards in which a 
second depolarisation cannot occur. 
 
Kcnj10 
 
The Kcnj10 gene encodes a subunit of the inwardly-rectifying potassium channel, Kir4.1, 
which is expressed in astrocytes and oligodendrocytes in the adult brain (Kalsi et al., 
2004), and in the VZ of the developing mouse brain (our own data). Outside of the 
cerebrum, it is expressed in the Bergmann glia of the cerebellum and the Müller glia of 
the retina (Takumi et al., 1995, Ishii et al., 2003), which are cell types also noted for their 
expression of Sox9 (Pompolo and Harley, 2001, Poche et al., 2008). The fact that Kcnj10 
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is expressed in the Müller glia of the retina is interesting, because it has been shown that 
these glia are capable of neurogenesis (Fischer and Bongini, 2010). This complements our 
finding in the previous chapter that Kcnj10 is also expressed in radial glia cells, further 
strengthening the argument that Kcnj10 is important in some way for the identity of 
progenitors. 
 
In physiology, the term ‘rectification’ refers to the direction of greatest ease for ion flow. 
Almost all channels, by their nature, allow ions to move in both directions (inwards and 
outwards) – ‘inwardly rectifying’ channels allow greater flow in the inward direction than 
in the outward direction at all membrane potentials. The KCNJ10 subunit can either be 
assembled as a homotetramer with three other KCNJ10 proteins, or as a heteromer with 
other inwardly-rectifying K+ (Kir) channel subunits, of which about 20 are known. To 
date, KCNJ10 has been reported to form heteromers with two other Kir subunits: Kir5.1 
(Tucker et al., 2000) and Kir2.1 (Fakler et al., 1996); in both cases, the resulting channel 
is more strongly rectifying than the Kir4.1 homotetramer, which is considered weakly 
rectifying. The Kcnj10-/- mouse shows a ‘dysmyelinating’ phenotype, that is, very little 
myelin is formed around the axons of either the central or peripheral nervous systems in 
these mice (Neusch et al., 2001). Disruption of the Kcnj10 gene is one of very few cases 
in which a gene not directly involved in the production or export of myelin components 
exhibits a dysmyelinating phenotype, suggesting a role for Kcnj10 in the specification of 
oligodendrocytes and Schwann cells. 
 
Kir Channels and Their Role in Glia 
 
One of the textbook properties of glial cells is their highly negative RMP (close to the EK, 
and much greater than that of neurons), which was originally observed by Kuffler in 
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amphibians, and his predecessors working on the leech (1966; references therein). 
Modern electrophysiological techniques have shown that the RMP of glial cells, 
especially astrocytes is heterogeneous, however, the principle still holds true. One key 
benefit for astrocytes and oligodendrocytes of having a steep electrical gradient across 
their membranes is that it aids in one of their principal functions in the CNS, that of K+ 
uptake and K+ spatial buffering/siphoning. These are mechanisms by which K+ ions, 
released by neurons during periods of intense activity, are absorbed by glia or re-
distributed through the glia syncytium. Mounting evidence suggests that Kir channels are 
the major contributors to K+ removal/re-distribution in the CNS. For instance, when 
isolated toad retinas are bathed in a solution of Ba2+, a specific inhibitor of Kir channels, 
and stimulated with light, they fail to properly buffer K+ (Oakley et al., 1992). 
Additionally, there is evidence that the Kir channel we are interested in is of special 
importance for this process, since the genetic ablation of Kcnj10 results in the membrane 
potential of Müller glia, which perform the mainstay of K+ siphoning in the retina, being 
reduced by 10-fold (Kofuji et al., 2000). Kir channels are the main source of K+ 
conductance in glial membranes, and as such have a central role in setting the glial RMP 
(Butt and Kalsi, 2006). 
 
A Role for K+ Channels in Neural Progenitors? 
 
Striking evidence for the importance of K+ channels in neural progenitor proliferation 
comes from the phenotype of a mouse deficient in a voltage-gated K+ channel, Kv1.1. 
These mice exhibit megencephaly (excessive growth of the brain) affecting principally 
the hippocampi and ventral cortex, which was found to have resulted from increased 
proliferation in the subgranular zone (SGZ) of the adult hippocampus, which is a well-
characterised neural stem cell niche (Almgren et al., 2007). However, over-expression 
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studies have presented a more complex picture for the role of these outward, voltage-
gated channels. Vautier and colleagues (2004) over-expressed three voltage-gated K+ 
channels in oligodendrocyte progenitors and found that two of them, Kv1.3 and Kv1.4, 
increased proliferation (which is surprising in the context of the Kv1.1 phenotype), 
whereas a third, Kv1.6, decreased proliferation. In another study linking K+ currents and 
NPC behaviour, the antidepressant Spadin, which blocks a two pore domain K+ channel, 
TREK-1, was also shown to increase neurogenesis in the adult SGZ (Mazella et al., 
2010). 
 
Kir Channels and the Neural Stem Cells of the Adult SVZ 
 
In addition to Kv channels, Kir channels may also have a role to play in the behaviour of 
neural progenitors. A number of authors have shown that Kir4.1 is expressed in the 
slowly-proliferating (GFAP+Nestin+) astrocytes of the adult subventricular zone in mice, 
but not in the differentiating migratory (DCX+) cells of the rostral migratory stream 
(RMS; Pruss et al., 2011, Liu et al., 2006, Yasuda et al., 2008). Furthermore, Kir channels 
are expressed in a cyclical fashion in line with cell-cycle progression in cultured 
astrocytes, and their inhibition leads to cell cycle arrest (MacFarlane and Sontheimer, 
2000, Pappas et al., 1994). These findings support the idea that Kir channels are important 
for the cycling state of progenitors, and that their loss may in some way be necessary for 
differentiation, possibility through a depolarisation-based mechanism. An alternative 
mechanism by which altering the permeability of a cell to K+ might affect its physiology 
comes from potential effects on intracellular Ca2+ concentration ([Ca2+]i). Changing the 
conductance of the membrane to K+ is likely to affect the distribution of other ions as they 
attempt to compensate, and restore electrochemical balance. Shi and colleagues (2007) 
showed that depolarising hippocampal neural progenitors using KCl did in fact increase 
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[Ca2+]i, and that the Ca2+ influx was coming from the extracellular environment, not the 
endoplasmic reticulum, which often serves as an intracellular reservoir for Ca2+. [Ca2+]i is 
known to have a number of effects on cellular physiology, which are brought about by the 
interaction of Ca2+ ions with a protein called calmodulin (CalM). CalM is a ‘dumbbell’ 
shaped molecule that can interact with a number of proteins in its unbound state. Binding 
of CalM to Ca2+ ions changes its conformation and thus its protein targets. A third 
possibility is that regulation of K+ conductance might exert its effects through modulation 
of cell volume, which is known to influence the cell cycle (Rouzaire-Dubois and Dubois, 
1998). Rouzaire-Dubois and Dubois noted that there was a concomitant increase in cell 
volume that accompanied the decrease in proliferation brought about by K+ channel 
blockers in neuroblastoma/glioma hybrid cells. They then asked if simply changing the 
volume of a cell by altering the culture medium osmolarity would have a similar effect on 
proliferation; and they found that it did: An increase in cell volume was associated with a 
decrease in proliferation rate. Thus, they proposed that the effect of K+ channel blockers 
on proliferation could be explained by consequent changes in cell volume. 
 
A Potential Role for K+ Channels in the Maturation of Oligodendrocytes 
 
Two lines of evidence point to a specific role for Kir4.1 in the differentiation of 
oligodendrocytes. Firstly, Kir channels are strongly up-regulated in terminally 
differentiated oligodendrocytes resulting in hyperpolarisation (Knutson et al., 1997), and 
secondly, the genetic ablation of Kir4.1 leads to depolarised, morphologically immature 
oligodendrocytes (Neusch et al., 2001). Interestingly, a normal number of 
oligodendrocytes are observed in the Kir4.1-/- spinal cord, indicating that in the absence of 
Kir4.1, oligodendrocytes can advance in their differentiation program. However, the 
oligodendrocytes that form fail to produce myelin both in vitro and in vivo. The authors 
 
- 154 - 
describe these ‘immature’ oligodendrocytes as being round, showing greater somatic area, 
and forming fewer connections with other cells of the CNS.  
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Results 
 
A number of lines of evidence support Kcnj10 as a potential transcriptional target of 
SOX9. Firstly, it has been shown to be down-regulated in the neural progenitors of the 
telencephalon in the absence of Sox9 by microarray, RNA-Seq and RT-qPCR (~3-fold 
[qPCR data]). We can also further define the nature of this down-regulation as affecting 
the NPCs of the dorsal telencephalon more than the ventral telencephalon (in situ data, 
Chapter 5). Our suspicion that this K+ channel subunit may be a direct target of SOX9 is 
increased by the finding that SOX9 binds two regions within the only intron of Kcnj10 
(marked A and B in Figure 6-1). Both of these sites are highly conserved in mammals, as 
shown by the ‘Placental Mammal Basewise Conservation’ and the multiple alignment of 
this region in a number of mammalian species (Figure 6-1). Since SOX transcription 
factors are known to commonly bind DNA in concert with other transcription factors, the 
40bp either side of each SOX9 binding site was examined to see if there might be a 
binding site for a potential binding partner using MatInspector (part of the Genomatix 
suite of bioinformatics tools; http://www.genomatix.de/). The consensus binding sites 
found are shown in Figure 6-2. In both SOX9 binding regions, a ZFP263 binding site 
(V$ZNF263 matrix; Frietze et al., 2010) is located very close to the SOX9 binding site, 
but on the opposite strand (15bp upstream at Site A; overlapping with the region bound 
by SOX9 at Site B). Very little is known about this transcription factor, except that its 
homolog is widely expressed in human tissues (Yokoyama et al., 1997). 
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Figure 6-1 Both of the SOX9 binding sites in the first intron of the Kcnj10 gene are highly 
conserved across mammalian species. 
 
 
Figure 6-2 Transcription factor binding sites within 40bp of each SOX9 binding site (limited to 
those transcription factors expressed in the CNS). 
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In addition to the evidence of SOX9 binding to a conserved non-coding region of the 
Kcnj10 locus, and an effect of SOX9 on the expression of Kcnj10, this candidate is also 
expressed in the expected distribution for radial glia cells – strongly and uniformly in the 
VZ (in situ data; Chapter 5). These two lines of evidence, combined with the fact that 
modulation of K+ channel expression has been shown to affect proliferation in a number 
of contexts, lead us to the hypothesis that Kcnj10 may mediate the reduced proliferation 
of Sox9Δ/Δ NPCs in the neurosphere assay. We therefore asked if inhibiting K+ currents 
through these channels could re-capitulate this aspect of the Sox9Δ/Δ phenotype. For this 
we used two Kir channel blockers, one that is widely-used in the literature, and believed 
to be specific to Kir channels (as opposed to other K+ channels), Ba2+ ions, and another, 
fluoxetine, which has been reported to be specific to Kir4.1 (Ohno et al., 2007). In order 
to better interpret these studies, it was felt that it would be useful to know which Kir 
subunits are expressed on CD133High cells, and since we have RNA-Seq data from wild-
type CD133High cells as part of a previous experiment, the data was utilised to answer this 
question. 
 
Expression of Kir Subunits in CD133High Cells 
 
The expression of all Kir subunits with >1 read aligning per kilobase of CDS are shown 
in Figure 6-3. Three Kir channels subunits are expressed in our sorted cell population: 
Kir3.1, Kir6.2 and our subunit of interest, Kir4.1. As was mentioned in the introduction to 
this chapter, Kir4.1 has only been reported to form heteromers with Kirs 2.1 and 5.1, 
neither of which are expressed in our CD133High cells, which leads us to the conclusion 
that Kir4.1 subunits are assembled as homotetrameric channels on the surfaces of radial 
glia. There have been no reports of heteromeric channels being formed from Kirs 3.1 and 
6.2, so these are also likely to be in the form of homotetrameric channels. It is important 
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to bear in mind that although three channels may be present on the surfaces of progenitors 
in the VZ of the embryonic forebrain, not all may be open and influencing the 
electrochemical gradient of K+; for instance, Kir6.2 is ‘ATP-dependent’ and is thus closed 
at physiological ATP concentrations, and the opening of Kir3.1 is controlled by 
interactions with G-proteins. This leaves open the possibility that Kir4.1 might be the 
dominant inwardly-rectifying potassium channel in radial glia, as is the case in Müller 
glia, which also express other subunits (Kofuji et al., 2000, Raap et al., 2002). Kir4.1 is 
also the dominant inwardly-rectifying K+ channel in oligodendrocytes, demonstrated by 
the lack of Kir currents in the oligodendrocytes of Kir4.1-/- mice (Neusch et al., 2001). 
These oligodendrocytes are also depolarised, suggesting that Kir4.1 is the dominant K+ 
channel responsible for setting their RMP. 
 
 
Figure 6-3 The expression of Kir subunits in CD133High cells from the embryonic VZ. Only those 
subunits with >1 read aligning per 1kb of CDS were included. 
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The Effect of Kir Channel Blockade on the Proliferation of NPCs 
 
Ba2+ ions are thought to inhibit all Kir currents, whereas fluoxetine was found in a recent 
report to be a specific inhibitor of Kir4.1 (Ohno et al., 2007). Subsequent studies have 
shown the precise residues responsible for the specific inhibition of Kir4.1 by fluoxetine 
(Furutani et al., 2009). Fluoxetine is better known as a treatment for depression in human 
patients that is believed to work by preventing re-uptake of serotonin (5-HT) via an 
interaction with the serotonin transporter, SLC6A4 (Sangkuhl et al., 2009, Stahl, 1998). 
Therefore, Ba2+ ions would be expected to block all Kir currents in NPCs, whereas 
fluoxetine would be expected to show the contribution of Kir4.1 currents specifically. 
One potential complicating factor is that fluoxetine may be a more effective inhibitor of 
Kir4.1 than Ba2+ ions, which only reduce astrocytic Kir currents by 63% (Liu et al., 
2006). 
 
In order to see if these two agents could mimic the loss of Sox9 in vitro, we harvested and 
dissociated dorsal telencephalons from E14.5 WT embryos and cultured them in the 
presence of bFGF and EGF. We assayed a diverse range of Ba2+ concentrations (Figure 
6-4), and found that although slight reductions in the rate of neurosphere formation were 
seen at concentrations in the range 1-100μM, only at 1mM did we seen a statistically 
significant reduction (65% reduction in neurospheres over 300μm in diameter; p = 0.039). 
Although one author claims that Kir channels are sensitive to 100μM Ba2+ and that higher 
concentrations affect other K+ channels (Liu et al., 2006), many other authors have used 
concentrations of 1mM and above to block Kir currents (Neusch et al., 2001). 
 
A more pronounced effect on NPC proliferation is seen with fluoxetine (Figure 6-5), 
which would not be expected to impair the function of the other two Kir channels 
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expressed in CD133High cells. With this inhibitor, formation of neurospheres is completely 
ablated at 10μM. However, we suspect that fluoxetine may be interacting with other 
receptors on the surfaces of E14.5 neural progenitors at these concentrations since this 
loss of neurosphere-forming ability is seen below the IC50 of fluoxetine on Kir4.1 
(15.2μM; Ohno et al., 2007). Additional suspicions are raised by the initial proliferation-
enhancing effects of fluoxetine at concentrations distant from its IC50 (1nM and 10nM). 
In its clinical application in treatment of depression, fluoxetine, a selective serotonin 
reuptake inhibitor, is thought to exert its effects via negative allosteric modulation of the 
serotonin transporter, SLC6A4 (Sangkuhl et al., 2009, Stahl, 1998). However, an effect 
on SLC6A4 could not have affected our results since interrogation of our CD133High 
RNA-Seq data reveals no expression of the gene encoding this transporter. Having said 
this, it is possible that fluoxetine interacts with other receptors, and pharmacogenomic 
studies have implicated a number of targets, including other receptors involved in 
serotonergic neurotransmission such as the 5-HT2A receptor (Serretti and Artioli, 2004). 
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Figure 6-4 The effect of Ba2+ ion concentration on the rate of neurosphere formation (assayed at 
7DIV). 
 
 
Figure 6-5 The effect of fluoxetine concentration on the rate of neurosphere formation (assayed at 
9DIV). 
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Although these experiments support a role for Kir4.1 in actively proliferating cells, we 
cannot be certain in either case that these inhibitors are not exerting non-specific effects 
on other channels or receptors. To overcome this limitation, we decided to knock-down 
expression of Kcnj10 by RNA interference (RNAi). The difficulty of doing this in a 
culture-based system is introducing the vector carrying the short-hairpin RNA (shRNA) 
into a majority of the cells in order to assess the phenotype produced. The strategy we 
adopted for this was electroporation with a plasmid containing both the shRNA against 
Kcnj10 and the puromycin-resistance gene, and then a period of enrichment with 
puromycin after transfection. Despite various attempts at this experiment, involving 
exhaustive combinations of different Kcnj10 shRNA clones, concentrations of puromycin 
and length (as well as timing) of puromycin exposure, I was unable to get significant 
knockdown of Kcnj10 (by RT-qPCR). The extent of knock-down was always assayed at 
the end of the enrichment process, so there should not have been time for the selection 
against shRNA-expressing cells. In hindsight, rather than attempt to obtain a cell 
population in which all cells are expressing a plasmid, I would have used an shRNA 
plasmid containing GFP. Two populations of E14.5 dorsal telencephalons could be 
transfected, one with a scrambled shRNA linked to GFP, and one with the Kcnj10 shRNA 
linked to GFP. After allowing these cells to form neurospheres, the number of GFP+ 
spheres as a proportion of all spheres could be counted. I would then expect a proportion 
of the neurospheres formed from the control-transfected cells to be GFP+, whereas those 
transfected with a plasmid containing the Kcnj10 shRNA together with GFP I would 
expect to be all (or mainly) GFP-, showing that only untransfected cells in the latter 
cultures could form neurospheres. 
 
Another aspect of the Sox9Δ/Δ phenotype, recently published by our lab, is the fact that 
Sox9Δ/Δ neurospheres fail to generate astrocytes or oligodendrocytes upon removal of 
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growth factors (Scott et al., 2010). Therefore, I asked if ablation of Kir currents might 
affect the differentiation of NPCs. It was found that, in the presence of 1mM Ba2+ ions or 
1μM fluoxetine (the highest concentration that permitted neurosphere formation), only 
astrocytes (marked by GFAP expression) or neurons were formed normally (Figure 6-6). 
Markedly fewer oligodendrocytes were formed (by PDGFRα immunohistochemistry), 
and those cells that did appear to express PDGFRα did so to a much lesser degree than 
untreated cells, or those treated with an inhibitor of a different type of channel (GABAA 
in this case). This finding suggests either that a change in the K+ gradient across the 
membrane, or an initially hyperpolarised state is required for oligodendrocyte 
differentiation. This could be clarified by asking if Cs+ ions (which block Kir channels, 
without depolarisation) or KCl (which would depolarise NPCs) could re-capitulate this 
effect. 
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Figure 6-6 The effect of two inhibitors of Kir currents on the differentiation of neural progenitor cells. Ba2+ ions are regarded as a general inhibitor of Kir channels; 
fluoxetine has been reported to be a specific inhibitor of Kir4.1. The GABAA channel antagonist, gabazine, was used as a control in this experiment. 
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Discussion 
 
The fact that Kcnj10 is expressed in neurospheres (Figure 5-9), and may be a 
transcriptional target of SOX9, raised the possibility that this K+ channel subunit might be 
involved in mediating the poor proliferation of Sox9Δ/Δ NPCs in the neurosphere assay. 
Supporting an important functional role for Kir4.1, I find that it is one of only three Kir 
channels expressed in wild-type CD133High cells. Since Kir channels have been shown to 
make a substantial contribution to the RMP of adult NPCs (Yasuda et al., 2008), this 
suggests that loss of Kir4.1 might have a dramatic effect on the RMP of radial glia, and 
hence diverse physiological processes within them. 
 
The functional studies set out in this chapter also support a role for Kir4.1 in the ability of 
NPCs to form neurospheres in culture. Generalised blockade of Kir currents with Ba2+ 
ions reduced the proliferation of NPCs in the neurosphere assay at 1mM, a concentration 
commonly used for this purpose (e.g. Neusch et al., 2001). However, the situation for an 
inhibitor reported to be specific to Kir4.1, fluoxetine (Furutani et al., 2009, Ohno et al., 
2007), was more complex. At low concentrations (1-10nM), fluoxetine appeared to 
increase the proliferation of NPCs through a mechanism that is unknown, but which 
cannot be mediated by the serotonin transporter SLC6A4, since expression of this protein 
is not seen in CD133High cells. However, at 1μM, a reduction is seen, and at 10μM, no 
neurospheres at all were formed. Since the IC50 of fluoxetine has been reported to be 
15.2μM, this effect would appear to have occurred at too low a concentration for us to be 
confident that the effect is mediated by Kir4.1. Unfortunately, RNAi experiments 
intended to show definitively that Kcnj10 is required for neurosphere formation have not 
so far been successful. However, Kcnj10 remains an attractive candidate for a gene that 
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may be involved in mediating the reduced growth rates of neurospheres formed from 
Sox9Δ/Δ NPCs. 
 
There are a number of mechanisms by which a change in the K+ permeability of a cell 
might affect cellular processes, such as proliferation/cell-cycle progression. One possible 
mechanism is cell swelling, which often accompanies Kir channel blockade. Rouzaire-
Dubois and Dubois (1998) showed that manipulating cell volume using hypo- or 
hypertonic culture medium mimicked the changes in proliferation brought about by K+ 
channel modulation. Another mechanism might involve changes in intracellular Ca2+ 
concentration as a result of cell depolarisation since intracellular Ca2+ ions are known to 
influence many cellular processes through binding to Calmodulin. A third way might be 
through an effect resulting from changes in intracellular pH (Pappas et al., 1994), or 
finally, some other consequence of depolarisation of the cell. 
 
Other authors have reached a different conclusion about the effect of Kir channels on the 
proliferation of NPCs, but this could be explained either by methodological differences or 
differences in the electrochemical gradients of adult versus embryonic NPCs. Yasuda and 
colleagues (2008) investigated the K+ channel subunits expressed in adult NPCs (using 
dissociated neurospheres, formed from the SVZ) and found that two types, Kv and Kir, 
predominated. They found that the Kv blocker tetra-ethyl-ammonium (TEA) reduced the 
proliferation of these cells, whereas Ba2+, which inhibits Kir channels, enhanced 
proliferation. However, on closer inspection, we find that they have used the number of 
cells obtained from dissociating neurosphere cultures as a measure of proliferation, and 
there is only a very modest increase in sphere number, and actually a decrease at 1mM. 
However, the spheres themselves are larger, accounting for the increase in total cell 
number post-dissociation.  
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Effect of Ba2+ and Fluoxetine on NPC Differentiation 
 
Surprisingly, I find that inhibition of Kir currents with both Ba2+ ions and fluoxetine leads 
to abnormal morphology of oligodendrocytes and significantly reduced expression of 
PDGFRα, which suggests that Kir currents are necessary for the specification, 
differentiation or maturation of OPCs. However, the phenotype of the Kir4.1-/- mouse 
reveals that Kcnj10 is not required for the formation of OPCs, but is required for their 
maturation (Neusch et al., 2001). Thus, loss of Kcnj10 expression could not explain the 
depletion of OPCs observed in the Sox9Δ/Δ spinal cord (Stolt et al., 2003) or the postnatal 
cortex (our own data). However, this observation might reveal a role for Sox9 in the later 
stages of oligodendrocyte maturation, in addition to its requirement for their initial 
generation. 
 
A Role for Kcnj10 in Establishing the Conditions for Gliogenesis? 
 
I have raised the hypothesis that Sox9 might set up a state in neural progenitors that 
creates the conditions for gliogenesis a number of times in this thesis; Sox9 is expressed 
from the earliest stages of neurogenesis in the dorsal telencephalon (from ~E10.5; Scott et 
al., 2010), yet gliogenesis does not occur in this region of the CNS until after birth. 
Perhaps hyperpolarisation, brought about by expression of Kcnj10, is a pre-requisite for 
the transduction of some other stimulus that induces gliogenesis? One possible 
mechanism for this relates to the likely effects of a change in the RMP on the 
concentration of other ions within the cell that might affect the functioning of ligand-
gated channels. 
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Further Work 
 
In order to strengthen the evidence for a direct transcriptional relationship between Sox9 
and Kcnj10, it is essential to know more about the relative timing of onset of Kcnj10 and 
Sox9 expression in the developing CNS. Is it, for example, that Kcnj10 is expressed from 
the first instance of Sox9 expression (~E9.5 in the mouse) or does it arise later, suggesting 
the requirement of a co-factor, or a less direct relationship, perhaps mediated by an 
intermediate transcription factor? 
 
I would also like to confirm that Sox9 loss affects the RMP of NPCs in culture, which 
could be done by comparing the RMP of Sox9Flox/Flox NS cells with or without Cre-
adenovirus. In the course of these experiments, we could also ask if Sox9 deletion leads to 
changes in intracellular Ca2+ or pH, or to cell swelling, that might illuminate its role in 
NPC physiology. It is also important to show what effect Kcnj10 knock-down has on 
NPC behaviour in the neurosphere assay. Rather than attempting to obtain a homogenous 
population of transfected cells, I would use plasmids that co-expressed GFP with the 
Kcnj10 shRNA and ask if spheres were formed from these GFP+ cells, and if they were, 
how their sizes and relative frequencies compared to those expressing a construct 
containing GFP and a scrambled shRNA. It would also be important to ask whether 
electroporation with a Kcnj10 expression construct could rescue proliferation in Sox9Δ/Δ 
neurospheres. 
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Chapter 7 DBI as a Candidate SOX9 Target 
Involved in Mediating the Impaired Neurosphere-
Forming Ability of Sox9Δ/Δ Neural Progenitors 
 
Apart from Kcnj10, the other candidate that was felt highly likely to be implicated in the 
Sox9Δ/Δ neurosphere phenotype was diazepam-binding inhibitor, DBI. This was based on 
two lines of evidence: Firstly, from our transcriptional profiling experiments and 
subsequent confirmation by qPCR, we know that Dbi expression is reduced in Sox9Δ/Δ 
CD133High cells (2.1-fold by qPCR). It is also clear that Dbi is expressed in the same 
pattern as Sox9 within the rostral forebrain (Figure 5-7). These observations, together 
with the finding that a region of the first intron of Dbi is bound by SOX9, make it likely 
that Dbi is a transcriptional target of SOX9. Unlike other potential targets identified in 
Chapter 5, Dbi is expressed uniformly in the VZ, and not significantly in other regions of 
the embryonic brain, making it a good candidate for a gene regulated by SOX9 that might 
influence the behaviour of progenitors. There is considerable evidence that a proteolytic 
product of the DBI protein is an endogenous antagonist of GABAA receptors, which are 
cell-surface Cl- channels. In order to test the hypothesis that SOX9 might influence 
progenitor behaviour through an indirect effect on GABAA channels, I have used 
pharmacological manipulation to establish if modulation of GABA signalling might 
recapitulate the effect of SOX9 on NPC behaviour in the neurosphere assay. 
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Introduction 
 
GABA and the GABAA Receptor 
 
Gamma-aminobutyric acid (GABA) is widely known as the major inhibitory 
neurotransmitter of the adult brain, where it induces hyperpolarisation of post-synaptic 
membranes and thus increases the threshold for an action potential in the post-synaptic 
neuron. GABA achieves this by increasing the permeability of the cell to Cl- ions, which 
are many times more concentrated outside the cell than inside it. The transient influx of 
Cl- ions results in hyperpolarisation, which lessens the likelihood of future action 
potentials in that neuron. This effect is mediated by binding of GABA to one of three 
classes of GABA receptor, GABAA, GABAB or GABAC. GABAA and GABAC are 
ionotropic receptors, that is, they are themselves ion channels and binding of GABA 
increases the likelihood of the channel being in an open state. The GABAB receptor is a 
metabotropic receptor, which is not itself an ion channel, but is instead linked to a G-
protein which, via second messengers, influences the opening of Cl- channels elsewhere 
in the membrane. GABAC receptors are a variant of the GABAA channel, defined 
functionally by their insensitivity to bicuculline. 
 
Seventeen different GABAA subunits have been described to date, which can be grouped 
by sequence homology into 6α, 4β, 4γ, 1δ and 2ρ subunits (Möhler et al., 1997). The 
GABAA receptor is a pentameric channel that is usually composed of a combination of 
two α-, one β- and two γ-subunits. The potential combinations of these subunits, and 
splice variants thereof, give rise to a formidable array of receptor subtypes, which may 
have slightly different pharmacological profiles. DBI, which is the focus of this chapter, 
is an allosteric antagonist of GABAA channels. This means, DBI, or a proteolytic 
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fragment of it, binds to a site separate from the sites of GABA-binding, of which there are 
two. Aside from the GABA binding sites, there are also three other important modulatory 
sites that affect the probability of channel opening: The barbiturate site, the 
benzodiazepine/β-carboline site, and the neurosteroid site (Upton and Blackburn, 1997). 
 
The adoption of GABA as a neurotransmitter has been a relatively recent innovation in 
evolution; although it has an ancient origin: GABA is synthesised by plants, and GABA 
receptors, resembling the GABAB type, are expressed by the earliest phylum of Metazoa, 
the Porifera sponges (Shelp et al., 1999, Perovic et al., 1999). This leaves open the 
possibility that GABA may have other roles, possibly as a signalling molecule in a more 
general sense. There is mounting evidence that this may be the case in the developing 
mammalian CNS, where both the enzymes required for GABA synthesis and receptors 
equipped to respond to it are expressed in distinct regions of the progenitor zones of the 
forebrain (Lo Turco and Kriegstein, 1991, LoTurco et al., 1995, Ma and Barker, 1995). 
 
GABA Signalling in CNS development 
 
LoTurco and colleagues showed in 1995 that GABA has a strong inhibitory effect on the 
proliferation of neural progenitor cells (NPCs) in culture. This effect was found to be 
mediated by GABAA receptors, and binding of GABA to its receptor in this context was 
shown to bring about membrane depolarisation. This is counter-intuitive, since opening of 
a membrane Cl- channel usually results in hyperpolarisation. However, it was found that 
in NPCs, the gradient of Cl- is reversed, with a high intracellular concentration of Cl- ions. 
This led another group to investigate the expression of GAD67, an enzyme required for 
the biosynthesis of GABA, and a number of GABAA subunits in the embryonic brain and 
spinal cord. They found that GAD67 is expressed in the SVZ of the dorsal telencephalon, 
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and that the α4-, β1- and γ1-subunits of the GABAA receptors are expressed in the VZ. 
Other subunits (α3, β3 and γ2) where confined to the cortical plate (CP), suggesting that 
they were destined to form the GABA receptors conventionally found in synapses. It is 
interesting to note that the pattern of subunit expression in both the embryonic VZ and CP 
is different to that commonly observed in the adult brain (two α-, one β- and two γ2-
subunits; Möhler et al., 1997). These findings raise the possibility that in the dorsal 
telencephalon, GABA, secreted by the cells of the SVZ, might be signalling back to the 
progenitors of the VZ, stimulating their proliferation. Other authors have assayed GABA 
concentration in the embryonic brain directly and found that GABA is by far the most 
highly expressed neurotransmitter in both the developing cerebellum (assayed from E15) 
and the developing olfactory bulbs (assayed from E13; Miranda-Contreras et al., 1999, 
Miranda-Contreras et al., 2000). 
 
In addition to expression in the embryo, a recent paper has shown that both GAD and 
GABAA subunits are expressed in neurospheres derived from the SVZ neural stem cell 
niche of the adult brain (Nguyen et al., 2003). There is also evidence that neurospheres 
derived from the embryonic brain maintain their responsiveness to GABA over several 
passages (Sah et al., 1997). 
 
How Might GABA Affect the Proliferation of NPCs? 
 
Most importantly from our perspective, GABA has been found to depolarise NPCs from 
the dorsal telencephalon of the rat brain (Lo Turco and Kriegstein, 1991). This effect was 
abolished by pre-treatment with bicuculline, a specific antagonist of GABAA channels, 
and enhanced by diazepam, a positive allosteric modulator of GABAA channels (LoTurco 
et al., 1995). To the surprise of the investigators, it was found that GABA induces Cl- 
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efflux from the cell, and infusion of the cell with a solution that did not contain Cl- ions 
prevented GABA-induced depolarisation. Changes in intracellular Ca2+ concentration 
were also noted, and the shifts in Ca2+ ions resulting from GABA application resembled 
to the authors those seen with voltage-gated Ca2+ channels. This was confirmed by 
blockade of the Ca2+ channels with La3+ ions. Thus, the authors showed elegantly that Cl- 
efflux mediated by GABA binding to GABAA receptors led to membrane depolarisation, 
which through the activation of voltage-gated Ca2+ channels, inhibited DNA synthesis 
(using [3H]-thymidine and bromodeoxyuridine (BrdU) assays). Using slice cultures, they 
showed that this is in fact a physiological mechanism by which proliferation is regulated, 
by demonstrating that addition of GABAA channel antagonists to cortical slices 
significantly increases proliferation in the VZ. 
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Diazepam-Binding Inhibitor 
 
DBI was first identified in 1983 by Guidotti and colleagues as the first endogenous ligand 
of the benzodiazepine/β-carboline recognition site of the GABAA receptor. Many years 
previously, it had been discovered that the anxiolytic/hypnotic drug, diazepam, exerted its 
effects by modulation of GABAergic transmission (Polc and Haefely, 1976). This began a 
search for an endogenous compound that might interact with this site. Guidotti and 
colleagues showed that DBI is at least one endogenous ligand of the benzodiazepine/β-
carboline site by demonstrating its ability to displace both diazepam and its antagonist, β-
carboline, from this site on crude synaptic membranes, but not GABA, which binds at a 
separate site. They also elegantly demonstrated the in vivo relevance of this effect by 
showing that intraventicular infusion of DBI abrogated the anti-conflict effect of 
diazepam in thirsty rats (Vogel test). Shortly after Guidotti et al. identified DBI and 
described its function, the benzodiazepine/β-carboline recognition site was found to be 
located on the γ2-subunit of the GABAA receptor (Pritchett et al., 1989). However, inverse 
agonists such as DBI can exert weak effects on receptors that include the γ1-subunit but 
not the γ2, showing that the benzodiazepine/β-carboline site is not wholly dependent on 
the presence of a γ2-subunit (Puia et al., 1991). In addition to GABAA receptors, DBI is 
known to bind ‘peripheral-type’ benzodiazepine sites, which are located on mitochondrial 
membranes in secretory tissues (Parola et al., 1993, Upton and Blackburn, 1997). 
 
However, DBI’s status as a neurotransmitter was quickly challenged on two counts: First, 
it is expressed in many tissues, not just the brain, and secondly, it carries no ‘export 
signal’ from the cell, and so it was not thought to be secreted (Shen et al., 2006). On the 
basis of its high expression in the liver, and its lack of a signal sequence, Knudsen and 
Nielsen (1990) asserted their view that DBI was more likely to be an acyl-CoA binding 
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protein, involved in lipid biosynthesis. However, the authors of the original paper re-
asserted their findings that DBI is able to displace [3H]diazepam, and that intraventricular 
administration of DBI abrogates the anti-conflict effects of diazepam. They suggested that 
although full-length DBI lacks a signal sequence, proteolytic derivatives of the protein 
might be secreted from the cell. For instance, Slobodyansky and colleagues (1989) 
identified a secreted polypeptide thought to be formed from proteolysis of DBI 
(triakontatetraneuropeptide [TTN]); however, they find that this protein does bind to 
‘central’ type benzodiazepine/β-carboline sites, so would not modulate the activity of 
GABAA channels. 
 
Genetic ablation of the Dbi locus has yielded conflicting results. Landrock and colleagues 
(2010) find that deletion of the Dbi gene is embryonic lethal, whereas Neess and 
colleagues (2011) find a much milder phenotype involving delayed activation of lipo- and 
cholesterogenic gene expression programs following weaning, although the latter result 
seems the most likely in light of the fact that a naturally-occurring deletion that includes 
the Dbi locus gives rise a mild phenotype limited to sparse, greasy hair (Lee et al., 2007).  
 
- 176 - 
Results 
 
Surprisingly, the site identified by ChIP-Seq as being bound by SOX9 lies in intron 3-4 
(the last intron) of Dbi. However, due to the small size of the gene, and the relative 
shortness of the two preceding introns, this site is only 5.2kb upstream of the 
transcriptional start site. Like the two regions identified in Kcnj10, this SOX9 binding site 
lies within a region that is highly conserved within mammalian species (in metatherians 
as well as eutherians; Figure 7-1). Other parts of the same intron show no conservation at 
all with non-rodent species, suggesting that there is a role for this region in the regulation 
of Dbi transcription. Unlike the two SOX9 binding sites identified in Kcnj10, this binding 
site is not associated with a ZFP263 binding site. However, there are similarities between 
the factors binding close to SOX9 in the Kcnj10 locus and at this site. The site in Dbi is 
close to a ‘Barbie box’, which is shared by many barbiturate-inducible genes. This site is 
also present in the vicinity of Binding Site A in Kcnj10 (Figure 6-1). In addition, two 
binding sites for a MEIS1A/HOXA9 heterodimer are present in the vicinity of the SOX9 
binding site in Dbi, and Binding Site B in Kcnj10 is also close to a MEIS1A/HOXA9 
binding site. 
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Figure 7-1 The SOX9 binding site identified by ChIP-Seq is highly conserved across mammalian 
species. 
 
 
Figure 7-2 Transcription factor binding sites within 40bp of the SOX9 binding site. 
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In order to ascertain if DBI might mediate the effect of loss of Sox9 on the formation of 
neurospheres, cell suspensions from E14.5 dorsal telencephalons of wild-type MF1 mice 
were cultured in the presence of a variety of concentrations of i) an agonist of the GABAA 
receptor (muscimol), and ii) two specific antagonists of GABAA channels, SR-95531 and 
bicuculline (Figure 7-3). Since there is a lack of an antagonist of GABAA channels in the 
Sox9Δ/Δ (DBI), it might be expected that an agonist of GABAA receptors such as 
muscimol would at least partially recapitulate the Sox9Δ/Δ phenotype and hence reduce the 
rate of neurosphere formation. This is in fact what was seen: At 100nM, there was a small 
reduction in neurosphere number after 6 days in vitro (15% relative to untreated NPCs, 
which is not statistically significant); however, between 100nM and 1μM, there was a 
significant drop in neurosphere number (to 59% of the untreated level; p = 0.03), and this 
change occurs close to the EC50 of muscimol (1.7μM). Conversely, one might expect 
treatment with an antagonist to produce the reverse effect, an increase in the rate of 
neurosphere formation, and again this is what was seen with the GABAA antagonist, SR-
95531. This result is particularly striking, with a 3-fold increase in the number of 
neurospheres from 100nM to 1μM, which is the range in which the IC50 for this 
antagonist lies. Unfortunately, the same effect is not seen with bicuculline, which is also a 
specific antagonist of GABAA receptors, although it is possible that the subunit 
composition of embryonic GABAA receptors differs from that of adult GABAA receptors. 
However, LoTurco and colleagues (1995) were able to antagonise the depolarisation 
elicited by GABA using bicuculline, although this was in NPCs from a slightly later time 
in development (E16.5). 
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Figure 7-3 The effect of various concentrations of two antagonists, SR95531 and bicuculline, and 
one agonist of GABAA channels, muscimol, on the proliferation of NPCs in the neurosphere assay 
(N=3). 
 
 
  
EC50 = 1-4µM 
 
IC50 = 0.1-1µM 
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Rescue 
 
Although these in vitro results are consistent with previous findings that the activation of 
GABAA channels can inhibit cell-cycle progression, and thus might be a mechanism by 
which loss of Sox9 could impair neurosphere formation, we have not proven this link. In 
order to show this, I attempted to rescue the Sox9Δ/Δ phenotype using SR-95531. I 
reasoned that, if the major reason why Sox9Δ/Δ NPCs were proliferating poorly was the 
unrestrained activity of GABAA channels, leading to depolarisation and cell-cycle arrest, 
restoring normal inhibition would eliminate this restraint on proliferation, and result in 
similar rates of neurosphere formation between SR-95531-treated Sox9Δ/Δ NPCs and SR-
95531-treated Sox9F/F NPCs. If, however, another mechanism was mediating the defect, 
SR-95531 might increase proliferation in Sox9Δ/Δ NPCs, but not to wild-type (+ SR-
95531) levels. To distinguish these two possibilities, I cultured E14.5 NPCs from Sox9F/F 
embryos containing a ROSA26 reporter transgene, to which a Cre adenovirus was added. 
To control dishes, a GFP adenovirus was added in place of the Cre adenovirus. Both Cre-
treated and control dishes showed high transduction rates, close to 100%. However, in 
these experimental conditions, no reduction in neurosphere numbers was seen after Sox9 
deletion. One explanation for this might be that by E14.5, several days of Sox9 expression 
has set in motion genetic programs which are then resistant to its removal. Were I to 
repeat this experiment, I would use Sox9F/F;NesCre cells, and compare them to Sox9F/F cells, 
with and without SR-95531. This would allow us to ask, in cells never exposed to Sox9, if 
an antagonist of GABAA channels could achieve maximal rates of neurosphere formation 
(equivalent to wild-type cells + SR-95531), and thus determine if the loss of GABAA 
channel inhibition is the major cause of the Sox9Δ/Δ neurosphere phenotype.  
 
- 181 - 
Discussion 
 
Dbi appears to be a good candidate for a direct target of SOX9 that might influence the 
proliferation of neural progenitors. It is down-regulated in the absence of Sox9, expressed 
in the same domain as Sox9, and its final intron contains a highly conserved region that 
includes a SOX9 binding site. Previous work has demonstrated that GABA strongly 
inhibits proliferation (LoTurco et al., 1995), and our own data shows that activation of 
GABA receptors reduces neurosphere-forming ability. Moreover, inhibition of GABA 
signalling in cortical slices (LoTurco et al., 1995), and in neurospheres (our own data), 
substantially increases proliferation/neurosphere formation, demonstrating a role for 
endogenously secreted GABA in controlling proliferation. In the context of the 
neurosphere assay, these findings suggest a model in which GABA released within 
neurospheres, but probably not by NPCs (since GAD is expressed in the SVZ of the 
embryonic brain), depolarises NPCs. A potential model for how DBI might mediate the 
poor proliferation of Sox9Δ/Δ NPCs in the neurosphere assay is shown in Figure 7-4. In the 
wild-type situation, a fragment of DBI (such as octadecaneuropeptide, ODN) might be 
secreted by NPCs, and may, in an autocrine or paracrine fashion, dampen down the 
activation of GABA receptors, allowing cell-cycle progression. However, in the absence 
of SOX9, Dbi transcription would be radically reduced, meaning that there would be no 
opposition to the action of GABA with the result that the majority of Sox9Δ/Δ NPCs would 
fail to form neurospheres of substantial size. 
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 Figure 7-4 Potential model illustrating how reduced expression of DBI might contribute to the 
poor growth rates of Sox9-deficient neurospheres. ODN – octadecaneuropeptide. 
 
In the developing embryo, GABA appears to be secreted by the cells of the SVZ, whereas 
the GABAA receptor subunits are confined to the VZ (Ma and Barker, 1995). This is 
interesting in the context of the increasing size of the SVZ, relative to the VZ, during 
corticogenesis. It is conceivable that as the number of GABA-secreting SVZ cells 
increases, this has an inhibitory effect on proliferation within the VZ. It is not yet clear to 
what extent this mechanism is important in controlling neurogenesis, although it is 
interesting to note that the GABAA receptor, with its multiple modulatory sites, would be 
capable of integrating a number of pro- and anti-proliferative signals. The effect of 
GABAA channel activation on proliferation is thought to be mediated by an increase in 
cytosolic Ca2+ (Ma et al., 1998a), although it is also possible that other mechanisms, such 
as cell swelling, or altered intracellular pH might be the cause. 
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GABAA or GABAC? 
 
The findings of this chapter suggest that the effect of GABA on NPCs is mediated by 
bicuculline-insensitive channels. This is not in agreement with the work of LoTurco and 
colleagues (1995), who showed that bicuculline could prevent the depolarisation of NPCs 
by GABA, although this was at a later time-point (E16.5). The bicuculline-insensitivity of 
these GABA channels suggests that a definition of GABAC may be more appropriate. It is 
possible that subunit expression in the embryonic VZ is dynamic, and that the subunit or 
units that render GABAA channels susceptible to bicuculline might not be expressed until 
after E14.5. 
 
Potential SOX9 Binding Partners? 
 
Binding sites for the MEIS1A/HOXA9 heterodimer, which is believed to participate in 
Gata1 transactivation (Pillay et al., 2010), were found both at the ‘B’ binding site of 
Kcnj10 (Figures 6–1 and 6–2), and at the site in the final intron of Dbi. However, an 
initial inspection of the entries for these genes in the Allen Brain Atlas does not show any 
significant expression in the embryonic forebrain. If this were confirmed by my own in 
situs, it would rule out these factors as potential binding partners for SOX9 in the 
developing CNS. Barbiturate-inducible elements (‘Barbie boxes’) are also present in both 
Kcnj10 Site A and the Dbi site. The Barbie box is thought to be bound by a repressor 
(Bm3R1) in most instances, but can be displaced by an activator (Bm1P1) when this is 
expressed (reviewed in Sueyoshi and Negishi, 2001). 
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Further Work 
 
Our existing data on the pharmacological manipulation of GABAA channels shows the 
effect of modulation of GABA by antagonists that act on the GABA binding site. This 
does not show that an effect on proliferation can be brought about by DBI itself. Since 
recombinant DBI is now available commercially, it would obviously strengthen our 
argument to show that DBI itself can enhance proliferation. Furthermore, showing that 
this effect can be blocked by flumazenil, which binds to the benzodiazepine/β-carboline 
site, would show that this effect was mediated by GABAA channels and not other DBI 
receptors, such as the peripheral-type found on the surface membranes of mitochondria 
(Upton and Blackburn, 1997). Ultimately, only a rescue experiment could provide direct 
evidence that Sox9 is affecting proliferation through this mechanism. In addition to 
proliferation, it would be interesting to see if GABAA/GABAC activation by muscimol or 
GABA could affect the differentiation capacity of NPCs upon growth factor withdrawal, 
because this is another aspect to the abnormal behaviour of Sox9Δ/Δ NPCs noted in Scott 
and colleagues’ paper (2010). 
 
 
  
 
- 185 - 
Chapter 8 General Discussion 
 
The phenotype of the Sox9Δ/Δ embryo reveals that in the absence of Sox9, radial glia are 
specified, begin to produce neurons at the expected time, and give rise to normal numbers 
of intermediate progenitors during corticoneurogenesis. Further to this, neurons of 
different layer-fates are generated and migrate to their intended positions in the 
developing cortical plate. However, Sox9Δ/Δ mice do show a profound deficit of 
oligodendrogenesis in the MGE during embryonic development and in the postnatal 
cortex. This is consistent with the findings of Stolt et al. (2003) and Scott et al. (2010), 
who both saw defects of oligodendrogenesis in Sox9Flox/Flox;NesCre mice. This dramatic 
reduction in OPC numbers supports a requirement for Sox9 in the specification of OPCs. 
 
It is surprising, however, that a gene expressed throughout corticogenesis (from E10.5; 
Scott et al., 2010), should have no apparent effect on this process when it is removed. 
There are several possible explanations for this: First, because the Nestin-Cre becomes 
active fractionally after Sox9 is first expressed, the NPCs of the dorsal telencephalon will 
have already been exposed to SOX9, and this brief exposure may have been sufficient to 
set in motion genetic programs, for instance, specifying NPC identity, which are then 
refractory to its removal. However, it has been shown that fewer neurospheres are formed 
at E14.5 using the same strategy to delete Sox9 (the Nestin-Cre), showing that this initial 
exposure to SOX9 is not sufficient for normal neurosphere generation later in embryonic 
development (Scott et al., 2010). 
 
Another possible explanation for the lack of a cortical phenotype is that another 
transcription factor, expressed in the embryonic VZ, but down-regulated in neurospheres, 
might be compensating for SOX9 loss by binding to the same regions within the genome. 
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Since there is a high degree of homology between different SOX proteins, particularly in 
their HMG boxes, the most likely candidates to compensate for SOX9 are other SOX 
proteins expressed in NPCs. Re-analysis of the RNA-Seq data from E16.5 dorsal 
telencephalons reveals that Sox genes of the SoxC subfamily, Sox4, Sox11 and Sox12 are 
the most strongly expressed Sox genes in cells enriched for CD133 expression (CD133High 
cells), with between 692 and 13,033 reads mapping to these loci per kilobase of their 
CDS (Figure 8-1). However, Sox4 and Sox11 are expressed only in newly-formed neurons 
arising in the VZ (Bergsland et al., 2006), and Sox12 is expressed in both mature neurons 
and NPCs, but more intensely in the former (Hoser et al., 2008). Also highly expressed in 
CD133High cells are Sox5 and Sox6. These transcription factors are known to be expressed 
throughout the VZ of the developing spinal cord, which supports a compensatory role in 
progenitor identity. However, recent evidence suggests that they antagonise SOX9 
binding during neurogenesis (Stolt et al., 2006). Sox21 is also found in the CD133High 
cells; however, in the spinal cord its expression was found to be restricted to newly-
formed neurons, and ectopic expression causes progenitors to differentiate and up-
regulate neuronal markers (Sandberg et al., 2005), suggesting that its role is antagonistic 
to Sox9. 
 
Figure 8-1 Expression of Sox genes in wild-type CD133High cells. Those genes with <1 read 
mapping per kilobase of CDS were omitted.  
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Because of the close homology between SOX9 and the other two members of the SOXE 
subfamily, SOX8 and SOX10, both within and outside their HMG boxes, several authors 
have suggested that these two proteins are the best candidates to compensate for SOX9 
(Stolt et al., 2003, Scott et al., 2010). This is supported by the finding that these two 
transcription factors show functional redundancy with SOX9 in the oligodendrocyte 
lineage (Finzsch et al., 2008, Stolt et al., 2005). However, neither Sox8 or Sox10 are 
significantly expressed in the CD133High cells, and evidence from the literature shows that 
Sox10 is only expressed in a restricted region of the VZ in the spinal cord (the pMN 
region; Stolt et al., 2002, Stolt et al., 2005, Kellerer et al., 2006, Finzsch et al., 2008) and 
Sox8 expression is also restricted to the ventral spinal cord (Stolt et al., 2005, Kellerer et 
al., 2006), suggesting that these two factors could not compensate for a function of Sox9 
in NPCs as a whole. This leaves Sox1 and Sox2, which are relatively highly expressed in 
CD133High cells (302 and 432 reads mapping per kilobase, respectively), and are restricted 
to the progenitors of the VZ (Bylund et al., 2003, Graham et al., 2003). 
 
One final possibility is that SOX9 provides added stability to a complex of transcription 
factors that will still bind and transactivate in its absence, but less reliably, and such a 
phenotype may be highly dependent on genetic background. This is analogous to the 
synergistic effects of SOX5, SOX6 and SOX9 in the transactivation of the Col2a1 gene in 
10T1/2 cells, in which SOX5 and SOX6 will enhance transcription, but when SOX9 is 
also present, transactivation is considerably more efficient (Lefebvre et al., 1998). 
 
This leaves two possible scenarios for functional compensation by SOX proteins in NPCs 
of the embryonic VZ: Either one of the SOXB1 proteins are able to compensate for SOX9 
loss (probably SOX1 or SOX2 as these are the most strongly expressed; Figure 8-1), or 
SOX5/SOX6 act synergistically with SOX9 to transactivate genes important for 
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progenitor identity and multipotency, but antagonistically at sites important for 
transactivation of genes required for oligodendrocyte differentiation (as shown by Stolt et 
al., 2006). The former possibility would be amenable to compound deletion by examining 
the phenotype of Sox1F/F;Sox9F/F;NesCre and Sox2F/F;Sox9F/F;NesCre mice for premature 
differentiation of NPCs or disordered corticogenesis. 
 
Transcriptional Profiling 
 
As I alluded to in the General Introduction, Sox9 expression long precedes the onset of 
gliogenesis in all regions of the CNS, which is the sole abnormality of the Sox9Δ/Δ 
mutants observed in our phenotypic analysis (Chapter 3). This led us to hypothesise that 
Sox9 may establish the conditions, perhaps expression of a receptor (or receptors), that 
are responsible for initiating gliogenesis. In order to answer this question, I performed 
transcriptional profiling experiments on E16.5 CD133High cells from the dorsal 
telencephalon, to identify differentially expressed genes that may account for an altered 
ability of Sox9Δ/Δ NPCs to respond to a gliogenic signal. The rationale for choosing E16.5 
dorsal telencephalons is that this is a time-point just before the onset of gliogenesis in this 
region, which would occur around the time of birth (Kessaris et al., 2006). This 
experiment highlighted one category of molecular function, the VEGF receptors, whose 
members were consistently down-regulated in the absence of SOX9. Since VEGF 
receptors are known to be important for the initial specification of OPCs (Le Bras et al., 
2006), this might explain the reduction in OPC numbers seen in the Sox9Δ/Δ CNS. 
Analysis of the categories of molecular function affected by Sox9 loss also revealed the 
up-regulation of a transcription factor (Tlx) that inhibits astrocyte differentiation, which 
might explain the delayed transition from glio- to neurogenesis in the spinal cords of 
Sox9Δ/Δ mice observed by Stolt et al. (2003). Another potential repressive target of SOX9, 
 
- 189 - 
Runx3, is expressed in newly-formed neurons and is known to negatively regulate 
proliferation in other contexts (Li et al., 2002), suggesting that suppression of this factor 
may be important in progenitor identity. 
 
Candidate Downstream Targets of SOX9 
 
Since I now had a dataset of Sox9 targets, albeit from a late time-point in neurogenesis, I 
decided to use these target lists to try to identify an individual target or group of targets 
that might explain the observation in the paper of Scott and colleagues (2010) that, even 
late in neurogenesis, Sox9Flox/Flox;NesCre NPCs exhibit poor neurosphere-forming ability 
within the neurosphere assay. By overlapping the target lists from the RNA-Seq and 
microarray experiments, two lists were refined, one of consistently up-regulated genes 
across the two experiments, and one of consistently down-regulated genes. Because the 
members of these lists had met the criterion for statistical significance in two independent 
experiments, the probability of them appearing on this list by chance was very slim. 
Consequently, all of the 13 putative down-regulated genes tested were confirmed by 
qPCR, as were 3 of the 5 up-regulated targets. Furthermore, using a ChIP-Seq dataset 
generated by another group at our Institute, I found that 11 of the 13 had a SOX9-bound 
region within 20kb of their transcriptional start site, and 3 had two such sites. In order to 
look for primary targets of SOX9, in situ probes were made against all 13 down-regulated 
candidates; unfortunately time did not allow the expression patterns of the up-regulated 
genes to be explored. When the resulting expression patterns were examined, it was found 
that six of the 13 candidates were expressed in the same distribution as Sox9, which 
would be consistent with these genes being primary targets of SOX9. Of the remaining 
seven, a proportion were expressed in the SVZ, and interestingly, two (Hopx and 
Tnfrsf19) were expressed in the medial VZ, the region from which radial glia would be 
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about to migrate to form the indusium griseum. This observation suggests that Hopx and 
Tnfrsf19 might lie downstream of Sox9 in specifying future indusium griseum (IG) cells. 
However, since these cells are only induced in a defined region of the Sox9 expression 
domain, the involvement of a co-factor would be required, and in light of recent 
observations that FGFR1 is important for the specification or delamination of these cells, 
I think that an effector of FGF signalling might be this co-factor, perhaps by 
synergistically activating genes required for IG specification/delamination. 
 
Since loss of Sox9 produces a proliferation defect in NPCs in the neurosphere assay, any 
target of SOX9 involved in mediating this effect would have to be expressed in 
neurospheres derived from wild-type tissue. Consequently, RT-PCR was performed to 
compare the expression of the six remaining candidates in wild-type neurosphere cultures 
and E14.5 dorsal telencephalons. Expression of three genes, Kcnj10, Dbi and Arhgef3, 
was found to be maintained after 7 days in vitro, and since one of these is an ion channel 
and another a modulator of GABA signalling, we asked if pharmacological manipulation 
of these cell-surface proteins could re-capitulate the impaired neurosphere-forming ability 
of Sox9Δ/Δ NPCs. 
 
Functional Studies 
 
Two of the candidates, Kcnj10 and Dbi, were chosen for further investigation to establish 
if their down-regulation might be the cause of the proliferation defect or the lack of 
multipotentiality exhibited by Sox9Δ/Δ NPCs. It was found that an analogue of GABA, 
muscimol, reduced the growth rates of neurospheres in a dose-dependent fashion, and that 
inhibition of GABA signalling using SR95531 radically enhanced neurosphere formation. 
This supports a role for DBI in the proliferation defect observed in Sox9Δ/Δ neurospheres. 
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In the wild-type situation, opening of GABAA channels in response to GABA would be 
dampened by the action of DBI or a fragment thereof. However, in Sox9Δ/Δ neurospheres, 
significantly lower levels of DBI would be unable to prevent the opening of the GABAA 
channels, resulting in depolarisation of the NPCs, and cell-cycle arrest (a phenomenon 
demonstrated by LoTurco et al., 1995). Down-regulation of Kcnj10 may also affect 
proliferation of NPCs, since blockade of inwardly-rectifying channels by Ba2+ ions 
reduces neurosphere numbers, as does fluoxetine, which is believed to block the specific 
Kir channel formed by homotetramers of KCNJ10, Kir4.1. In addition to an effect on 
proliferation, down-regulation of Kcnj10 may also explain or contribute to the loss of 
OPCs in the Sox9Δ/Δ since in differentiation assays of neurospheres, those exposed to 
either Ba2+ ions or fluoxetine exhibit a specific defect of oligodendrocyte differentiation. 
Neurospheres differentiated in the presence of either of these two inhibitors give rise to 
morphologically normal neurons and astrocytes, but the oligodendrocytes formed show 
fewer processes, a less differentiated morphology, and lower expression of PDGFRα. 
 
In conclusion, I have identified two potential mechanisms for the impaired proliferation 
of Sox9Δ/Δ NPCs in the neurosphere assay: The first is that loss of SOX9 results in the 
reduced secretion of a negative modulator of GABA, causing NPCs to become 
depolarised and undergo cell cycle arrest. However, the loss of the inwardly-rectifying K+ 
channel, Kir4.1, also appears to affect their proliferation. Further studies attempting to 
rescue the Sox9Δ/Δ phenotype will be required to determine which of these mechanisms is 
the most important in producing the observed phenotype. Surprisingly, corticogenesis 
proceeds normally in the Sox9Δ/Δ despite SOX9 being expressed in the progenitors that 
give rise to these neurons, and this may be because the Nestin-Cre acts too late (after 
NPC specification) or because another SOX protein compensates for its loss by binding to 
the same sites within the genome. The best candidates to fulfil this compensatory role are 
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proteins of the SOXB1 subfamily because these are expressed within the VZ during 
corticoneurogenesis. I also find that VEGF receptors are down-regulated in the absence of 
Sox9, which may explain the dramatic reduction in OPCs seen in the Sox9Δ/Δ CNS, and 
screening of down-regulated targets by examining their expression patterns revealed two 
genes (Hopx and Tnfrsf19) that might be responsible for the failure of midline glia 
populations, necessary for formation of the corpus callosum, to be specified and migrate 
to the correct location in the developing brain. 
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Appendix A 
 
RNA-Seq Up-Regulated Gene List (p ≤ 0.05, fold change ≤ -1.25) 
 
Rank Gene Symbol Fold Change p-value 
1 1700028P14Rik Inf 0.033 
2 5830416P10Rik Inf 0.022 
3 A330049M08Rik Inf 0.036 
4 Aass Inf 0.003 
5 Aire Inf 0.039 
6 AL596181.1 Inf 0.013 
7 AL929524.1 Inf 0.013 
8 Bbox1 Inf 0.034 
9 Cdkl1 Inf 0.021 
10 Cyp4f14 Inf 0.019 
11 Gm10103 Inf 0.033 
12 Gm10109 Inf 0.039 
13 Gm10609 Inf 0.036 
14 Gm6756 Inf 0.022 
15 Gm9793 Inf 0.021 
16 Grb7 Inf 0.033 
17 Grem2 Inf 0.004 
18 Hal Inf 0.039 
19 Hoxc11 Inf 0.036 
20 Hsf4 Inf 0.039 
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Rank Gene Symbol Fold Change p-value 
21 Kcna5 Inf 0.033 
22 Kdm4d Inf 0.033 
23 Lbp Inf 0.036 
24 Lefty2 Inf 0.041 
25 Lrrc34 Inf 0.034 
26 Mlph Inf 0.039 
27 Mthfr-ps1 Inf 0.034 
28 Myof Inf 0.021 
29 Naif1 Inf 0.017 
30 Runx3 Inf 0.033 
31 Slc35d3 Inf 0.045 
32 Slc9a3 Inf 0.041 
33 Spn Inf 0.007 
34 Tlr5 Inf 0.033 
35 Tmem139 Inf 0.033 
36 Ttc36 Inf 0.033 
37 Zdhhc19 Inf 0.034 
38 Si 41.27 0.001 
39 Palm2-Akap2 24.37 0.006 
40 Lama3 23.52 0.006 
41 Lipt1 18.88 0.015 
42 Runx2 16.57 0.040 
43 Gm5048 14.89 0.038 
44 Gm5423 14.11 0.037 
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Rank Gene Symbol Fold Change p-value 
45 Thnsl2 12.67 0.044 
46 Sfn 9.79 0.046 
47 Lxn 9.08 0.027 
48 Cnpy1 8.80 0.006 
49 Xdh 8.60 0.007 
50 Mybph 8.29 0.004 
51 Ttr 7.99 0.003 
52 AL845463.1 7.54 0.002 
53 Gm10335 6.90 0.028 
54 D17H6S56E-3 6.78 0.010 
55 Gm10751 6.77 0.019 
56 Gm12500 6.34 0.000 
57 Gm10197 6.29 0.027 
58 Npsr1 6.10 0.043 
59 Gm6043 6.07 0.043 
60 Sh3tc1 6.05 0.027 
61 Tspan1 5.96 0.020 
62 Fam122a 5.82 0.042 
63 Zfp566 5.75 0.003 
64 5430435G22Rik 5.19 0.025 
65 Adrb2 5.03 0.041 
66 Slc2a5 4.68 0.001 
67 Abcc6 4.52 0.006 
68 Gm10480 4.07 0.040 
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Rank Gene Symbol Fold Change p-value 
69 Itgax 4.07 0.004 
70 Ccdc78 3.96 0.034 
71 Gpd1 3.69 0.010 
72 Rab40b 3.67 0.045 
73 Hfm1 3.15 0.001 
74 Gm6790 3.09 0.004 
75 Adamts8 3.07 0.048 
76 a 2.92 0.046 
77 Trim13 2.89 0.006 
78 Heph 2.87 0.028 
79 Pla2g16 2.87 0.035 
80 Ttpal 2.79 0.042 
81 Greb1l 2.79 0.004 
82 Tcfl5 2.77 0.002 
83 Gm5160 2.76 0.006 
84 Thsd1 2.68 0.028 
85 Ifitm3 2.59 0.038 
86 Tspyl4 2.47 0.030 
87 Itgae 2.46 0.044 
88 Glcci1 2.44 0.011 
89 Lgals1 2.42 0.020 
90 Otx2 2.41 0.045 
91 Mxra8 2.41 0.021 
92 Prokr1 2.36 0.019 
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Rank Gene Symbol Fold Change p-value 
93 Mppe1 2.35 0.043 
94 Gm5239 2.34 0.002 
95 Ampd2 2.33 0.002 
96 Pdzd7 2.33 0.031 
97 1700022I11Rik 2.33 0.023 
98 Gm10252 2.33 0.011 
99 Tesc 2.25 0.020 
100 Bhlhe41 2.23 0.046 
101 Sstr2 2.19 0.028 
102 Rhoc 2.18 0.042 
103 Gadl1 2.13 0.007 
104 Pdpn 1.97 0.003 
105 Calb2 1.96 0.047 
106 2810417H13Rik 1.94 0.023 
107 Dmp1 1.94 0.003 
108 Slc7a8 1.93 0.000 
109 Rfpl4 1.91 0.001 
110 Nup62 1.91 0.017 
111 C1galt1 1.87 0.050 
112 Asb4 1.86 0.002 
113 Eln 1.84 0.004 
114 F8a 1.80 0.042 
115 Hist2h4 1.79 0.043 
116 Has1 1.77 0.025 
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Rank Gene Symbol Fold Change p-value 
117 Ablim3 1.74 0.012 
118 Egfr 1.72 0.004 
119 Arap1 1.70 0.027 
120 Golga7b 1.68 0.026 
121 Serf2 1.67 0.009 
122 U2af1l4 1.66 0.043 
123 Cdh22 1.61 0.046 
124 Lrdd 1.59 0.044 
125 Xist 1.56 0.000 
126 Ppp1r3e 1.52 0.027 
127 Slc25a13 1.47 0.039 
128 Aurkb 1.46 0.032 
129 Fbxo44 1.43 0.019 
130 Pcna 1.42 0.004 
131 St8sia3 1.39 0.010 
132 Nanos1 1.38 0.031 
133 Ier5l 1.37 0.042 
134 Zic1 1.36 0.037 
135 Vps25 1.33 0.021 
136 Hbb-b1 1.33 0.035 
137 Atrip 1.32 0.047 
138 Hes5 1.31 0.047 
139 Hsd17b7 1.31 0.028 
140 Tnc 1.29 0.034 
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Rank Gene Symbol Fold Change p-value 
141 Lama5 1.28 0.041 
142 Pla2g4b 1.27 0.008 
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RNA-Seq Down-Regulated Gene List (p ≤ 0.05, fold change ≥ 1.25) 
 
Rank Gene Symbol Fold Change p-value 
1 4930578I07Rik -Inf 0.022 
2 Ccdc103 -Inf 0.014 
3 Cdnf -Inf 0.031 
4 Gm10643 -Inf 0.031 
5 Gm13225 -Inf 0.017 
6 Gm5431 -Inf 0.021 
7 Lhb -Inf 0.036 
8 Mpo -Inf 0.008 
9 Prss33 -Inf 0.027 
10 Slc38a5 -Inf 0.027 
11 Tmem220 -Inf 0.027 
12 Creg2 -14.36 0.015 
13 Edn2 -13.29 0.044 
14 Fam43b -12.63 0.032 
15 Ankrd55 -10.70 0.010 
16 Ttll9 -9.57 0.026 
17 Oit3 -9.27 0.005 
18 Kirrel2 -7.76 0.045 
19 Ccdc162 -7.34 0.009 
20 Tmsb15b1 -6.96 0.027 
21 Enpp3 -5.73 0.032 
22 Ankrd29 -5.64 0.017 
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Rank Gene Symbol Fold Change p-value 
23 Barhl2 -5.55 0.038 
24 Gm5464 -4.97 0.043 
25 Col2a1 -4.78 0.000 
26 Calhm2 -4.32 0.036 
27 C2cd4b -4.31 0.038 
28 Zfp322a -4.30 0.007 
29 Rasgef1a -4.23 0.011 
30 Lamc2 -4.16 0.033 
31 5830403L16Rik -3.89 0.004 
32 Arhgef3 -3.85 0.037 
33 Prelp -3.83 0.030 
34 Ttc30a2 -3.30 0.023 
35 4930420K17Rik -3.30 0.027 
36 Ephx3 -3.25 0.046 
37 Rbm12 -3.24 0.006 
38 Fam82a1 -3.15 0.014 
39 Alas2 -2.91 0.033 
40 Ism1 -2.90 0.002 
41 Xlr3b -2.82 0.008 
42 Abca8b -2.81 0.028 
43 Hopx -2.80 0.008 
44 Pdgfra -2.75 0.001 
45 Spata1 -2.74 0.046 
46 Stambpl1 -2.72 0.041 
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Rank Gene Symbol Fold Change p-value 
47 Six2 -2.65 0.000 
48 Sdf2 -2.57 0.036 
49 Gm8923 -2.55 0.032 
50 2810459M11Rik -2.55 0.012 
51 Metrnl -2.53 0.036 
52 Mtcp1 -2.52 0.000 
53 Micalcl -2.38 0.008 
54 Nme3 -2.36 0.027 
55 Sipa1 -2.31 0.000 
56 Ccdc28a -2.29 0.047 
57 40603 -2.25 0.000 
58 Gpnmb -2.24 0.037 
59 Il31ra -2.20 0.007 
60 L2hgdh -2.19 0.016 
61 Kl -2.16 0.002 
62 Mrpl33 -2.14 0.000 
63 Sft2d2 -2.13 0.019 
64 Gfra1 -2.12 0.016 
65 Psenen -2.11 0.010 
66 Myh14 -2.06 0.032 
67 Gm10174 -2.05 0.000 
68 Pappa -2.02 0.033 
69 Mrpl17 -2.00 0.046 
70 Zbtb7c -1.97 0.008 
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Rank Gene Symbol Fold Change p-value 
71 Plce1 -1.97 0.004 
72 Syde2 -1.97 0.016 
73 Insm2 -1.96 0.000 
74 Rlbp1 -1.96 0.000 
75 Slc25a44 -1.93 0.011 
76 Uty -1.88 0.000 
77 Col9a3 -1.86 0.019 
78 Slc38a3 -1.85 0.036 
79 Ppm1m -1.84 0.030 
80 Hist2h2aa2 -1.82 0.019 
81 Hmga1-rs1 -1.82 0.036 
82 1700069B07Rik -1.80 0.029 
83 Slc35e4 -1.77 0.039 
84 AI646023 -1.76 0.005 
85 Kcnj10 -1.76 0.043 
86 Ubiad1 -1.73 0.020 
87 Dynlt1c -1.71 0.006 
88 Ntn4 -1.69 0.048 
89 Dedd2 -1.67 0.026 
90 Rgs4 -1.67 0.013 
91 Eif2s3y -1.66 0.000 
92 Stim2 -1.64 0.007 
93 Eif2ak3 -1.63 0.017 
94 Hs3st1 -1.63 0.007 
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Rank Gene Symbol Fold Change p-value 
95 Dct -1.63 0.046 
96 Trex1 -1.58 0.002 
97 Dalrd3 -1.58 0.035 
98 Hba-a2 -1.58 0.009 
99 Poli -1.54 0.046 
100 Zfp277 -1.52 0.044 
101 Lypd6 -1.51 0.039 
102 Naa16 -1.51 0.018 
103 Zcchc14 -1.47 0.045 
104 Tnfrsf19 -1.47 0.025 
105 Mmd2 -1.45 0.019 
106 Dpm1 -1.43 0.000 
107 3110035E14Rik -1.42 0.045 
108 Neurog2 -1.41 0.008 
109 Kcnn1 -1.41 0.043 
110 Dbi -1.39 0.045 
111 Ptp4a1 -1.37 0.043 
112 Ccdc41 -1.32 0.034 
113 Rnasel -1.31 0.020 
114 Ddx3y -1.26 0.000 
115 Kdm5d -1.26 0.000 
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Appendix B 
 
Microarray Up-Regulated Gene List (p ≤ 0.05, fold change ≥ 1.25) 
 
Rank Gene Symbol Fold Change p-value 
1 Slc16a14 2.36 0.010 
2 B3galt6 1.82 0.045 
3 Fes 1.61 0.030 
4 Kcnc2 1.60 0.046 
5 Snord123 1.59 0.000 
6 Fam173b 1.54 0.000 
7 Gsta4 1.53 0.032 
8 Zbtb38 1.49 0.045 
9 Mrc2 1.48 0.017 
10 Htra1 1.46 0.028 
11 Wnt5b 1.46 0.013 
12 Fam167a 1.45 0.003 
13 Heph 1.44 0.020 
14 1110032F04Rik 1.41 0.004 
15 Myl9 1.40 0.047 
16 Npy2r 1.40 0.014 
17 Ino80d 1.39 0.037 
18 Gkn2 1.39 0.031 
19 Sdad1 1.39 0.033 
20 Ercc2 1.39 0.005 
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Rank Gene Symbol Fold Change p-value 
21 ENSMUSG00000074303 1.39 0.024 
22 Slc2a5 1.38 0.037 
23 Tmem67 1.38 0.048 
24 Fam59a 1.37 0.012 
25 Mafb 1.36 0.030 
26 Apobec1 1.36 0.025 
27 Csprs 1.35 0.043 
28 Panx2 1.35 0.012 
29 Cldn23 1.34 0.042 
30 Lfng 1.34 0.019 
31 Spinlw1 1.34 0.023 
32 Egln3 1.34 0.023 
33 Notch3 1.34 0.004 
34 Paqr7 1.34 0.013 
35 Bnc2 1.34 0.020 
36 Arhgef19 1.33 0.012 
37 Pdpn 1.33 0.013 
38 Tada1l 1.33 0.015 
39 C1galt1 1.33 0.043 
40 Doc2a 1.33 0.033 
41 Paqr6 1.32 0.012 
42 Runx3 1.31 0.011 
43 Wwc2 1.31 0.003 
44 Epb4.1l2 1.31 0.035 
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Rank Gene Symbol Fold Change p-value 
45 Chek2 1.31 0.049 
46 Mia1 1.31 0.021 
47 Icos 1.30 0.034 
48 Sema5a 1.30 0.006 
49 2600010E01Rik 1.30 0.001 
50 Tmem121 1.30 0.028 
51 Chd6 1.30 0.017 
52 Clip1 1.29 0.041 
53 Depdc6 1.29 0.006 
54 Mapk12 1.29 0.034 
55 Rpa3 1.29 0.016 
56 Gpc3 1.29 0.018 
57 1810014F10Rik 1.29 0.013 
58 4930579J09Rik 1.28 0.014 
59 Clspn 1.28 0.018 
60 Adam5 1.28 0.015 
61 Ccbp2 1.28 0.030 
62 Pcdh8 1.28 0.037 
63 Nab2 1.27 0.042 
64 Arap3 1.27 0.007 
65 Mybphl 1.27 0.027 
66 4833438C02Rik 1.27 0.017 
67 C79595 1.26 0.031 
68 Rad9b 1.26 0.049 
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Rank Gene Symbol Fold Change p-value 
69 Napepld 1.26 0.015 
70 Hoxb2 1.26 0.018 
71 Hes1 1.26 0.017 
72 Intu 1.26 0.016 
73 Fzd10 1.25 0.010 
74 Bcan 1.25 0.014 
75 Csn2 1.25 0.045 
76 Sord 1.25 0.034 
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Microarray Down-Regulated Gene List (p ≤ 0.05, fold change ≤ -1.25) 
 
Rank Gene Symbol Fold Change p-value 
1 Atp1a2 -2.37 0.038 
2 Matn2 -2.19 0.011 
3 Rlbp1 -2.00 0.000 
4 Pdgfra -1.87 0.028 
5 Hopx -1.82 0.002 
6 Abhd1 -1.79 0.041 
7 2810459M11Rik -1.59 0.003 
8 Plce1 -1.57 0.001 
9 Kcnj10 -1.55 0.048 
10 Abcb9 -1.55 0.019 
11 Nup133 -1.54 0.001 
12 Pdlim4 -1.49 0.011 
13 Col2a1 -1.49 0.014 
14 Mmd2 -1.49 0.007 
15 Foxn3 -1.48 0.010 
16 Hs3st1 -1.44 0.032 
17 Tnfrsf19 -1.44 0.002 
18 Tceb3 -1.41 0.013 
19 Ssu72 -1.41 0.004 
20 Cyp2j9 -1.39 0.037 
21 Scrg1 -1.39 0.032 
22 Slc5a2 -1.38 0.023 
 
- 210 - 
Rank Gene Symbol Fold Change p-value 
23 Dio2 -1.36 0.046 
24 Slc2a13 -1.35 0.018 
25 1700029I01Rik -1.35 0.008 
26 Sdf4 -1.34 0.006 
27 Dbi -1.34 0.040 
28 Slc39a14 -1.33 0.011 
29 Cdo1 -1.33 0.012 
30 Arhgef3 -1.32 0.004 
31 4930404N11Rik -1.32 0.029 
32 Pja1 -1.32 0.042 
33 Asrgl1 -1.31 0.018 
34 Gm9 -1.30 0.048 
35 Vdr -1.29 0.036 
36 Madcam1 -1.29 0.004 
37 100042016 -1.29 0.004 
38 Aif1l -1.29 0.045 
39 B930068K11Rik -1.28 0.025 
40 Sgms2 -1.28 0.039 
41 Ado -1.28 0.035 
42 Pcdh10 -1.27 0.029 
43 Lhb -1.27 0.008 
44 Prss23 -1.27 0.025 
45 AI646023 -1.27 0.017 
46 Wdr92 -1.26 0.026 
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Rank Gene Symbol Fold Change p-value 
47 5830403L16Rik -1.26 0.037 
48 Nedd9 -1.26 0.005 
49 Calm1 -1.26 0.040 
50 Stk39 -1.26 0.008 
51 Fbxo36 -1.26 0.009 
52 Tspan8 -1.26 0.041 
53 Tacc1 -1.26 0.010 
54 Tctex1d1 -1.26 0.037 
55 F3 -1.26 0.044 
56 Flt1 -1.26 0.004 
57 Pard6b -1.26 0.004 
58 2610028D06Rik -1.26 0.038 
59 Bnip2 -1.25 0.043 
60 2900024I21Rik -1.25 0.045 
61 Ptprz1 -1.25 0.027 
62 Stx11 -1.25 0.034 
63 Acss1 -1.25 0.015 
64 Cdh6 -1.25 0.007 
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